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The following thesis describes the development of a novel, targeted, lipid-based 
ultrasound contrast agent (UCA) for the assessment of coronary heart disease (CHD).  
The agent is currently being developed at the University of Edinburgh. 
The general aim of the research presented throughout this thesis was to further the 
development of the UCA described above and to demonstrate active targeting of the 
agent to a cellular surface under flow.  This was achieved through the specific 
objectives outlined below: 
 To optimise the agent for use with 40MHz intravascular ultrasound (IVUS). 
 To develop a flow chamber for the assessment of targeted microbubble 
attachment under high wall shear stress (WSS). 
 To develop a method of assessing microbubble attachment to cells under 
flow. 
 To demonstrate attachment of the in-house UCA to a cellular surface under 
flow conditions.  
The cardiovascular system and coronary heart disease are described in Chapter 1. 
This chapter explains the motivation for developing the UCA, in addition to 
providing some background information on the causes and current and developing 
diagnostic techniques for CHD. 
Ultrasound imaging techniques and UCAs are described in Chapter 2.   The use of 
UCAs is described and the interactions of UCAs with ultrasound explained through a 
review of the available literature.  Different methods used to produce microbubbles 
have been described and past, current and developing contrast agents identified.  In 
addition, a brief review of the literature and current understanding of ultrasound and 
UCA safety has been provided. 
Chapter 3 outlines the methods and techniques used to optimise the novel UCA for 
use with high-frequency intravascular ultrasound (IVUS).  A variety of techniques 
has been tried and investigated to produce the most echogenic microbubble sample.  
 
xxvi 
Echogenicity has been assessed using visual and radio-frequency (RF) analysis of 
IVUS images. 
A novel flow chamber designed for the assessment of microbubble attachment under 
known, high WSS has been described in Chapter 4.  The flow chamber design and 
purpose has been explained and calibration of the flow chamber using laser Doppler 
anemometry (LDA) has been detailed. 
The UCA has been developed for use with IVUS.  The scanner and transducer used 
for the optimisation and detachment investigations, detailed in this thesis, has been 
characterised and described in Chapter 5.   
Targeting of the UCA has been achieved through the attachment of antibodies to the 
microbubble shell.  Attachment of antibodies was via a streptavidin-biotin bridge.  
Chapter 6 identifies the techniques used to optimise antibody attachment to the 
microbubbles.   
The strength of the streptavidin-biotin bond has been tested up to 50Pa WSS as 
described in Chapter 7.  The novel flow chamber calibrated in Chapter 4 has been 
used to assess the WSS under which microbubbles remain attached to a streptavidin 
coated surface.  Attachment was assessed using the IVUS scanner described and 
characterised in Chapter 5. 
Cellular adhesion within the flow chamber and within micro flow slides has been 
investigated in order to determine the optimum technique for assessment of 
microbubble attachment to cells under WSS.  This work is detailed in Chapter 8. 
The final experimental chapter details the targeting of the UCA to a cellular surface 
in static conditions and under very low WSS.  Chapter 9 describes the development 
of methods leading to successful targeting of the UCA.   
Conclusions and evaluation of the techniques and methods used throughout this 
thesis can be found in Chapter 10.  This chapter outlines the advances made during 
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This thesis presents the development of a novel, targeted, lipid-based, microbubble 
ultrasound contrast agent (UCA) for assessment of coronary heart disease (CHD) 
with high frequency intravascular ultrasound (IVUS).  The targeting mechanisms 
assessed for microbubble attachment include a streptavidin-biotin mechanism, 
electrostatic mechanism and antibody targeting. 
The microbubble has been optimized for use with 40MHz IVUS through an 
investigation into the effect of various production methods on the echogenicity of the 
agent.  Echogenicity has been assessed from quantification of the RF data and 
determination of the mean ultrasound backscatter.  Agitation was found to be the 
optimal method of production resulting in a 3.94(±1.14)dB increase in the mean 
backscatter.  The stability of the agent has also been assessed over time and optimal 
storage of the agent determined.   
A novel flow chamber has been developed for assessment of microbubble 
detachment under very high WSS.  The flow chamber has been calibrated to 50Pa 
wall shear stress (WSS) using laser Doppler anemometry (LDA).  Higher WSS was 
achieved through the use of higher viscosity fluids.  The streptavidin-biotin bond has 
been assessed within the flow chamber and was found to be 75 times stronger than an 
electrostatic control.  
Antibody attachment to the microbubbles via a streptavidin-biotin bridge has been 
optimised with 91.20(±0.02)% of the microbubbles having antibodies attached.  A 
flow system has also been developed for assessment of microbubble attachment to 
cells under very low WSS. 
Microbubbles have been successfully targeted to SK-Hep-1 cells using acoustic 
radiation force.  In addition attachment of the microbubbles to SK-Hep-1 cells has 
been observed under 0.03Pa WSS in the Ibidi μ-slides. 
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Chapter 1 The Cardiovascular System and 
Coronary Heart Disease 
Coronary Heart Disease (CHD), also known as coronary artery disease, ischemic 
heart disease or atherosclerotic heart disease, is a type of cardiovascular disease 
(CVD) which affects the heart and blood vessels of the cardiovascular system.  It is 
the result of a build up of atheromatous plaque within the arteries of the heart.  With 
CHD causing over 100,000 deaths each year, it is the most common cause of 
mortality in the UK (BHF 2007). 
1.1. The Cardiovascular System 
The Cardiovascular system is the body‟s transport system and has the following 
functions  (Levick 2003): 
 To distribute nutrients and oxygen and remove waste from around the body 
according to requirements. 
 To facilitate temperature regulation. 
 To distribute hormones as required. 
 To produce penile erection during reproduction. 
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The cardiovascular system achieves this by means of a network of arteries, veins and 
capillaries.  These vessels transport blood to the various organs of the body whereby 
the oxygen or nutrients required are able to diffuse into the cells of the organ.   
A schematic of the cardiovascular circulation can be seen in Figure 1-1.  Blood is 
pumped from the right ventricle (RV) to the lungs via the pulmonary artery where it 
is oxygenated and is returned to the left atrium (LA) by the pulmonary veins, 
completing the short pulmonary circulation.  The LA then contracts and forces blood 
into the left ventricle (LV), followed by a ventricular contraction increasing pressure 
in the LV from 0 to 120mmHg (Arronson et al. 2004), and the blood is forced into 
the aorta travelling down the pressure gradient.   
 
Figure 1-1: Cardiovascular Circulation. 
The first arterial branch provides the coronary circulation with oxygenated blood, the 
aorta then splits into two, the first branch transports blood to the upper body, brain 
and lungs and the second transports blood to the lower body, abdominal cavity and 
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digestive tract where nutrients are collected.  Blood from the upper body is then 
returned to the right atrium (RA) of the heart via the superior vena cava and blood 
from the lower body returned by the inferior vena cava.  The RA then contracts 
forcing blood into the RV where it returns to the pulmonary circulation. 
1.1.1. The Heart and Blood Vessels 
The heart is a muscular pump which drives blood around the body by way of blood 
vessels.  The blood vessels are made up of arteries, which transport blood away from 
the heart and veins which transport blood back to the heart, these vessels are linked 
by smaller arteries called arterioles, capillaries and venules (small veins) as 
illustrated in Figure 1-2.  The structure of both veins and arteries can be seen in 
Figure 1-3 and consists of the following layers: 
Tunica Intima 
Sheet of flattened endothelial cells connected to the media by a thin layer of 
connective tissue and elastin.  A smooth layer to aid blood flow and act as a barrier 
to blood plasma. 
Tunica Media 
Smooth muscle cells containing collagen and elastin.  This layer is thicker in the 
arteries to enable the vessels to withstand higher pressures. 
Elastin 
A thin layer of elastin marks the boundary of the media and externa layers. 
Tunica Externa 
A sheath of connective tissue which tethers the vessel to surrounding tissue. 
Valve (Veins only) 
The valve is present to prevent blood at low pressures from flowing in the wrong 
direction along the vessel.  It is not required in the arteries due to the high pressure at 
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which the blood is propelled along by the heart, however, by the time the blood 
reaches the veins this pressure has dropped to approximately 15mmHg. 
 
Figure 1-2: Blood vessels, wall thickness and lumen diameter, data provided by Arronson et al. 









The Cardiovascular System and Coronary Heart Disease 33 
 
Figure 1-3: Structure of arteries and veins 
1.1.2. Coronary Circulation 
Due to the muscular nature of the heart it requires a continuous blood supply, 
carrying the necessary oxygen and nutrients, to enable it to propel blood around the 
body.  The coronary circulation is a network of arteries which fulfils this 
requirement; the coronary circulation can be seen in Figure 1-4.  The left and right 
coronary arteries originate from the aortic sinus at the base of the aorta.  The right 
coronary artery is 120-140mm in length and supplies the ventricles and right atrium 
in addition to the sinoatrial node via the posterior descending and right marginal 
branches. The left coronary artery supplies the ventricles and left atrium via the 
circumflex (60-80mm in length), left marginal and anterior descending arteries (100-
130mm in length).  The right and left coronary and marginal arteries are linked by 
anastomoses; however, these are not wide enough to maintain the necessary blood 
flow to the heart if one side of the coronary circulation is blocked.  In order for the 




The Cardiovascular System and Coronary Heart Disease 34 
 
Figure 1-4: The coronary circulation 
1.2. Cardiovascular Disease 
A cardiovascular disease is any type of disease which affects either the heart, or 
blood vessels.  There are a large number of such diseases as listed in Table 1-1 
below, these diseases are not independent and often occur simultaneously and as a 
result of one another.  However, the most common cardiovascular disease is 
coronary heart disease and so often the description is used to describe atheromatous 
plaque build-up in the arteries. 
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Type of disease Brief description 
Aneurysms Dilation of blood vessels. 
Angina Chest pain, often as a result of other 
disease. 
Arrhythmia Abnormal electrical activity in the heart 
resulting in irregular or distorted heart 
beat. 
Atherosclerosis Build up of atheromatous plaque in 
arterial blood vessels. 
Cardiomyopathy Disease of the myocardium (heart 
muscle). 
Cerebrovascular Accident (Stroke) Brain injury resulting from blood supply 
to brain being cut off. 
Cerebrovascular Disease Disease of blood vessels supplying the 
brain. 
Congenital Heart Disease Structural heart defects in infants. 
Congestive Heart Failure Structural or functional disorder 
impairing ability of heart to maintain 
normal function. 
Myocarditis Inflammation of myocardium. 
Valve Disease Failure of coronary or venous valves. 
Coronary Artery Disease Build up of atheromatous plaque in 
coronary arteries. 
Dilated Cardiomyopathy Weakened and enlarged heart. 
Diastolic Dysfunction Impaired heart relaxation. 
Endocarditis Inflammation of inner layer of the heart. 
Hypertension  High blood pressure. 
Hypertrophic Cardiomyopathy Thickening of the myocardium. 
Mitral Valve Prolapse Abnormally thick mitral valve. 
Myocardial Infarction  Heart attack. 
Venous Thromboembolism An embolism caused by segregation of a 
thrombus. 
Table 1-1: Cardiovascular Diseases, highlighted sections are those of interest in this study. 
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1.2.1. Atherosclerosis 
As explained previously, CHD involves the build up of atheromatous plaque within 
the arteries of the coronary circulation.  This is a disease known as atherosclerosis.  
Atherosclerosis can affect any arterial blood vessels and is caused by the formation 
of plaques within the arterial walls, resulting in hardening of the arteries.  Plaque 
formation is the result of a chronic inflammatory response(Blasi 2008; Maseri and 
Fuster 2003). 
Atherogenesis 
Development of an atherosclerotic plaque begins during childhood as lipids 
accumulate in the tunica intima.  Cholesterol and other lipids are transported around 
the body by lipoproteins.  The genesis of an atheroma is believed to be due to the 
oxidation of low density lipoproteins (LDLs) (Arronson et al. 2004; Kunitomo 2007).  
The presence of LDLs increases with the intake of cholesterol.   
As the presence of LDL in the blood stream is increased some of the LDL is able to 
pass through the endothelial monolayer of the arterial wall, here it reacts with oxygen 
free radicals to form oxidized-LDL.  Arronson (Arronson et al. 2004) suggests that 
the oxidized-LDL then goes on to cause or exacerbate endothelial cell damage and 
also enhance expression of adhesion molecules on the endothelial surface, prompting 
the inflammatory response (Figure 1-5a).  Circulating monocytes within the blood 
stream are attracted to the adhesion molecules and taken into the tunica intima, 
where they mature into macrophages.  Although uptake of LDL is usually highly 
regulated, in the presence of oxidized LDL the macrophages are unable to control 
uptake and become foam cells which form fatty streaks along the arterial wall, as 
illustrated in Figure 1-5b. 
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Figure 1-5: Diagram illustrating atherogenesis: a, absorption of LDL by cell wall; b, uptake of 
LDL by macrophages and formation of foam cells; c, growth and migration of smooth muscle 
cells; d, plaque forming an aneurism and rupture of plaque wall resulting in thrombus 
formation. 
The collective effect of the damaged endothelial layer and uptake of oxidized-LDL 
by macrophages contribute to growth of the smooth muscle cells within the tunica 
media which then migrate into the tunica intima forming a fibrous cap (Figure 1-5c 
and d).  As the foam cells are produced and die, the area beneath the fibrous cap fills 
with cellular debris and lipids causing the cell wall to distort (see Figure 1-5d).  In 
some cases the plaque will partially occlude the vessel lumen, creating a stenosis; 
alternatively the wall will distort outwards causing a bulge in the vessel at this point.  
This is known as outward remodelling.  Ultimately this can lead to the formation of 
an aneurism. 
Stable and Unstable plaque 
Two types of plaque can be formed as a result of atherogenesis; stable plaque or 
vulnerable (unstable) plaque.  Stable plaque is characterised by regular and 
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predictable angina pectoris (severe chest pain), particularly when the victim is 
undergoing strenuous exercise, this is due to a permanent narrowing of the lumen 
resulting from a build up of plaque.  When at rest the artery is able to provide the 
heart with all the blood it requires, however, when undergoing intense exercise the 
heart requires a greater amount of blood which, if slightly occluded, the artery is 
unable to provide, resulting in angina pectoris (pain).  With time, stable plaque can 
build up and eventually block off an artery leading to myocardial infarction, however 
this only accounts for about 30% of heart attacks (Cooley 1996).   
Vulnerable plaque is thought to be the leading cause of acute coronary syndromes 
(ACS) (Maseri and Fuster 2003), as a result a vast amount of research is being 
carried out into the causes and identifying factors of vulnerable plaque in the fight 
against CHD (DeMaria et al. 2006; Dickson and Gotlieb 2003; Fichtlscherer et al. 
2004; Galonska et al. 2008; Kips et al. 2008; Leber et al. 2008; Lind 2003; Maseri 
and Fuster 2003).  Maseri et al. (Maseri and Fuster 2003) specifies the identifying 
markers of vulnerable plaque as follows: 
 Complex coronary stenoses 
 Coronary plaque fissures 
 Fresh thrombi 
 Plaque inflammation 
It is believed that plaque instability is a consequence of a lipid-rich plaque with a thin 
fibrous cap, whilst a stable plaque will have a thick fibrous cap.  Dickson et al. 
(Dickson and Gotlieb 2003) suggests that there are three steps to the formation of a 
vulnerable plaque: 
 Transformation of a stable plaque into a vulnerable plaque, whereby there is a 
decrease in the smooth muscle cells of the fibrous cap resulting in thinning. 
 Destabilization of the vulnerable plaque, caused by fissures in the fibrous cap, 
further thinning and inflammation. 
 Complications following destabilization of the plaque resulting in plaque 
rupture. 
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When a vulnerable plaque ruptures platelets within the blood begin to clot around the 
„wound‟, a typical immune response.  If the blood clot (thrombus) continues to 
increase in size this can result in occlusion of the vessel, causing myocardial 
ischemia or infarction.  In some instances the thrombus may not occlude the vessel 
but under the pressure of the blood flow a small section may break off and travel 
along the vessel to a narrower part where it can occlude the artery causing an 
embolism, this can also result in myocardial infarction and sudden death. 
1.2.2. Symptoms and Diagnosis 
Atherosclerosis is asymptotic during the early phases and is therefore not detected 
until symptoms occur later in the disease or signs of atherosclerosis are found during 
routine examinations.  The disease is often not picked up until a more serious 
condition is observed, such as angina or a myocardial infarction.  In the latter case 
this can sometimes result in death.  Kips (Kips et al. 2008) has described a variety of 
non-invasive and invasive methods of assessing the presence of vulnerable plaque. 
Many of the imaging modalities are designed to assess the degree of stenosis within 
an artery, however there is extensive research confirming that most acute myocardial 
infarctions are a result of non-stenotic plaques (Falk et al. 1995; Schroeder and Falk 
1995; Virmani et al. 2000).  As the plaque builds up the vessel responds by 
increasing the cross-sectional area retaining a large lumen and the sufferer therefore 
will not suffer from angina pectoris, meaning that vulnerable coronary plaques are 
largely asymptotic (Crouse et al. 1994; Glagov et al. 1987).   
Intravascular ultrasound (IVUS) and angiography, two invasive techniques which are 
in current clinical practice, are used to monitor the disease.  Some techniques derived 
from these imaging modalities are currently being researched and are described 
below.  In addition ongoing research is being done into non-invasive techniques. 
Invasive techniques 
Angiography is a contrast x-ray technique in which a radio-opaque iodine dye is 
injected into the blood vessels and thereby highlights the vessels in an x-ray image.  
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This technique has been used for more than fifty years (Rudd et al. 2005) in the 
assessment of CHD and is a high resolution technique.  It is an effective method of 
identifying stenosis within the arteries.  With over 300,000 angiography procedures 
performed annually in the UK (Hart and Wall 2002) it is currently the „gold 
standard‟ in CHD assessment.  However the limitations of angiography include the 
inability to identify non-stenotic plaques, and determining stability of identified 
plaques.  In addition the technique utilises ionising radiation. 
Intravascular ultrasound with frequencies of 20-50MHz is another popular imaging 
modality used to detect arteriosclerosis (DeMaria et al. 2006).  It involves an 
ultrasound transducer mounted onto a coronary catheter which is inserted into the 
coronary arteries and forms a cross-sectional image of the artery.  The higher the 
emitted ultrasound frequency the higher the axial resolution of the image, axial 
resolutions range from 200-100μm.  IVUS is discussed in more detail in Chapter 5.  
IVUS provides a real-time imaging technique capable of identifying calcified from 
fibrous plaques, however soft plaques and plaques with a thick fibrous cap produce a 
similar backscatter and therefore it is not possible to distinguish between the two.  
There are currently many new techniques emerging which utilise the benefits of 
IVUS in identifying soft plaques. 
Palpography and elastography are similar techniques utilising IVUS.  The techniques 
involve measuring the stress and strain of the arterial wall resulting in a strain 
diagram such as the one that can be seen in Figure 1-6.  This is achieved by studying 
and processing the ultrasound signals from the vessel under varying pressures.  
Because different materials deform differently under mechanical pressure they will 
have different strain values and will therefore be identifiable on a strain diagram.  
Recent studies have shown that soft plaques are associated with higher strain values 
than fibrous plaques and these techniques would therefore be able to distinguish 
between stable and unstable plaques (Schaar et al. 2006).  Palpography produces a 
strain diagram of the superficial wall, whilst elastography produces an image of the 
whole wall thickness.  This technique is currently under investigation (Schaar et al. 
2006).  The quality and value of these techniques are dependent upon the quality of 
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the ultrasound used and arrythmias and motion artefacts are both limitations of the 
modality. 
 
Figure 1-6: An elastography strain diagram (permission granted for reproduction (Biondi-
Zoccai 2006)). 
IVUS radio-frequency (RF) assessment involves the capture and fast Fourier 
transform (FFT) of the RF data from an IVUS examination.  This provides more 
detailed information than the IVUS image alone and the potential application of this 
technique to the determination of plaque stability is currently under investigation 
(DeMaria et al. 2006). 
Contrast IVUS is another IVUS technique which is currently being developed as a 
method to identify vulnerable plaques at the University of Edinburgh (Moran et al. 
2003b; Moran et al. 2006).  This technique will involve the injection into the blood 
stream of a high-frequency, microbubble, ultrasound contrast agent targeted to 
inflammation receptors associated with vulnerable plaques, once attached to the 
plaques the contrast agent is highly echogenic and will therefore enable identification 
of the extent of vulnerable plaques within the coronary arteries.  This technique is the 
focus of this thesis and the benefits of contrast IVUS would include the ease of 
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identifying vulnerable plaques, real-time imaging and cost effectiveness of 
ultrasound imaging.  The technique however is invasive and therefore carries the 
associated risks, in addition adverse reactions to ultrasound contrast agents have been 
documented (Dijkmans et al. 2005). 
In addition a variety of optical techniques including angioscopy (Thieme et al. 1996), 
optical coherence tomography (OCT) (Yabushita et al. 2002; Zimarino et al. 2007) 
and spectroscopy (Pedro R. Moreno 2003; Wang et al. 2002) are currently 
undergoing clinical trials.  Angioscopy uses a mini-camera which is inserted into the 
coronary arteries by way of a catheter, when imaged; a lipid-rich artery will glisten 
yellow whilst a healthy artery will glisten white (Kips et al. 2008; Ueda et al. 2003), 
the ability to distinguish between stable and vulnerable plaque is however limited.  
OCT uses infrared light to obtain images at the microscopic level, it is an incredibly 
high resolution technique (4-20μm) and is capable of determining the thickness of 
the fibrous cap, however the technique is high-risk as the blood must be rapidly 
flushed through the vessels which can result in endothelial damage and induced 
ischemia.  Spectroscopy depends upon the Raman-effect in which the wavelength of 
backscatter light is dependent upon the molecule reflecting the light, it is therefore 
possible to determine the chemical composition of the plaque.  However 
spectroscopy has a penetration depth less than 1.5mm and must also be used in  
conjunction with another imaging technique such as IVUS in order to obtain 
structural information about the plaque. 
Non-invasive techniques 
Non-invasive ultrasound of frequencies between 3.5-10MHz can be used in the 
assessment of plaque and is commonly used in studies of the carotid arteries, 
however coronary arterial imaging still poses many problems (DeMaria et al. 2006).  
 Single photon emission tomography (SPECT) and Positron emission tomography 
(PET) are nuclear imaging techniques which involve the introduction of a 
radioisotope to the body, if the radioisotope can be conjugated to a compound 
involved in the atherosclerotic process then it will become possible to identify the 
areas of high plaque density.  PET involves the introduction of a positron emitting 
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radioactive tracer compound to the body, the emitted positrons annihilate with 
electrons within the body producing two γ-photons at 180 to each other.  A 
surrounding scintillator detector will be set to coincidence detection such that when 
two γ-photons are detected at the same time a line between the two detectors will 
identify where the annihilation occurred and therefore the location of uptake of the 
tracer. SPECT involves an isotope emitting gamma radiation which is identified by a 
scanner in a similar manner to PET.  SPECT and PET are both low resolution 
techniques (Lodge et al.  2005) relative to ultrasound and angiography as identified 
in Table 1-2, in addition these techniques involve the use of highly ionising radiation 
and therefore continue to remain in the research domain. 
Multi-slice computed tomography (CT) is a rotational X-ray technique in which the 
source and detector rotate around the patient to build up a 2 dimensional cross-
sectional image.  It is 17% faster than single slice CT (Pawelski 2005) and therefore 
reduces the amount of motion artefacts; however it also entails higher radiation 
doses.  Multi-slice CT might be able to distinguish between fibrous and lipid-rich 
plaques (Galonska et al. 2008; Leber et al. 2008). 
Magnetic resonance imaging (MRI) has previously been investigated as a method to 
assess myocardial ischemia and viability using intracellular sodium MRI (Jansen et 
al. 2006).  In addition MRI is a technique which shows significant promise in the 
detection of atherosclerotic plaque.  Magnetic resonance angiography is useful in 
assessing the arterial lumen and high-resolution MRI can help to identify plaque 
components (Chun Yuan 2004; Hyafil and Fayad 2007).  The disadvantage of MRI is 
the cost and examination time, the spatial resolution of MRI is improved with longer 
examination times.  There is also research being done into the use of MRI contrast 
agents (Frías et al. 2008). 
The advantages and disadvantages and stages of research for each imaging technique 
described above have been summarised in Table 1-2. 
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Angiography 10 n/a Poor 
High resolution 






OCT 4-20 4-20 1-2mm High resolution High-risk Clinical studies 
Spectroscopy n/a n/a 1.5mm 





Ultrasound 600 400 n/a Non-invasive Low-resolution Clinical use 
Multi-slice 
CT 

























Table 1-2: Imaging modalities for assessment of atherosclerotic plaque (Kips et al. 2008) 
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1.2.3. Treatment 
Treatment of atherosclerosis is either via lifestyle changes or pharmaceuticals, in the 
more advanced cases surgical intervention is required.  There are a variety of drugs 
which are currently in use globally aimed at thinning the blood or interrupting the plaque 
formation.  Surgical intervention can be either an angioplasty procedure, which expands 
narrowed vessels, or bypass surgery to create an increased blood supply to affected 
areas. 
Asymptotic patients are often treated using aspirin or other drugs which prevent plaque 
rupture (Wald and Law 2003).  However treatment of such patients is controversial and 
currently much emphasis is on lifestyle changes to prevent development or worsening of 
the disease. 
1.2.4. Causes 
There are many causes of atherosclerosis, the most well known are illustrated in Figure 
1-7.  These include smoking, diabetes and high blood pressure.  Some aspects are within 
a person‟s control, such as the level of exercise, smoking and diet choices.  However, 
some of the factors are independent of personal choice such as gender, age, or a genetic 
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Figure 1-7: Flow diagram describing direct and indirect causes of atherosclerosis and relations 
between them. 
As mentioned, age is a determining factor in the development of atherosclerosis as the 
fatty deposits build up over time, eventually forming atherosclerotic plaque.  However, 
by being aware of the environmental factors which exacerbate and speed up the 
development of plaque there is control over development and progression of the disease. 
Blood viscosity is increased by a number of the known causes of atherosclerosis; age, 
smoking and obesity.  It is also known that the viscosity of blood is directly related to 
the hematocrit of the blood see Figure 1-8.  Hematocrit is a measure of the percentage of 
red blood cells within a sample of blood.  A study by De Backer et al. (De Backer et al. 
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2002) suggested that blood viscosity has no direct correlation to CAD  however, as 
blood viscosity is a measure of the shear stress between layers of a fluid it can therefore 
be surmised that blood viscosity will have a direct effect on the shear stress which is 
related to causes of atherosclerosis. 
 
Figure 1-8: Relationship of hematocrit and blood viscosity (permission given for reproduction 
(Klabunde 2005)) 
It has been documented that a laminar, constant shear stress is in fact atheroprotective 
and therefore a constant high shear stress is beneficial in the prevention of atheromas.  
However, when low or oscillatory shear stress occur this can lead to the development of 
atherosclerotic plaques (Cunningham and Gotlieb 2004).  The development of 
atherosclerotic plaques at areas of low or non-linear shear stress is due to damage to the 
endothelial cell wall, resulting in the arrival of inflammatory markers which instigate the 
development of plaque. 
Similarly, flow velocity, which is directly proportional to the wall shear stress can also 
cause an increase in atherogenesis if the flow is non-linear. 
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The main factors relating to the formation of atherosclerotic plaques are the endothelial 
damage caused by smoking, high blood pressure and low or oscillatory wall shear stress 
and the quantity of cholesterol and LDLs in the diet. 
1.3. Summary 
Coronary heart disease is one of the major causes of mortality in the western world and 
despite a greater understanding of the disease morphology CHD is still the number one 
killer in the UK.  Prevention and treatment of the disease is possible however, due to its 
asymptotic nature, prediction of myocardial events is not always possible.  A number of 
researchers are investigating different methods of identifying the extent of the disease in 
individuals.  IVUS is already in routine use for the assessment of CHD although it is not 
yet able to distinguish between stable and vulnerable plaques.   
It is evident that a method of identifying vulnerable plaque in the coronary arteries is 
required in order to assess the risk of a patient with CHD suffering a myocardial 
infarction.  Targeted UCAs are a promising solution to this problem.  Edinburgh 
University is currently developing a targeted microbubble UCA for use with high-
frequency IVUS.  Although the development is still in its infancy the UCA will be 
targeted to inflammation markers exhibited by vulnerable plaques within the coronary 
arteries. 
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Chapter 2 Ultrasound Contrast Agents 
 
Ultrasound has become increasingly popular as an imaging modality in the past few 
decades with over 20% of medical imaging in the UK being ultrasound examinations 
(Department_of_Health 2008) as illustrated in Figure 2-1.  Ultrasound is widely used in 
cardiology, obstetrics, gynaecology and abdominal imaging.  Another clinical use of 
ultrasound includes Doppler ultrasound which provides a measure of blood flow using 
the Doppler shift.  More recent developments in ultrasound have enabled 3-D or 4-D 
ultrasound scans which are popular in obstetrics fields. 
Superior transducer materials and enhanced signal processing techniques (Ali et al. 
2008) have resulted in improved image resolution, signal to noise ratio and sensitivity of 
ultrasound scanners.   
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Figure 2-1: Number of diagnostic imaging examinations by modality. 
The introduction of Ultrasound Contrast Agents (UCAs) has also improved ultrasound 
both diagnostically and therapeutically.  The advantages of ultrasound over its 
competitors are that it is the most cost-effective modality to run (Bierig and Jones 2009; 
Picano 2005); ultrasound scanners are also compact and can therefore be used at a 
patient‟s bedside.  In addition it is a real-time method of producing images and does not 
utilize ionizing radiation.  The more recent development of UCAs has extended the 
capability of ultrasound, allowing for assessment of perfusion, in addition to furthering 
its use both diagnostically and therapeutically, as described throughout this chapter.  The 
predominant clinical use of UCAs is in echocardiography and UCAs are licensed for 
both ventricular opacification and endocardial border delineation (Harvey et al. 2000) 
which can help to identify abnormalities in the heart wall.  In addition UCAs are used as 
tracers in the study of cirrohsis of the liver (Cosgrove 2006).   
The use of contrast agents in ultrasound was first approached in the 1960s when 
cardiologist Charles Joyner noticed transient echoes occurring after injections of 
indocyanine green through a catheter in the left ventricle (Gramiak and Shah 1968; 
Harvey et al. 2000).  Joyner put the source of these echoes down to small air bubbles 
formed on the catheter tip.  Although initially after their discovery there was no further 
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investigation or development of UCAs, in the past three decades the field has evolved 
dramatically. 
2.1. Ultrasound Contrast Agents 
An ultrasound contrast agent has been described as; 
 “…an exogenous substance that can be administered either in the blood pool or in a 
cavity to enhance ultrasonic signals…” 
(Correas et al. 2001).   
Ideally a UCA should be non-toxic and capable of producing an enhancement to the 
ultrasound signal.  Additionally it should be capable of crossing the pulmonary capillary 
bed and stable for the duration of the investigation, it must also be safe for intravenous 
injection and introduction into other body cavities. 
Ophir and Parker (Ophir and Parker 1989) described the five different classes of 
ultrasound contrast agents as; colloidal suspensions, emulsions, aqueous solutions and 
free and encapsulated gas bubbles.  It is the latter two which form the majority of 
commercial contrast agents and are the focus of most research today, they also provide 
the best enhancement with current imaging methods which utilize distinct properties of 
the microbubbles and are described in Section 2.2.  The evolution of microbubble 
contrast agents can be found in Table 2-1, and is described below. 
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First Generation Contrast Agents: (non transpulmonary)         
Agitated Saline   air no shell          
Echovist® Schering, Berlin air Galactose Tubal Patency  99% < 12µm; 
mean 3µm 




EU and USA 
approved 
Second Generation Contrast Agents: (transpulmonary blood pool agents)   
      
Levovist® Schering, Berlin air palmitic acid Blood pool 
enhancer 
99% < 10µm; 
mean 3µm 





Albunex® Mallinkrodt air sonicated albumin Ventricular 
opacification 
95% < 10µm; 
mean 3.8µm 
3-5 microsperes/ml B-mode/ colour 
doppler 
No longer available 
Third Generation Contrast Agents:  (transpulmonary, blood pool/organ specific agents)   
      
Optison™ (FS069) GE Healthcare octafluoropropane sonicated albumin Cardiac wall 
motion  
93% < 10µm 
    
EU and USA 
approved 




  Various  
  
Sonovue™ (BR1) Bracco Diagnostics 
Inc 





Definity®/Luminity  Lantheus Medical 
Inc 
octafluoropropane phospholipids Left ventricle 
opacification  
98% < 10µm 
    
EU and USA 
approved 
PESDA University of 
Nebraska 
perfluorobutane sonicated albumin Blood pool 
agent 
4.7µm 
    
Self-made 

















Sonavist® Schering air cyanoacrylate shell Liver studies mean 1µm 
  
Microbubble 
specific methods  
Sonazoid™ 
(NC100100) 
GE Healthcare perfluorobutane phospholipids Liver-specific  2.6μm  99.9% < 
7μm 
    
Japan approved 
BR14 Bracco perfluorobutane phospholipids Liver-specific mean 3µm 95% < 




biShpere™ POINT Biomedical  air biodegradeable 
polymers 
Renal studies 











Imagify™ (AI700) Acusphere Inc Decafluorobutane Poly-l-lactide-co-
glycolide   
Mean 2μm 
    
Awaiting approval 
Table 2-1:Current and past commercially available and developing microbubble contrast agents 2008 (Harvey et al. 2000) 
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Ultrasound contrast agents are generally classified into first generation, second 
generation and third generation contrast agents, dependent upon the gas contained and 
their stability in the blood flow.  However not all authors use the same classifications 
(Harvey et al. 2000; Harvey et al. 2002; Miller and Nanda 2004).  Agitated saline, the 
first widely used microbubble contrast agent is generally considered to be the earliest 
first generation agent.  The first commercial microbubble contrast agent was Echovist 
(Schering, Berlin), a galactose based first generation agent.  The air filled microbubbles 
originate from the water soluble galactose particles and are then released in suspension.  
Echovist was first marketed in 1991 and mostly used to assess fallopian tubal patency 
during infertility investigations (Calliada et al. 1998; Harvey et al. 2000).  Echovist, due 
to the advent of more stable agents, is no longer manufactured (NHS 2007).   
The variation in microbubble classification begins with the definition of a second 
generation agent.  Whilst Miller et al. (Miller and Nanda 2004) describe second 
generation agents as containing low solubility gases, Harvey et al. (Harvey et al. 2000; 
Harvey et al. 2002) consider second generation agents to be air filled microbubbles with 
a stabilising shell.  For the purpose of this thesis the author will follow the latter 
convention. 
By the latter convention, Levovist, Echovist‟s successor, is a second generation agent. 
This agent is also a galactose based contrast agent but with the addition of palmitic acid 
which acted as a shell stabilizer making the agent more stable.  Due to its improved 
stability, Levovist is widely used as a blood pool enhancer as it is able to withstand the 
higher pressures of the blood pool. 
Another second generation agent is Albunex (Mallinckrodt), these microbubbles are 
formed by sonication of albumin, and are air filled bubbles with a thin albumin shell, 
they have a mean diameter of 4µm (Cosgrove 1997).  Albunex was the first approved 
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UCA in the US for cardiac applications.  The bubbles have a short half-life of less that 
one minute and are very sensitive to pressure changes (Correas et al. 2001).  Albunex 
microbubbles are however no longer in production due to the introduction of more stable 
third generation contrast agents (Miller and Nanda 2004). 
Third generation contrast agents involve the use of low solubility gases, such as 
perfluorocarbons encapsulated inside either lipid or protein shells (although some agents 
defined as third generation contain air encapsulated by lipid or protein shells).  The low 
solubility gas takes longer to diffuse out of the shell than air and therefore increases the 
stability of the microbubble.  There are two main materials used to provide a stabilizing 
shell to these microbubbles, these are phospholipids and sonicated albumin.  Some of 
these third generation agents are detailed in Table 2-1. 
2.1.1. Producing microbubbles 
Methods of producing microbubble contrast agents include rapid agitation, stirring, 
sonication and mechanical techniques.  Sonication involves the application of sound 
waves in order to produce microbubbles; two contrast agents produced by sonication of 
human albumin include Albunex and PESDA (Perfluorocarbon-exposed sonicated 
dextrose albumin).  The latter is a third generation research agent and is formed by the 
sonication of albumin in the presence of a perfluorocarbon. 
Edinburgh University in-house microbubbles are a lipid-shelled contrast agent.  These 
microbubbles are produced by stirring the lipids during and after heating.  Due to the 
hydrophobic nature of the lipid tails (as illustrated in Figure 2-2a), when in the presence 
of a water solution, the tails will gather together to form small bubbles of air (micelles 
illustrated in Figure 2-2c) with the hydrophilic head sections of the lipids on the outer 
side.  Alternatively the hydrophobic tail sections may gather together in a lipid bi-layer 
as illustrated in Figure 2-2b.  The lipid bi-layer will then form a liposome (Figure 2-2d).  
The in-house microbubbles have been shown to form multilamellar liposomes in which 
there are many lipid bi-layers within the liposome, a multilamellar liposome can be seen 
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in Figure 2-2e and an image of the in-house multilamellar liposomal microbubble in 
Figure 2-3.  Stirring of the lipid suspension during the heating and cooling phases 
prevents larger bubbles from forming, thereby producing a suspension of microbubbles.  
Different methods have been investigated to increase the echogenicity of this agent and 
are discussed in depth in Chapter 3. 
 
Figure 2-2: Illustrating the: a, lipid molecule and the respective hydrophobic and hydrophilic 
moieties; b, a planar lipid bi-layer; c, a micelle with all the hydrophobic tails gathered in the centre; 
d, a liposome formed with a lipid bi-layer; e, a multilamellar liposome. 
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Figure 2-3: Electron micrograph image of the multilamellar in-house microbubble (courtesy of 
Professor J Ross). 
The commercial agent Definity/Luminity™ is formed by rapid shaking of the agent in 
the presence of perfluoropropane (Harvey et al. 2000).  This is achieved by use of the 
CapMix™ device which rapidly agitates small vials and is illustrated in Chapter 3.  
These microbubbles form in a similar manner to the in-house microbubble contrast 
agent. 
Less common means of contrast microbubble manufacture includes mechanical 
formation of microbubbles through gas injection, or through a mechanical high shear 
valve (double syringe needle) (Klibanov et al. 2004; Schneider et al. 2006).  Other 
methods proposed include micro-fluidization and milling (Cantrell 2000; Klibanov et al. 
2004).  However, the literature on these methods is limited. 
2.1.2. Interactions of Microbubbles with Ultrasound 
When an ultrasound field is incident on a microbubble, a range of interactions may occur 
including; reflection, refraction, scatter, absorption, oscillation or a combination of the 
five. 
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Reflection 
Reflection occurs when an acoustic wave is incident upon a boundary between two 
mediums of different acoustic impedances.  Acoustic impedance is characterised by the 
density and speed of sound through a medium as shown by Equation 2-1: 
cZ    
Equation 2-1: Acoustic impedance (Brown et al. 1999) 
Where Z = acoustic impedance, ρ = density and c = speed of sound. 
Since the acoustic pressures and velocities on either side of the boundary must be equal, 
yet must still satisfy the relationship in Equation 2-2 below, this gives rise to formation 
of a second sound wave in the first medium, this wave is known as the reflected wave 
which is illustrated in Figure 2-4. 
u
p
Z   
Equation 2-2: Pressure-velocity relationship of acoustic impedance. 
Where p is the acoustic pressure and u the velocity of sound through the medium. 
 
Figure 2-4: Reflection at a large boundary. 
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The greater the difference in acoustic impedance at a boundary, the greater the reflection 
observed.  Gases have an acoustic impedance of approximately 1×10
2
Pa·s·m-1 which is 
of an order of 10
3





 (Fields and Dunn 1973) (where 1Pa·s·m
-1
 is equal to 1rayl).  The 
reflection coefficient (R) is a function of the acoustic impendence of the different 
mediums (Z1 and Z2) and gives the percentage reflection at a boundary.  This is shown in 
















Equation 2-3: Reflection Coefficient. 
Refraction 
Refraction occurs when a wave meets a boundary of two different refractive indexes.  
The degree of refraction is dependent upon the incident angle of the wave.  Refraction in 
ultrasound imaging is a source of artefacts and is avoided and controlled where possible.  
Scatter 
Reflection, as described above occurs when the sound wave is incident on a boundary 
which is large relative to the acoustic wavelength.  When the sound wave is incident 
upon a boundary that is about the same size as the wavelength diffuse reflection is 
observed, where the sound waves are reflected at a range of angles.  If the boundary is 
very small relative to the wavelength Rayleigh scattering will take place (Brown et al. 
1999; Hoskins et al. 2002) this results in the reflection of the sound waves uniformly in 
all directions.  Red blood cells are 8-9μm (Brown et al. 1999) in diameter and therefore 
act as Rayleigh scatterers.  In addition, mediums which are non-uniform in density and 
stiffness will also cause scattering.  It is scatter that is predominantly observed in an 
ultrasound image.  Since microbubbles are of a size similar to red blood cells (5-10 μm) 
they also result in Rayleigh scattering. 
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Absorption 
When sound energy passes through a medium it can be absorbed by the molecules in 
that medium.  This happens when an energy transfer occurs and the sound energy is 
transferred to thermal energy or kinetic energy when the molecule vibrates.  Absorption 
of sound energy is dependent upon the frequency of the incident wave in addition to the 
properties of the material.  Attenuation of the ultrasound beam is largely caused by 
absorption. 
Oscillation 
If the radius of the bubble is significantly smaller than the wavelength of the incident 
ultrasound wave the bubble will begin to oscillate (Frinking et al. 2000). The degree of 
this oscillation is dependent upon the microbubble characteristics, such as the shell 
properties, gas contained and size, and also on the frequency of the ultrasound and the 
incident acoustic pressure.  It is a fortunate coincidence that microbubbles happen to 
resonate at the frequencies (1-40MHz) and pressures (0.45-3.80MPa (Barnett and 
Kossoff 1997)) utilized in diagnostic ultrasound (Cosgrove 2006; Harvey et al. 2000). 
Oscillations occur because the gas inside the microbubble is more compressible than the 
surrounding tissues and fluid, as a result the microbubble is able to expand and contract 
on insonation, in sympathy with the ultrasound wave.  The resonant frequency of the 
microbubble is inversely proportional to the radius and can be found in its simplified 












f   
Equation 2-4: free bubble resonance 
Where the resonant frequency is given by 0f , the bubble radius by r  and the ambient 
fluid pressure and density are given by 0P  and 0  respectively.  The symbol   is the 
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adiabatic ideal gas constant.  This equation is determined for a free gas bubble, more 
complex factors are involved when the microbubbles have a stiff stabilized shell and in 
this situation the equation must be modified to incorporate the surface tension of the 
shell, 






















Equation 2-5: Encapsulated microbubble resonance 
McDonald et al (2004) has also derived an equation for the microbubble resonant 
frequency which takes into account additional shell properties, the shell elasticity 





























Equation 2-6: MacDonald equation for encapsulated microbubble resonance frequency. 
This resonance response increases the backscatter from the microbubbles.  Backscatter is 
the most important factor in conventional fundamental imaging as this imaging mode 
relies upon backscatter echoes to generate images (Ophir and Parker 1989).  However, 
with new imaging modes now available the more complex microbubble behaviours are 
of greater interest. 
2.1.3. Mechanical Index 
The magnitude of the local acoustic pressure is a significant parameter when examining 
microbubble behaviour.  This factor is determined by the output pressure and attenuation 
of the ultrasound beam.  In order to characterize this pressure the mechanical index (MI) 
is a parameter used to estimate the output pressure of the transducer, it is commonly 
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used as a safety index (Duck 2008) as a threshold for potential of mechanical effects.  
The MI is the ratio of peak negative pressure (p-) (MPa) to the square root of the central 
frequency (fc) (MHz) as in Equation 2-7 (Frinking et al. 2000) it is a derated parameter 
and as such the parameter is deliberately stated as lower than its true value to take into 
account attenuation of the ultrasound beam. 
cf
p
MI   
Equation 2-7: Mechanical Index 
Depending upon the MI, the microbubble response can be divided into four different 
regimes, which are described as follows: 
MI < 0.1 
At this low acoustic power, the microbubbles oscillate linearly at the same frequency as 
the incident ultrasound beam.  Due to the impedance mismatch between the gas in the 
bubble and the surrounding medium, the microbubble acts as an extremely efficient 
scatterer, as mentioned above this is vital when using conventional imaging modes.  The 
scattering cross-section of a free non-encapsulated microbubble is given by Equation 2-8 










































Equation 2-8: Scattering cross-section 
Where   is the scattering cross section, k is the wave number of the acoustic field, r  is 
the radius of the bubbles, s  and   are the adiabatic compressibility of the scatterer and 
surrounding medium respectively and, s  and  , the densities of the scatterer and 
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medium respectively.  In order to take into account the backscatter from a collection of 
scatterers, a factor of N , where N  is the concentration of scatterers per unit volume 
should be included (Goldberg et al. 1994).  Additional considerations include the effect 
of a stabilized bubble where the boundary conditions of the microbubble become more 
complex this has been described by (Church 1995). 
Due to the low pressures applied to the microbubbles at this MI, there is little disruption, 
meaning that most of the microbubbles remain intact during the scan.  Therefore low MI 
imaging has applications in Doppler and fundamental imaging techniques if the agent 
produces an observable echo (Correas et al. 2001). 
MI: 0.1-0.5 
At higher insonating powers the microbubble interactions become more complex.  Due 
to the increase in pressure the contractions and expansions of the bubble begin to get 
larger, because the contractions of the bubbles are limited the expansions get bigger, 
leading to non-linear behaviour.  This non-linear behaviour gives rise to harmonic 
signals at multiples or fractions of the insonating signal frequency, this phenomena is 
discussed by (Correas et al. 2001; Cosgrove 2006).  These harmonic signals are unique 
to each type of microbubble and also enable the signal to be distinguished from that 
arising from soft tissue.  This is utilized very effectively with the harmonic imaging 
mode and pulse inversion imaging. 
MI ≥ 0.5 
When the MI reaches 0.5 or more, the incident pressure can be sufficiently high to cause 
microbubble disruption (Smith et al. 2007), dependent upon the microbubble shell 
properties.  This gives rise to a phenomenon known as stimulated acoustic emission 
(SAE) and many other factors which have in recent years been exploited through 
different imaging techniques (Fatemi and Greenleaf 1999).  Stimulated acoustic 
emission is used to describe the acoustic emissions observed when subjected to a 
localized oscillating force, such as an ultrasound field.  Microbubble disruption is also 
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being researched as a therapeutic tool both in thrombolysis therapy (Unger et al. 2001b) 
and also to enable drug or gene delivery to specific sites (Bekeredjian et al. 2005a; Liu et 
al. 2006; Tachibana and Tachibana 1999; Unger et al. 2001a). 
2.1.4. Microbubble phenomena 
Translation 
High-speed cameras (>10Mfps) provide a means of directly observing microbubble 
behaviour.  It has been observed that translations of microbubbles occurs both in the 
direction of the sound field and towards each other (de Jong et al. 2000a; Postema et al. 
2004b).  It is believed that microbubble translation in the direction of the sound field is 
caused by a primary radiation force which is the result of a pressure gradient occurring 
across the microbubble surface.  The primary radiation force has been investigated 
further in Chapter 9. 
Whilst primary radiation forces are attributed to the translation of microbubbles in the 
direction of the sound field, secondary radiation forces, caused by the varying pressure 
fields resulting from microbubble oscillation, can be attributed to the translation towards 
each other.  If the two microbubbles in question are both either above or below the 
resonant size, they will be attracted towards each other, however, if they oscillate out of 
phase, they will recede (Postema et al. 2004b).  Translation of microbubbles towards 
each other can lead to coalescence. 
Coalescence 
On occasions, during the expansion phase of the microbubbles oscillation, when two 
microbubbles lie next to each other, the pressure on the film between them increases to a 
point where it flattens and thins.  When the film reaches a critical thickness, usually 
about 0.1µm, the film between the bubbles ruptures and the bubbles coalesce.  
Microbubble coalescence has been observed by Yonemoto (2008) and Postema et al. 
(2004a).  This coalescence of microbubbles can pose a health issue; if it were to happen 
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in a small artery, of a size relative to the microbubble diameter, this could cause a 
blockage which, depending on the artery, could cause serious damage.  However the 
phenomena also has therapeutic potentials in drug and gene delivery (Postema et al. 
2004a; Postema et al. 2004b). 
Fragmentation 
The fission of microbubbles into smaller bubbles is known as fragmentation.  This was 
first observed with high-speed cameras in 2001 and Postema et al.(2002; 2004b) also 
captured images of this phenomenon using a fast framing camera and a high speed 
camera respectively.  Often the acoustical observations for fragmentation are coupled 
with microbubble destruction.  
Sonic Cracking 
Ultrasound incident upon a microbubble can cause defects in the microbubble shell 
causing gas to escape from the microbubble, this phenomena is known as sonic cracking.  
The exact mechanism behind this phenomenon is as yet unknown; it is thought to be due 
to tiny flaws in the microbubble shell which may cause some shells to crack whilst 
others remain intact. (Postema et al. 2004b). 
Jetting 
Jetting is the phenomena observed when a microbubble undergoes a rapid contraction 
near to a boundary.  Due to the boundary the collapse of the microbubble will be 
asymmetrical, which may lead to a high speed jet forming which projects through the 
bubble towards the boundary.  (Postema et al. 2004b). 
2.2. Ultrasound Imaging Techniques 
Initially, when the enhanced scattering properties from microbubbles were discovered it 
was thought that they would be used solely to increase the backscatter for fundamental 
(B-mode) and increase the sensitivity of Doppler techniques.  However, it was soon 
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determined that in order to get the optimum signal from contrast microbubbles other 
imaging techniques which capitalised on the non-linear properties of the microbubbles 
would give better contrast to tissue ratios in which the backscatter from the contrast 
agent is observably brighter than the observed scatter from surrounding tissue. Three 
techniques; harmonic imaging, pulse-inversion imaging and power modulation, were 
developed to image the contrast agents at low acoustic pressures thus reducing the 
disruption of the contrast microbubbles and thus allowing them to be imaged over a 
longer period of time. 
2.2.1. Fundamental Imaging 
This mode of imaging was commonly used in cardiology, in addition to imaging other 
parts of the body.  In fundamental imaging UCAs provided left ventricle opacification 
resulting in improved imaging of the endocardial border which enhanced detection of 
abnormalities in the wall motion (de Jong et al. 2000b; Frinking et al. 2000; Gramiak 
and Shah 1968).  Fundamental imaging is a low MI technique but is rarely used today 
due to the advent of improved imaging techniques.  In narrow vessels or areas of the 
body where the microbubble concentration is lower, this imaging mode is limited by 
tissue backscatter masking the grey-scale increase, this is known as a low contrast-to-
tissue ratio.  Therefore it is evident that other methods would be required to optimize the 
use of microbubbles in the presence of soft tissue.  These imaging techniques are based 
on specific microbubble properties. 
2.2.2. Harmonic Imaging 
Harmonic imaging employs the harmonic properties of tissue and microbubble contrast 
agents when in the presence of an ultrasound field.  As explained previously, when the 
microbubbles are in the presence of an ultrasonic field with MI greater than 0.1, they 
begin to undergo non-linear oscillations and produce harmonics at multiples or fractions 
of the incident frequency, most significantly the second harmonic (Correas et al. 2001; 
de Jong et al. 2000b; Frinking et al. 2000).  Similarly due to the non-linear elasticity of 
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tissue, it also demonstrates non-linear expansions and contractions which result in 
propagation of a second harmonic signal.  Browne et al. (2004) has shown that tissue 
harmonic imaging significantly improves the lateral resolution of ultrasound.   
Tissue harmonic signals increase with increasing acoustic pressure, so at low acoustic 
pressures (low MIs) the harmonic signal from the microbubbles will tend to be larger 
than that from the tissue, hence the harmonic signals received by the ultrasound can be 
used to distinguish the presence of microbubbles from tissue.  However, a narrow 
bandwidth is required in order to remove the contribution from the tissue signal which 
causes a loss of resolution, this results in a trade-off between the ability to detect 
contrast and the image resolution (de Jong et al. 2000b) as illustrated in Figure 2-5. 
 
Figure 2-5: Contrast harmonic imaging and transducer bandwidth. 
2.2.3. Pulse Inversion Imaging 
This imaging technique was developed to overcome the trade-off between the ability to 
detect contrast and image resolution.  In this mode a sequence of two pulses are 
transmitted, the second pulse being the same as the first but 180° out of phase.  If these 
pulses are both reflected from a linear reflector, when they are received the sum of the 
two reflected pulses is zero.  If there is a degree of non-linearity the sum of the two 
responses will not be zero and the remainder is related to the degree of non-linearity.  A 
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schematic of this imaging mode is shown in Figure 2-6.  Pulse inversion imaging is 
advantageous because it can operate over a wide bandwidth and therefore can be used 
without loss of resolution. (Correas et al. 2001; de Jong et al. 2000b; Frinking et al. 
2000). 
 
Figure 2-6: A schematic showing pulse inversion imaging; a, the sum of received pulses from a 
linear reflector and b, the sum of received pulses from a non-linear reflector such as microbubbles 
or tissue. 
Coded excitation has been used to improve the contrast to tissue ratio in ultrasound 
imaging and has been found to increase microbubble response by 10-13dB (Borsboom et 
al. 2003).  This technique involves excitation of the ultrasound using chirp sequences 
and results in enhanced axial resolution and bandwidth without the need for higher 
acoustic pressures (Oelze 2007).  However, despite some promise of improving non-
linear microbubble imaging Shen (2007)and Cheng (2007b) suggest that contrast to 
tissue ratio is consistently lower after excitation with pulse-inversion imaging. 
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In addition amplitude modulation has been shown to improve the contrast to signal ratio 
for pulse-inversion imaging (Eckersley et al. 2005).  In amplitude modulated pulse-
inversion imaging the second pulse is both phase and amplitude modulated.  This 
increases the sensitivity of the imaging technique to non-linear scatterers and was shown 
to improve the signal by 4dB on combination of the two techniques (Eckersley et al. 
2005). 
2.2.4. Subharmonic Imaging 
The second harmonic nature of microbubbles is exploited in harmonic imaging, 
however, as well as producing a second harmonic when undergoing non-linear 
oscillations the microbubbles also emit a subharmonic component (Forsberg et al. 2000); 
these are at half of the transmitted frequency.  The advantages of subharmonic imaging 
are described by Dollet et al. (2008) and Shi et al. (1999) and these are given below: 
 Subharmonic imaging displays a better contrast-tissue ratio as tissues do not 
generate sub-harmonic signals. 
 It gives a stronger signal than higher harmonics for high frequency ultrasound. 
 It is less sensitive to attenuation and non-linear propagation. 
Since subharmonics produces a stronger signal with high frequency ultrasound it is 
commonly used in conjunction with intravascular ultrasound (IVUS) (Shi et al. 1999).  
Goertz et al. have demonstrated potential use of subharmonics for vasa vasorum imaging 
with IVUS (Goertz et al. 2007).  However subharmonic imaging has lower spatial 
resolution. 
2.3. Microbubble Targeting 
There have been many advances in the field of ultrasound contrast agents in recent 
years.  The concepts of targeting microbubbles to specific tissues within the body and 
the delivery of drugs or genes to specific sites show great promise in both diagnostic 
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(DeMaria et al. 2006; Klibanov 1999; Klibanov et al. 1999) and therapeutic domains 
(Liu et al. 2006; Tsutsui et al. 2004). 
The requirements for a targeted microbubble were outlined by Klibanov (1999) as 
follows: 
 The microbubbles should be able to arrive at, and flow through the target site. 
 They should remain stable long enough to circulate and accumulate at the target 
site and also remain stable for the duration of the ultrasound examination. 
 The microbubble – target binding should be firm enough to withstand shear 
stresses from the blood flow. 
 They should provide a high target to background ratio in a short space of time. 
 The total amount of contrast agent required should be small. 
The shear stresses applied to the microbubbles whilst attached to the target are an 
important factor to consider when developing attachment mechanisms.  A study of these 
shear stresses and the affect of relatively low shear stresses (3.4Pa) on targeted 
microbubbles has been carried out by Butler et al. (2005) who showed that a 
streptavidin-biotin bond can withstand physiological WSS in normal humans.  
2.3.1. Targeting methods 
Different targeting mechanisms are illustrated in Figure 2-7.  Targeting can be achieved 
through either electrostatic (Figure 2-7a) or chemical (Figure 2-7b) attachment 
properties of the microbubble itself, for example, albumin and certain lipid shelled 
microbubbles are retained within the microcirculation of damaged and inflamed tissue 
(Lindner 2002a; Lindner et al. 1998).  Another method of attachment can be through 
incorporating either ligands or antibodies in the surface of the microbubble (Figure 2-7c, 
d and e) which will attach to specific biological markers on the surface of cells.  There 
are a variety of ways to achieve this but two of the most commonly employed are 
ligand-binding and antibody-antigen binding. 
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Figure 2-7: Targeting of microbubbles to a receptor coated surface, a, via electrostatic forces, b, via 
chemical interactions with microbubble shell, c, attachment of antibodies or ligands directly to 
microbubble shell, d, attachment of antibodies or ligands via a PEG spacer arm and e, attachment 
of antibodies or ligands via a streptavidin-biotin bridge (Lindner 2002b). 
Ligands and Antibodies 
A ligand is a molecule which binds specifically to cell receptor sites, in biological 
applications this allows for cell to cell recognition.  Ligands have been used for targeting 
of microbubbles by Unger (2004) and Lindner (2002a). An antibody consists of a Y-
shaped protein produced by the body to neutralize bacteria and viruses (4-Antibody 
2009), each different type of virus and bacteria has an individual antigen and each 
antigen has a corresponding antibody.  Antibody targeting of UCAs has been 
demonstrated by Korosoglou et al (2006) and Della Martina (2007).  Occasionally 
however antibodies can lead to an unwanted immune response (Parham 2004).  Ligands 
have the advantage because they are less bulky than antibodies making them easier to 
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attach to the microbubbles.  Finally antibodies are not stable during storage and the 
processes (Klibanov 1999) involved in producing microbubbles can cause them to 
become inactive.  However, antibodies do hold some advantages, there are a variety of 
them available against a range of antigens, and the affinity of the antibody-antigen 
interaction is high (Klibanov 1999).   
2.3.2. Targeted Microbubble Preparation 
The targeting ligands or antibodies to be attached can be added to the microbubbles 
before or after they have formed, the time-point at which they are added depends on the 
stability of the ligand or antibody during the microbubble production. 
A range of attachment methods as described by Klibanov (Klibanov 1999) and Linder 
(Lindner 2002b) are illustrated in Figure 2-7 and described below: 
 Proteins incorporated into the microbubble shell can covalently bind to the 
ligands. 
 An „anchor protein‟ can be incorporated into the microbubbles shell which the 
ligand can be attached to later. 
 An avidin-biotin arm can be introduced to facilitate non-covalent bonding of the 
ligand. 
It is important to purify the microbubble preparation at various stages during production 
to remove all constituents which are not incorporated in the shell as otherwise they can 
provide ligand binding sites and when the contrast agent is in use these „loose‟ ligands 
can block the binding site.  Other factors to take into account regarding binding ability 
of the microbubbles are their ability to come into direct contact with the target surface, 
the shear stress applied to the vessel wall by the flowing blood, and also the number of 
ligand-receptor pairs formed and the affinity (strength) of the interaction.  It is thought 
that the incorporation of a spacer arm, for example in the avidin-biotin formation can 
facilitate attachment of the ligands to the target site as the ligands have some flexibility 
and therefore more ligands will be able to attach to the site (Klibanov 1999). 
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Uses of microbubble targeting already under study include the attachment of 
microbubbles to thrombi, for which the ligands involved are targeted to platelet 
glycoprotein 11b/111a Integrin which accumulates at sites of thrombi, this particular 
application also has a therapeutic advantage as the attachment  of microbubbles to the 
thrombus can cause clot lysis (Lindner 2002a).  In addition to targeting thrombi, it has 
also been shown that inflammation can be targeted as albumin and certain lipid shelled 
microbubbles are retained within the microcirculation of injured and inflamed tissue as 
there are interactions between these microbubbles and activated leukocytes.  Targeting 
of dysfunctional endothelium has also been demonstrated by (Weller et al. 2002).  Other 
potential applications of targeted microbubbles include assessment of malignant tumours 
and diseased tissues (Dai et al. 2006; Kaufmann and Lindner 2007; Lathia et al. 2004; 
Migaleddu et al. 2009). 
2.3.3. Therapeutic Ultrasound 
There are many potential therapeutic applications of ultrasound (ter Haar 2007).  
Thrombolytic therapy (Tachibana 2004), which is already a well established treatment, 
and tissue repair (Jackson et al. 1991) are just two of the more commonly explored 
areas.  These methods have been studied and improved over many decades.  However, in 
more recent times, therapeutic ultrasound has become a more complex field due to the 
discovery and advancement of microbubbles as a contrast agent. 
Ultrasound has been thought to increase cell permeability (known as sonoporation) 
(Dijkmans et al. 2004) which can help drugs and genes injected into the body pass the 
cell membrane barrier. It is also believed that ultrasound can aid thrombolysis, the break 
up of thrombolytic clots, and therefore has an application in treating Deep Vein 
Thrombosis among other conditions which cause or are caused by thrombi (Dijkmans et 
al. 2004).  Ultrasound has also been shown to encourage transdermal drug delivery 
(delivery of drugs through the skin such as nicotine or oestrogen patches) (Tachibana 
and Tachibana 1999). 
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The presence of contrast microbubbles can improve the therapeutic effects of ultrasound 
(Tachibana and Tachibana 1999).  The key mechanism believed to produce this 
enhancement is microbubble destruction (Bekeredjian et al. 2005b; Stride and Saffari 
2003b), although it has been suggested that simply the presence of microbubbles 
provides some enhancement.  Microbubbles can also be used as vehicles to carry drugs 
or genes through the body and if targeted, to specific sites (Lanza and Wickline 2001; 
Liu et al. 2006; Unger et al. 2004). 
Ultrasound targeted microbubble destruction (UTMD) 
The mechanisms involved in microbubble destruction (Bekeredjian et al. 2005a; 
Tachibana and Tachibana 1999; Unger et al. 2001a) which may enhance the delivery of 
drugs incorporated into the microbubbles include: 
 Pore formation which occurs after microbubble destruction 
 Inertial cavitation in which micro-jets can be formed which can help to penetrate 
cell membranes 
 Secondary shock waves as a result of inertial cavitation can cause high local 
temperatures and high shear stresses which may aid drug or gene delivery to 
cells. 
The advantages of delivering drugs or genes via UTMD are threefold; firstly the drug or 
gene vectors can be delivered directly to the target region and can result in a higher 
concentration in the focal area, secondly by transporting the drugs and gene vectors 
encased in the encapsulated bubbles the effect on healthy tissues are limited and 
therefore more powerful drugs can be used, finally destruction of the microbubbles can 
enhance the delivery of the drug or gene into the target cells. 
UTMD has also been shown to produce therapeutic effects without any transported 
substances.  This is through heating effects produced by inertial cavitation, microjetting 
and other microbubble phenomena described earlier.  The use of UTMD in thrombolysis 
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has been shown in dogs (Culp et al. 2003).  It has also been suggested that UTMD in 
skeletal muscle can induce arteriogenesis (Bekeredjian et al. 2005b). 
Production of drug or gene loaded microbubbles 
Unger (2001a; 2001b), Dijkmans (2004) and Liu (2006) have all described the variety of 
ways in which drugs or genes can be attached to microbubbles.  These are illustrated in 
Figure 2-8 below. 
 
Figure 2-8: Ways of incorporating drugs or genes into microbubbles. 
2.4. Safety 
2.4.1. Ultrasound 
Ultrasound is one of the safest imaging procedures due to the fact that an ultrasound 
examination does not involve the use of ionising radiation.  However, despite this, 
ultrasound, especially when contrast agents are used, can pose some degree of risk to the 
patient and this must be assessed carefully. 
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As the output power of the ultrasound is increased the theoretical risk to the patient is 
increased.  An increase in output power will result in an increase in the local acoustic 
pressure which can cause cavitation effects or cellular damage (Clinical Safety 
Statement for Diagnostic Ultrasound 2006; Church 2002; Duck 2008; Singh 2007).  The 
MI, as described in Section 2.1.2, is used to provide a safety reference number for the 
acoustic output of the ultrasound system and guidelines as to the use of MI in routine 
ultrasound examinations are provided by the British Medical Ultrasound Society 
(BMUS) and displayed in Table 2-2 (BMUS 2006). 
 
MI> 0.3  
There is a possibility of minor damage to neonatal lung or intestine. If 
such exposure is necessary, try to reduce the exposure time as much as 
possible. 
MI> 0.7 
There is a risk of cavitation if an ultrasound contrast agent containing gas 
micro-spheres is being used. There is a theoretical risk of cavitation 
without the presence of ultrasound contrast agents. The risk increases 
with MI values above this threshold. 
TI> 0.7 
The overall exposure time (including pauses) of an embryo or foetus 
should be restricted in accordance with maximum recommended 
exposure times for a foetus. 
TI> 1.0 Eye scanning is not recommended, other than as part of a foetal scan. 
TI> 3.0 Scanning of an embryo or foetus is not recommended, however briefly. 
Table 2-2: BMUS ultrasound safety parameters. 
The heating effects of ultrasound must also be considered in relation to the safety of an 
ultrasound examination.  As an ultrasound beam is attenuated by soft tissue this will 
cause an increase in local temperature which could lead to cellular damage.  A thermal 
index (TI) is used to quantify the degree of heating and BMUS guidelines for TIs are 
outlined in Table 2-2 above. 
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Provided the acoustic outputs and MI and TI are considered carefully and the 'as low as 
reasonably acheivable' (ALARA) principle is adhered to when an ultrasound 
examination is being planned the use of ultrasound as a non-invasive imaging technique 
is considered safe (BMUS 2006; ECMUS 2008). 
2.4.2. UCAs 
The safety effects of UCAs must also be carefully considered.  These issues have been 
discussed by various authors (Bekeredjian et al. 2005b; Correas et al. 2001; Duck 2008; 
ECMUS 2008; Harvey et al. 2000; Stride and Saffari 2003a).  UCAs have to date had a 
good safety profile when used with recommended clinical parameters for acoustical 
energy and microbubble concentration (Alvarez Sanchez et al. 2009; Dolan et al. 2009), 
although minor reactions include warm facial sensations, alteration of taste and general 
flush in about 1-5% of examinations (Correas et al. 2001), adverse reactions which can 
involve allergic reactions, chest pain, headache and nausea are very rare although they 
have been documented (Dijkmans et al. 2005).   
Prior to being approved, a UCA must undergo extensive clinical trials as outlined by the 
Food and Drug Administration (FDA) in the US (Federal Food, Drug, and Cosmetic Act 
(FD&C Act) 2005) and by the Medicines and Healthcare Products Regulatory Agency 
(MHRA) in the UK (MHRA 2008) to ensure that there are no serious toxicological 
effects related to their use, the beneficial affects of their application must outweigh any 
deleterious effects. 
Despite the excellent safety profile of UCAs with regards to toxicological effects there 
are significant bioeffects related to the use of microbubbles in ultrasound examinations.  
These bioeffects can be due either to thermal effects of UCAs or non-thermal effects.  
Although previously the localized heating due to UCAs was thought to be acceptable 
and non-damaging for low power US (Hilgenfeldt et al. 2000), these investigations were 
only carried out for free microbubbles.  Stride et al (2004) has considered the effect of 
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an encapsulating shell on thermal effects of contrast agents and shown that the 
encapsulated microbubbles may pose a greater risk of thermal damage.   
One significant bioeffect from both thermal and non-thermal effects, is cellular 
membrane damage which can be caused by sonoporation, this has been observed by 
Miller et al. (2004).  Williams et al (2007) has similarly observed nephron damage in rat 
kidneys with the use of microbubble UCAs. Damage to cellular membranes can result in 
cell lysis (cell death) (Samuel et al. 2006). 
Dalecki et al (2007) has described other bioeffects which have been observed with the 
use of UCAs.  These include hemolysis (Dalecki et al. 1997), damage to the 
microvasculature (Miller and Gies 1998) and effects on cardiac rhythm (Dalecki et al. 
2005), all of which could be potentially harmful to a patient. 
Due to the potential harm of UCA bioeffects they continue to be studied in depth.  
However, to date there have been minimal deaths associated with the use of UCAs 
(Main et al. 2009) and the benefits of using UCAs is still believed to significantly out-
weigh the risks (Dolan et al. 2009). 
2.5. Summary 
UCAs are a useful tool in both the diagnostic and therapeutic fields of ultrasound.  
Diagnostically contrast agents can enhance conventional ultrasound scans and also 
provide scope for the development of new and improved imaging modes such as 
harmonic and sub/super harmonic imaging. In addition, targeting of the microbubbles 
can enable imaging of specific conditions such as endothelial inflammation or the 
presence of thrombi in blood vessels.  Therapeutically, UCAs can provide a vehicle for 
the transport of drugs and genes and be delivered to specific sites through targeting, and 
microbubble phenomena such as jetting and inertial cavitation can encourage the uptake 
of these substances.  Unloaded microbubbles can also be used to promote thrombolysis 
and angiogenesis.   
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Through researching the various microbubble phenomena scientists have been able to 
improve ultrasound as both a diagnostic and therapeutic tool.  Because of the rarity of 
adverse reactions to the agents, ultrasound contrast imaging has proved to be a safe 
option for improving diagnostic imaging techniques and the therapeutic effects may in 
time be developed to deal with many diseases and conditions. 
Future possibilities for the use of ultrasound contrast agents include diagnosis and 
treatment of inflammatory conditions such as irritable bowel syndrome or Crohn‟s 
disease, and also for the detection and treatment of malignant tumours among the 
already used techniques such as thrombolysis and angiogenesis.  In addition specific 
targeting of UCAs may help to determine the extent of vulnerable plaque formation in 
coronary heart disease which is the focus of this thesis. 
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Chapter 3 Optimization of a Novel, Lipid-
Based, Microbubble Ultrasound Contrast 
Agent for High Frequency Ultrasound 
The in-house microbubble contrast agent has been developed by the University of 
Edinburgh (Butler 2005; Moran et al. 2006).  The microbubble has been developed to be 
targeted to atherosclerotic plaque within the coronary arteries as a method of identifying 
vulnerable plaques in coronary heart disease as described in Chapter 1.  Attachment of 
the in-house microbubble to vulnerable plaque will be achieved by incorporating 
antibodies or peptides which target inflammatory sites such as those exhibited in 
vulnerable atherosclerotic plaques (Lindner 2001, 2002a).  A variety of methods have 
been employed to maximize the echogenicity of the agent with high-frequency IVUS 
imaging: 
 Sonication 




 Varying the chemical composition of the shell 
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3.1. Production of In-house UCA 
Previously the in-house UCA has been produced using a solvent method (Moran et al. 
2006), this has since been adapted for production of the agent without the use of 
solvents.  The current standard procedure for producing the in-house microbubble 
involves combining a selection of lipids in the quantities outlined in Table 3-1, hydrating 
the lipids for a period of two hours, whilst stirring, and then heating the lipids to 78°C 
for one hour.  The suspension is then allowed to cool overnight with continued stirring 
(Ross and Moran 2006). The lipids used in the production of the in-house contrast agent 
include phosphatidylcholine (PC), cholesterol (CHOL), phosphatidylethanolamine (PE), 
phosphatidlyglycerol (PG) and a biotinylated phospholipid (BIOTIN) the latter is 
incorporated for targeting purposes. 
 
Bubble type 
Quantity of constituent (mg) per 4ml saline 
PC CHOL PE PG BIOTIN 
70% PE/1% Bio 18 10 70 1 1 
45% PE/5% Bio 30 18 45 2 5 
1% Biotin 55 30 11 3 1 
3% Biotin 53 30 11 3 3 
5% Biotin 56 30 6 3 5 
15% Biotin 52 30 - 3 15 
20% Biotin 47 30 - 3 20 
70% PE 19 10 70 1 - 
30% CHOL* 56 30 11 3 - 
60% PC 60 30 8 2 - 
Table 3-1: Various in-house microbubble compositions (* standard composition) 
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3.2. Assessment of In-house UCA 
Assessment of the in-house UCA was carried out through qualitative and quantitative 
analysis of the backscatter (echogenicity) produced by a sample of microbubbles, 
visualization under a high power microscope and measurement of the size distribution of 
each sample of microbubbles. 
3.2.1. Echogenicity 
The echogenicity of a sample was assessed using a 40MHz Atlantis™ SR Pro coronary 
imaging catheter in combination with a Clearview IVUS scanner (Boston Scientific, US) 
as described in Chapter 5.  In order to assess the echogenicity of a sample IVUS images 
were captured and the mean backscatter from a ROI in each sample was calculated. 
IVUS images were captured by a PC linked to the scanner via a video out cable.  Images 
on the screen were then captured using a Matrox Intellicam (Matrox Imaging, Canada) 
program and saved. 
In order to quantify the echogenicity of the microbubble samples it was necessary to 
eliminate the effects of transducer and scanner set up, as each transducer and scanner 
combination is unique.  Radio frequency (RF) data was collected in order to avoid the 
effects of signal processing by the scanner and compared to the RF data from a perfect 
reflector in order to eliminate unavoidable variations in the scanner and transducer set-
up. 
The RF data was captured by a digitizing card (Gage Applied CS8500, Gage Applied 
Technologies, Lachine, Canada) added to the PC linked to the RF-Out socket on the 
IVUS scanner.  RF line data was captured, 8 bits at 250Msamples per second, for each 
microbubble sample.  The optimum sampling frequency (fs) can be found with Equation 
3-1, where B is the maximum signal frequency (60MHz).  Optimal smapling frequency 
must therefore be greater than 120Msamples per second. 
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Bf s 2  
Equation 3-1: Sampling frequency 
The data was then analysed using a program previously written for this purpose by Dr. 
Robin Watson (Medical Physics, University of Edinburgh) in IDL (ITT Visual 
Information Solutions, USA).  Analysis was performed by comparing the echo in a 
region of interest (ROI) (2mm from the image centre) to the echo received from a 
perfect reflector at the same distance; the software pathway is described in Appendix B.  
For the purpose of this investigation the perfect reflector was an air-water interface, the 
signal from which was collected after each contrast agent measurement session and is 
described more fully in Appendix C.  The perfect reflector does not demonstrate the 
observed increase in backscatter relative to a clinical scenario, however the perfect 
reflector is easily reproducible and enables a comparison of the variation in mean 
backscatter from different microbubble samples.  Tissue mimicking material (TMM) has 
been produced and compared to the mean backscatter from the microbubbles in the 
stability trials and can be seen in Figure 3-14. 
Three ROIs were analysed for each microbubble sample so that an average backscatter 
power for the whole image could be calculated.  All errors presented throughout this 
chapter are one standard deviation of three different microbubble samples unless 
otherwise stated.  Figure 3-1 illustrates a region of interest at line 100.  Features of the 
IVUS image and scan converted images are described in Chapter 5 and Appendix B 
respectively. 
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Figure 3-1: ROI at line 100, distance 660 (approx 2mm from transducer) on a scan converted IVUS 
image reconstructed from RF data. 
The mean backscatter, in addition to other parameters, was then printed to a text file 
which could be opened in Microsoft Excel (Microsoft Corporation, USA) to compare the 
numerical backscatter for each sample. 
3.2.2. Optical imaging of microbubbles 
The microbubbles were optically imaged using bright-field microscopy with a Leica 
DMIRB fluorescence microscope (Leica Microsystems, UK).  Objective lenses used 
include; 10x with a numerical aperture of 0.25 and 40x with a numerical aperture of 
0.55, the eyepiece of the microscope had 10x magnification and a numerical aperture of 
0.22.  Microscopic images were captured in Openlab (Improvision, UK) using a 
Hamamatsu C4742-95 digital camera (Hamamatsu Photonics UK) connected to a 
Macintosh computer (Apple Inc, USA). 
3.2.3. Sizing of microbubbles 
A Malvern Mastersizer (Malvern Instruments, UK) was used to acquire the size 
distributions.  This is achieved through measuring the diffraction pattern of a beam of 
laser light as it passes through a sample.  In addition to the size distribution, this 
technique provides a value for the median microbubble size.  The Malvern Mastersizer 
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can be seen in Figure 3-2.  Predicted optimal microbubble size can be found in 
Appendix A. 
 
Figure 3-2: Malvern Mastersizer 
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3.3. Optimization Techniques 
A variety of techniques have been investigated in order to determine the optimal 
production method of the microbubble UCA: 




 Addition of mannitol or trehelose 
 High temperature production 
 High shear mixing 
The echogenicity of the microbubbles was also investigated over initially a 24 hour 
period and then a 3 month period to observe variations with time.  Microbubble samples 
were characterized within one week of production and all trials were carried out with a 
minimum of three samples being assessed, with the exception of the three month time 
trial (section 3.3.2) for which only one of each sample was assessed due to time 
limitations and the large quantity of microbubbles required. 
In addition to the effect of agitation on the size and echogenicity of the microbubble 
samples the length of agitation was investigated. 
3.3.1. Composition comparison 
Three of the different compositions as outlined in Table 3-1 were compared for 
echogenicity; this included the 70% PE, 30% cholesterol and 60% PC compositions.  
These compositions were chosen as they make the basis of all the other compositions, 
except for the biotinylated agents.  The effect of biotin on the echogenicity of the agent 
has previously been investigated by Butler et al. (Butler 2005) and found to have no 
effect. 
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3.3.2. Stability Trials 
In order to determine if the agent could be produced in advance of studies and stored 
until required, an investigation into deterioration of the agent was carried out.  The 
initial investigation involved measuring the echogenicity and size of samples of standard 
and agitated 30% cholesterol microbubbles at intervals over a 24 hour period.  A 
suspension was produced the day before investigation and left to cool and stirred 
overnight.  The echogenicity was then investigated at fifteen minute intervals for the 
first hour and then hourly intervals for eight hours.  The following day a measurement 
was collected at 24 hours after the agent had been removed from the hotplate.   
The second stability trial involved a study of the agent‟s echogenicity over a three month 
period to assess the shelf life and optimum storage of the agent.  A 32ml suspension of 
microbubbles was produced and split into four vials of 8ml.  One of the samples was 
produced in the manner outlined above, one sample was agitated (see section 3.3.3) and 
one sample was sonicated, these samples were refrigerated.  The final sample was 
agitated and stored at room temperature for the period of investigation. 
All four samples were measured once a week and the size distribution of the samples 
were measured every four weeks. 
3.3.3. Agitation 
Agitation of the agent was achieved through use of the CapMix (3M ESPE AG, 
Germany) device illustrated in Figure 3-3.  The agent to be agitated was transferred to a 
suitable vessel and agitated, initially, for 45s.  Preliminary investigations assessed the 
difference in echogenicity and size distribution of a control and agitated sample of 
microbubbles.  Further studies encompassed a comparison of agitation of the 
microbubbles directly after the heating stage of production and agitation after the 
cooling stage.  A final investigation was carried out into how the length of agitation 
effects the microbubble population. 
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Figure 3-3: CapMix device 
3.3.4. Sonication 
A MSE Soniprep 150 bench mounted ultrasonic disintegrator (Sanyo, Japan) was used to 
sonicate microbubble samples using the exponential microprobe.  The tip of the 
microprobe was placed centrally within the sample using markings on the probe and the 
suspension was sonicated for 45s.  An initial comparison between sonicated, agitated 
and control samples was carried out followed by an investigation into the effect of 
sonication directly after the heating stage.  The Soniprep 150 device can be seen in 
Figure 3-4. 
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Figure 3-4: MSE Soniprep 150 (Sanyo, Japan) 
3.3.5. Diffusion 
Diffusion was investigated as a method to increase the gas content of the microbubbles.  
To achieve this nitrogen gas was bubbled through the microbubble suspension via a 
small diffusion stone for two hours after the suspension had been heated as illustrated in 
Figure 3-5.  Half of the sample was then agitated and then compared to a control sample. 
 
Figure 3-5: Diffusion of nitrogen gas through a microbubble suspension. 
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3.3.6. Addition of Mannitol or Trehelose Sugars 
Mannitol and Trehelose had previously been incorporated into the solvent production 
method of producing the in-house microbubble contrast agent (Moran et al. 2007).  
Mannitol and Trehelose are sugars which are known to stiffen the microbubble shell 
when incorporated into the mixture (Ross and Moran 2007).  Initial trials involved 
adding 5%, by weight, of mannitol or trehelose to the dry lipid mixture.  Further studies 
involved adding 10, 15 and 20% of mannitol or trehelose to the dry lipids and comparing 
this to a control sample. 
3.3.7. High Temperature Production 
In some of the previous samples which were produced crystalline structures were 
observed under the microscope within the microbubble samples.  The author and 
colleagues believed the formation of the crystals to be due to the production temperature 
being below the transition temperature for one of the lipids.  As a result of this 
consideration it was decided that an investigation into different production temperatures 




Temperature ranges were maintained by continuous observation of the water bath 
temperature during the one hour heating period. 
3.3.8. High Shear Mixing 
Mechanical mixing has previously been used to produce microbubble suspensions by a 
number of researchers (Klibanov et al. 2004; Schneider et al. 2004; Schneider et al. 






, Germany) hand-held high shear homogenizer 
was used to provide high shear mixing to the microbubble suspensions, Figure 3-6 
shows the homogenizer dipped into a microbubble suspension.  The homogenizer was 
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used to combine the lipids in the saline during the hydration phase at a low speed setting 
for 60s to disperse the lipids evenly prior to heating.  In addition the homogenizer was 
used on three different samples after the heating stage to encourage formation of smaller 
microbubbles.  The results from both investigations were then compared to a control 
sample. 
 
Figure 3-6: High shear mixing of a microbubble suspension using a homogenizer. 
3.4. Results 
3.4.1. Composition Comparison 
Figure 3-7, shows the IVUS images of the three different microbubble compositions 
investigated.  From these images it is evident that the 70% PE composition produces the 
least echogenic sample and that the 30% cholesterol sample is the most echogenic.  This 
is verified in the quantified data shown graphically in Figure 3-8 where 0dB represents 
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Figure 3-7: IVUS images of a, 30% cholesterol composition; b, 60% PC composition and; c, 70% PE 
composition of microbubbles. 
 
Figure 3-8: Bar chart illustrating the average, mean backscatter of the different microbubble 
compositions. 
The size distributions of each different composition of microbubble are illustrated in 
Figure 3-9, where it can be seen that the 60%PC sample produces a narrow size 
distribution with the lowest median microbubble diameter, this is verified by the 
microscopic images seen in Figure 3-10 which show the variation in microbubble sizes 
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for each sample.  Mean microbubble sizes for the 30% cholesterol, 60% PC and 70% PE 
composition microbubbles were 11.9(±3.4)µm, 7.4(±3.0)µm and 28.2(±14.3)µm 
respectively. 
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Figure 3-10: Microscopic images of different microbubble compositions (x40 magnification; scale 
bars equal to 25μm). 
Due to the more echogenic nature of the 30% cholesterol microbubble composition it 
was used in further optimization trials despite having a slightly larger microbubble 
diameter and wider size distribution. 
3.4.2. Stability trials 
Initial time trials were carried out over a 24 hour period to assess any variations in 
echogenicity over this time.  Figure 3-11 and Figure 3-12 illustrate the echogenicity and 
median microbubble sizes respectively within the first 24 hours after production.   
 
Optimization of a Novel, Lipid-based, Microbubble Ultrasound Contrast Agent for High 
Frequency Ultrasound  94
  
 
Figure 3-11: Mean backscatter produced by standard and agitated microbubble samples over 24 
hours. 
 
Figure 3-12: Mean microbubble size at 1, 7 and 24 hours after production of a standard and 
agitated microbubble sample. 
Over the initial 24 hour time period the microbubbles showed a 2% variation in 
echogenicity and 1.5% variation in size, it was therefore decided that an investigation 
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over a longer time period was necessary in order to determine the shelf life of the in-
house microbubble UCA.  Figure 3-13 illustrates the size distributions at 1, 7 and 24 
hours after production also suggesting very little variation. 
 
Figure 3-13: Microbubble size distributions at 1, 7 and 24 hours after production for agitated and 
control microbubble samples. 
Figure 3-14 and Figure 3-15 show the variation in echogenicity and median microbubble 
size over a three month period for four different microbubble samples.  This data 
suggests that with the exception of the control sample stored at room temperature the 
echogenicity shows a slight increase over fourteen weeks.  Similarly, the average 
microbubble diameter over the fourteen weeks shows less than 1μm variation for the 
control and agitated refrigerated samples but increases by 15.7μm over the 14 weeks for 
the microbubble sample stored at room temperature.  The increased microbubble 
diameter is thought to be due to coalescence of the microbubbles at room temperature. 
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Figure 3-14: Echogenicity of the in-house UCA over a three month period (no error bars present as 
only one investigation was possible due to time and material constraints), TMM - tissue mimicking 
material. 
 
Figure 3-15: Average microbubble diameter over a three month period. 
In light of the results collected and illustrated above the microbubbles should be stored 
in the refrigerator and can be used for up to three months after production provided no 
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other signs of deterioration are visibly evident on use.  Some samples presented mould 
or coagulation after long periods of un-use and were therefore discarded. 
3.4.3. Agitation and Sonication 
The mean backscatter produced by the agitation or sonication of the in-house UCA is 
compared to a control sample in Figure 3-17 below.  This data shows that there is a 
slight increase in echogenicity of the samples on agitation and sonication with agitation 
producing the largest increase of 3.9(±1.0)dB.  This is supported by the IVUS images 
seen in Figure 3-16. 
 
Figure 3-16: IVUS image comparison of; a, control; b, agitated and c, sonicated samples. 
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Figure 3-17: Echogenicity comparison of agitated, sonicated and control microbubble samples. 
The microbubble size distributions are shown in Figure 3-18 below.  Agitation and 
sonication of the samples produces very similar size distributions which are narrower 
than the control sample.  Due to the narrower size distribution and 3.9(±1.0)dB increase 
in echogenicity, agitation will be used in production of future microbubble samples.  
Figure 3-19 shows the microscopic images of the three samples.  Optically measured 
microbubble sizes are comparable with the size distributions produced by the Malvern 
Mastersizer. 
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Figure 3-18: Microbubble size distributions, agitation and sonication comparison. 
 
Figure 3-19: Microscopic images of control, agitated and sonicated microbubble samples. 
If agitation is to be used to optimize future microbubble samples it is important to know 
the optimum agitation time.  Figure 3-20 shows the mean backscatter produced by 
varying the time that a sample is agitated from 15s agitation to 240s.  It is important to 
note that although there is an initial increase in the echogenicity from agitating the 
sample there is also a steep decline in the echogenicity if the agitation time exceeds 60s.  
The microbubble size distributions, as seen in Figure 3-21, show that the average 
microbubble size decreases with agitation time.  
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Figure 3-20: Mean backscatter produced by varying agitation time. 
 
Figure 3-21: Size distributions produced by different agitation times. 
The above data suggests that the optimum agitation time for the in-house microbubble 
UCA is 45s. 
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3.4.4. Diffusion 
The microbubble samples were diffused with nitrogen gas directly after the heating 
stage.  It was found that this diffusion technique did slightly increase the echogenicity of 
the microbubble suspension by 1.6(±1.2)dB, and agitation of the diffused sample 
produced an increase in the mean backscatter of 3.0(±1.5)dB.  This data can be seen in 
Figure 3-22 below.  However the size distribution data in Figure 3-23 shows that 
diffusion of the microbubbles alone produces a wide size distribution with two peaks, 
suggesting that up to 50% of the microbubble suspension has a diameter greater than 
20μm.  For this reason if diffusion was to be used as a method to optimize the 
microbubble suspension it would be important to agitate the sample after diffusing to 
maintain a narrow size distribution with a small average microbubble diameter in order 
for the UCA to be used in vivo. 
 
Figure 3-22: Mean backscatter produced by diffusing microbubble suspension with nitrogen, 
compared with a control sample. 
 
Optimization of a Novel, Lipid-based, Microbubble Ultrasound Contrast Agent for High 
Frequency Ultrasound  102
  
 
Figure 3-23: Microbubble size distributions for control, diffused and agitated samples. 
3.4.5. Addition of Mannitol or Trehelose Sugars 
With the exception of some anomalies the addition of mannitol and trehelose to the 
microbubble composition did not appear to significantly improve the echogenicity of the 
microbubbles.  An increase in the amount of mannitol added appeared to cause a slight 
decrease in the echogenicity as illustrated by the linear trend line in Figure 3-24.  The 
size distributions produced by different quantities of mannitol and trehelose are shown 
in Figure 3-25; these suggest that the addition of mannitol causes an increase in the 
average microbubble size which may account for the decrease in echogenicity of these 
samples. 
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Figure 3-24: Mean backscatter at varying percentages of mannitol and trehelose. 
 
Figure 3-25: Size distributions produced by different percentages of mannitol and trehelose. 
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3.4.6. High Temperature Production 
Figure 3-26 below shows the decrease in echogenicity observed for increasing 
production temperatures during the heating phase of the microbubble production.  This 
data suggests that the optimum temperature range is between 70 and 80°C.  However the 
transition temperature of the lipids lies between 60 and 77°C ('Avanti Catalogue 2008' 
2008) so for all experiments the temperature was maintained above 77°C to ensure 
incorporation of all lipids into microbubble shell.   
 
Figure 3-26: Mean backscatter produced by increasing production temperatures. 
Figure 3-27 shows the size distributions produced by different production temperatures, 
all illustrate narrow size distributions with similar modal sizes suggesting that 
production temperature does not affect the sizes of the microbubbles; the author believes 
that the decrease in echogenicity could be due to degradation of the lipids at high 
temperatures. 
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Figure 3-27: Size distributions observed at different production temperatures. 
3.4.7. High Shear Mixing 
The effect on the microbubble samples of mixing the lipids under high shear stress was 
assessed before and after the heating phase of production.  It was found that both 
methods produced an increase in the echogenicity of the microbubble samples as shown 
in Figure 3-28 below. A smaller increase in echogenicity of the microbubbles was seen 
when combining the lipids with the high shear mixer before heating, but this difference 
was still >4dB.  A significant increase of 8.4dB was seen when the microbubble sample 
was mixed after the heating phase. 
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Figure 3-28: Mean backscatter produced by the high shear mixing device. 
Although mixing after the heating phase produced the most significant increase in 
echogenicity it can be seen in Figure 3-29 below that this method produces a much 
wider size distribution with a greater average microbubble size.  The greater 
microbubble size is not ideal for future in-vivo use and therefore high shear mixing 
before heating would be the optimum method to adopt. 
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Figure 3-29: Average size distributions produced by high shear mixing of microbubble samples. 
3.4.8. Summary 
The chart in Figure 3-30 shows the relative echogenicity of each optimization technique 
investigated.  This data shows that the three techniques which improve the echogenicity 
of the in-house microbubbles are agitation, sonication and high shear mixing.  The 
control illustrated in Figure 3-30 was taken as an average of a variety of control samples, 
reproducibility of the in-house microbubble is varied, all results illustrated are taken as 
an average of at least three samples and any extreme variants were discarded and results 
collected again.  There is a statistically significant difference in the mean backscatter 
from microbubbles produced using the different techniques (p<0.001). 
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Figure 3-30: Comparison of different optimization techniques and their effect on the mean 
backscatter of the microbubble sample. 
3.5. Discussion 
Different chemical compositions and production techniques have been compared.  This 
was in order to optimize the echogenicity of the in-house UCA for use with 40MHz 
IVUS.  The echogenicity of the in-house agent has been assessed through the analysis of 
the RF data for each sample of microbubbles produced.  In addition the agents have been 
observed under a microscope and their size distributions assessed. 
An investigation into the chemical composition and its effect on the mean backscatter of 
the microbubbles has shown that the 30% cholesterol composition was the most 
echogenic sample.  The 30% cholesterol microbubbles were also the most reproducible 
composition with the smallest standard deviation in the results.  Since reproducibility is 
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an important factor in production of the in-house agent this was also a deciding factor in 
the selection of a composition for further optimization.   
A variety of different techniques have been investigated in the optimization of the in-
house agent.  These have been compared in Section 3.4.8.  From the comparison of 
results it was found that agitation and high shear mixing produced the most echogenic 
samples; this is inline with techniques used by other authors (Klibanov et al. 2004; 
Schneider et al. 2004; Schneider et al. 2006).  Diffusion of the in-house agent was found 
to increase the microbubble size and as a result of this the mean backscatter of the 
samples was reduced. 
Agitation was selected as the optimum production method for the in-house microbubble 
and an investigation carried out into the length of agitation and its effect on the mean 
backscatter of the microbubbles.  This suggested that microbubble size decreases as the 
agitation time increases.  In addition the mean backscatter results suggest that 
echogenicity increases with agitation time up to 45s and then decreases sharply as 
agitation time is increased beyond 60s.  The author believes that agitating the 
microbubble samples for longer than one minute causes the microbubble sizes to drop 
below their resonance radius for 40MHz ultrasound, therefore making the samples less 
echogenic. 
The stability of the in-house agent over time has also been assessed.  There was found to 
be little significant variation in the mean backscatter of the agent over a 24 hour period. 
In addition it was discovered that the agent, if stored in a glass vessel at 2-5°C, can be 
stored for up to three months with minimal variation in the mean backscatter.  However, 
it is advised that the agent is observed carefully after long storage periods as some 
samples have shown signs of fungal growth.  This was likely to be due to contamination 
of the storage vessels. 
The optimum microbubble size for resonance at 40MHz was 1.4µm diameter as 
presented in Appendix A.  This is smaller than the size of microbubbles produced 
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throughout this investigation as, using the techniques demonstrated throughout this 
Chapter, it wasn't possible to reduce the microbubble diameter further.  However this 
result was calculated using approximate values for the shell properties, fluid density and 
pressure.  The results presented in Section 3.4.3 show that the echogenicity of the 
microbubbles dropped off with decreasing microbubble diameter suggesting that the 
larger 5-6µm microbubbles are resonating at 40MHz.  Further investigations into 
micorbubble size, shell properties and resonance frequencies would need to be carried 
out in order to confirm this. 
3.6. Summary 
The data collected and illustrated in this chapter suggest that, of all the optimization 
techniques applied, agitation and high shear mixing produced the optimum microbubble 
suspension in terms of echogenicity and mean backscatter.  However it is also important 
for an optimum microbubble sample to have a narrow size distribution with a small 
average microbubble diameter such that when reaching in-vivo studies the microbubbles 
will be small enough to pass through the vascular system.  In conclusion, the production 
techniques which were employed for continued production of the microbubbles include 
high shear mixing prior to the heating phase of production and agitation post heating 
phase.  In addition to improving the echogenicity and size distribution of the 
microbubble samples this also reduces production times.  The final method of 
production can be seen in Appendix D. 
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Chapter 4 Laser Doppler Anemometry 




In order to assess the strength of attachment of a targeted microbubble ultrasound 
contrast agent under shear stress it was necessary to design a flow chamber in which the 
wall shear stress (WSS) on the cell surface could be accurately measured.  Laser 
Doppler anemometry (LDA) has previously been used to acquire velocity profiles of low 
flow volumes within a novel chamber from which WSS has been calculated (Butler et al. 
2005).  In this chapter the development of a novel, high flow volume, flow chamber and 
the methods used to ascertain the WSS within the flow channel at different flow 
volumes and with different viscosity fluids is described.   
Human physiological flow volumes in the coronary arteries lie between 80 and 
120ml/min (Arronson et al. 2004).  The flow chamber for this investigation has been 
designed to be used up to flow volumes of 350ml/min to enable assessment of very high 
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WSS.  This was in order for attachment of the agent to be assessed under expected 
physiological wall shear stress in mice of 40Pa (Cheng et al. 2007a) for future small 
animal studies. 
Different viscosity fluids have been observed in order to take into account viscosity 
variations due to hematocrit as described in Chapter 1 and to increase the maximum 
WSS attainable within the flow chamber.  Glycerol solutions have been used to produce 
different viscosity fluids, varying from a 40% glycerol solution (by mass) to 80% 
glycerol with a range of viscosities from 0.0045Pa·s to 0.0599Pa·s. 
4.2. Measuring flow velocity 
There are several different methods currently used to measure flow velocity in different 
situations including, Doppler flow wire, particle image velocimetry (PIV) and laser 
Doppler anemometry (LDA).   
A Doppler flow wire consists of a piezoelectric crystal mounted on the tip of a guide 
wire, about 0.014 inches (0.356mm) in diameter.  Also known as a Doppler guide wire, 
it is predominantly used in cardiology to measure the velocity of blood in the coronary 
vessels (Gorski and Watson 2005; Millar 1988).  This is an invasive technique and the 
physical presence of the guide wire within the flow can effect the measurements made, it 
is therefore not suitable for this application. 
PIV is an optical method of acquiring flow velocities and is commonly used to assess 
aerodynamics around vehicles and aircraft.  The set-up requires a laser focused into a 
light sheet, a camera, and seeding particles suitable for the flow to be studied.  As the 
seeding particles are carried through the light sheet by the flow they scatter light.  At 
least two exposures are needed from the camera in order to measure the velocity, when 
two frames have been collected the frames are divided into interrogation areas (IAs) and 
the displacement vector of the scattered light in each IA is calculated.  The velocity of 
flow in the IA can then be calculated if the time between the frames is known.  The 
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advantages of PIV are that no invasive probes are required and with high speed data 
analysis data can be collected in real time.  However, due to the light sheet it would not 
be an effective or efficient technique for measuring the flow through a small channel in 
the parallel plate flow chamber described in Section 4.3. 
LDA is a high resolution optical technique which uses laser light scattered from seeding 
particles within the flow to calculate the fluid velocity components from the Doppler 
Effect.  LDA is an accurate method of determining flow profiles within small channels 
and as a result it the method of choice in determining the flow profiles within the flow 
chamber developed. 
4.2.1. Laser Doppler Anemometry 
LDA has been used to assess the velocity profiles within the flow chamber.   The first 
reported use of LDA was in 1964, when the first velocity measurements using a 
reference beam system were made (Yea and Cummins 1964).  This reference beam 
system can be seen in Figure 4-1.  The laser beam is split and one beam focused through 
a flow tube containing scattering particles, the scattered laser light from this beam is 
then collected through a port in the flow tube and focused onto the detector.  The other 
beam is focused directly onto the detector acting as a reference beam, with zero velocity 
value.  The frequency of the scattered light can then be used to calculate the flow 
velocity, when compared to the reference beam. 
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Figure 4-1: Reference beam system used by Yea and Cummins in 1964 adapted from image by 
Butler  (2005). 
This reference beam system has evolved into a dual beam system, the type of system 
which has been used for the investigations outlined in this chapter.  The dual beam 
system is composed of a single beam, split into two.  One beam is then passed through a 
Bragg cell and frequency shifted and both beams pass through a beam expander before 
bisecting to form a measurement volume, as illustrated in Figure 4-2a.  The purpose of 
the frequency shift in the second laser beam is to enable identification of the direction of 
flow; the beam expander is designed to reduce the measurement volume and therefore 
improve the resolution of the system.  Figure 4-2b shows how the backscattered light is 
collected by the photodiode for processing. 
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Figure 4-2: Dual beam LDA system: a, beam splitter, Bragg cell and beam expander; b, 
backscattered light from measurement volume (adapted from Dantec Dynamics reference material 
(DantecDynamics 2007)). 
The LDA Fringe Model 
The fringe model is often used to describe how velocity measurements can be acquired 
through the use of LDA (Durst et al. 1976; Watrasiewicz and Rudd 1976).  As the 
coherent laser beams cross they create a fringe pattern as illustrated in Figure 4-3.  When 
the seeding particle is introduced to the flow and passes through this fringe pattern it 
scatters light back to the sensor at a frequency which is proportional to the velocity of 
the particle.  If it is assumed that the particle is travelling at the same velocity of the 
fluid the fluid velocity at that discreet point can be calculated using Equation 4-1. 
fd dfv   
Equation 4-1: Fluid velocity 
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Where fd is the scattered frequency and df is the fringe spacing calculated from Equation 







Equation 4-2: Fringe Spacing 
 
Figure 4-3: Fringe model 
4.3. Flow Chamber Development 
Butler et al (2005) initially developed a novel parallel plate flow chamber in order to 
measure the wall shear stress which would act upon a surface to which microbubbles 
could be attached.  The flow chamber was calibrated to 3.4Pa.  This flow chamber 
exhibits the following features: 
 Glass slide at front of chamber making it suitable for use with LDA system. 
 6×2mm flow channel, 120mm in length. 
 Two sample wells for attachment of microbubbles onto agar. 
 Inlet and outlet reservoirs in order to stabilise the flow entering the flow channel. 
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In order to more accurately assess the wall shear stresses upon surfaces within coronary 
blood vessels at higher WSS, a new flow chamber has been designed as illustrated in 
Figure 4-4.  The new flow chamber has been produced with a 3×3mm flow channel to 
more accurately resemble the cross section of a 3mm coronary artery, and the flow 
channel has been increased to 300mm in order to ensure that a fully developed flow 
profile is formed.  The new flow chamber also exhibits a 140mm agar channel for 
attachment of microbubbles to a cellular surface.  A glass microscope slide has been 
incorporated in the observation region for compatibility with the LDA system and two 
holes with 2mm diameter have been drilled behind the agar sample for IVUS 
investigations.  Inlet and outlet reservoirs are also present with wider inlet and outlet to 
enable higher flow volumes. 
Large bore Luer style connectors were used to attach tubing to the inlet and outlet of the 
flow chamber.  The fluid travels through the tubing, propelled by the pump, and through 
the inlet identified on the left of Figure 4-4c.  The inlet reservoir is then filled and the 
fluid travels along the flow channel of the central panel in Figure 4-4b and across the 
agar surface which is embedded in the rear panel such that it is flush with the back 
surface of the flow channel.  The front panel in Figure 4-4a encases the front of the flow 
channel.  The outlet reservoir then prevents turbulence occurring as the fluid passes out 
of the flow chamber and back through the pump. 
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Figure 4-4; Schematic of parallel plate flow chamber showing features of a, front panel, b, central 
panel and c, rear panel (not to scale). 
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A photograph of the assembled flow chamber can be seen in Figure 4-5 identifying the 
various features. 
 
Figure 4-5: Photograph of assembled flow chamber. 
4.3.1. Reynolds Number and Entrance Length 
In order to accurately assess the wall shear stress (WSS) to which microbubbles will be 
subjected, it is important to understand the flow regime within the flow chamber.  
Laminar flow occurs when a fluid flows in parallel layers as illustrated in Figure 4-6, 
whilst turbulent flow is characterised by chaotic fluid motion.  In blood vessels flow is 
often turbulent due to the many bifurcations and the surface variations.  However, for 
the purpose of these investigations the flow chamber has been developed such that 
laminar flow can be maintained to enable an accurate assessment of the WSS.  In true 
laminar flow a parabolic flow profile will be developed due to the drag between each 
layer of fluid, this is illustrated in Figure 4-6. A fully developed flow profile is achieved 
when the profile is parabolic and unchanging. 
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Figure 4-6: Laminar parabolic flow 
Initially derived in 1883 (Reynolds 1883; Rott 1990), the Reynolds number is the ratio 
of viscous to inertial forces within a fluid and is used to predict flow regimes.  Low 
Reynolds numbers suggest laminar flow whilst much higher Reynolds numbers indicate 
turbulent flow. The Reynolds number is used in fluid dynamics to determine whether 
turbulent flow can be expected and is also valuable in modelling aerodynamic shapes 
(Streeter 1962). The Reynolds number is defined in Equation 4-3 below (McDonald 





















Equation 4-3: Reynolds number 
Where Re is Reynolds number, ρ is density of the fluid, µ is the dynamic viscosity, υ the 
kinematic viscosity, h and sv  the characteristic length or hydraulic diameter and mean 
fluid velocity respectively (all SI units). 
The hydraulic diameter is the equivalent diameter for a non-circular channel and can be 
found in Equation 4-4 (Nichols and O'Rourke 1990), where A is the cross-sectional area 
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and U is the perimeter of the channel in contact with the fluid.  The dynamic viscosity is 
the absolute viscosity of a fluid whilst the kinematic viscosity is the dynamic viscosity 






Equation 4-4: Hydraulic diameter 
Reynolds numbers for the newly designed and developed chamber lie between 332 and 
1935 for flow volumes of 60 to 350ml/min.  The critical Reynolds number, at which 
laminar flow becomes turbulent lies in the region of 2000 to 3000 which suggests that 
laminar flow can be assumed in the flow chamber. 
The entrance lengths (Le) within the flow chamber can be determined from Equation 4-5 
(Richards 1989).  This gives the distance at which a fully developed flow profile can be 
assumed.  
hLe Re06.0  
Equation 4-5: Entrance length 
 For water at flow volumes of 60-350ml/min in the flow chamber the entrance length lies 
between 59.7mm to 348mm.  The chamber is only 300mm in length and as such at 
350ml/min the flow profile may not be fully developed.  At all other flow volumes 
studied and for all glycerol concentrations a fully developed flow profile can be assumed 
within the observation region.  Reynolds numbers and entrance lengths derived from 
Equation 4-3 and Equation 4-5 respectively, at all glycerol solutions for the flow 
volumes investigated are given in Table 4-1. 
 


















60 332 59.7 81.5 14.7 16.0 2.89 6.72 1.21 
80 442 79.6 109 19.6 21.4 3.85 8.96 1.61 
100 553 99.5 136 24.5 26.7 4.81 11.2 2.02 
120 663 119 163 29.3 32.1 5.77 13.4 2.42 
140 774 139 190 34.2 37.4 6.73 15.7 2.82 
160 884 159 217 39.1 42.7 7.69 17.9 3.23 
180 995 179 245 44.0 48.1 8.66 20.2 3.63 
350 1935 348 475 85.6 93.5 16.8 39.2 7.06 
Table 4-1; Reynolds numbers and entrance lengths for different viscosity fluids, at various flow 
volumes. 
4.4. Method 
The apparatus was set up as illustrated in Figure 4-7 below.  The LDA probe volume 
was focused on the observation region, through the microscope slide, during 
measurements in order to avoid scattering from surface inconsistencies in the Perspex.  
This was achieved by moving the laser on its traverse until the point where the beams 
converge sat over the observation region of the flow channel. 
 
Figure 4-7; Experimental set-up for LDA investigations (arrows signify direction of flow) 
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The fluid under investigation was propelled through the chamber by a Micropump 
(IDEX corporation, Vancouver, WA USA), which was powered by a 30V power pack. 
The fluid was seeded with Timiron® Super Silk (Merck, NJ USA), a fine powder with 
particle size range of 3-10µm. 
4.4.1. Flow chamber 
The parallel plate flow chamber was sealed with silicone grease and the different panels 
were firmly clamped together.  Water or glycerol solution was then passed through the 
system at the maximum pump voltage for five minutes in order to remove bubbles from 
the system, this was verified visually. 
The pump voltages were then calibrated in order to produce the flow volumes listed in 
Table 4-1.  Calibration details can be found in Appendix E.  The chamber was visually 
checked for leaks, bubbles and any blockages in the flow channel.  Flow volumes were 
measured daily and whenever the flow chamber was taken part for cleaning to ensure 
reliable results, this was achieved in the manner described in Appendix E. 
4.4.2. LDA 
The position of the measurement volume was controlled by a traverse system with three 
dimensional translations.  Prior to beginning measurements it was necessary to 
determine a (0,0,0) co-ordinate so that the location of the flow profile could be 
ascertained in relation to a central position, and to ensure that flow profiles were 
collected at the same position along the flow channel.  For the purpose of these 
investigations the (0,0,0) co-ordinate was established as the centre of the flow channel as 
illustrated in Figure 4-8.   
 
Laser Doppler Anemometry  124 
 
Figure 4-8; Location of traverse (0,0) co-ordinate, relative to flow channel; (110x and 140x locations 
identified) 
4.4.3. Preliminary investigations 
In order to find the location of 0z , the centre of the flow channel in the z-plane, a 
selection of flow profiles from front to back of the channel were acquired at the (110, 
0)mm co-ordinate, 0y  was located visually and measurements were taken at 110mm 
along the flow channel, in the observation region.  It was assumed that the location of 
the peak velocity would indicate the centre of the flow channel in the z-plane if a 
parabolic velocity profile was produced.  Once this position was determined the probe 
volume was moved to the centre of the channel and the system was re-set at this 
location.  Flow profiles produced through the z-plane can be seen in Appendix F.  This 
procedure was repeated each time the chamber was set-up. 
When the (0,0,0) co-ordinate was established measurement sets were collected between 
4)(4  mmy , at two different locations along the flow channel, 110x mm and 
140x mm, as illustrated in Figure 4-8.  To ensure that a fully developed flow profile 
had been established, these flow profiles were then compared to a parabolic, quadratic 
trend-line, to confirm that parabolic flow was achieved.  These results can be seen in 
Figure 4-9.  The flow profiles in Figure 4-9 suggest that a fully developed flow profile is 
produced at 110x  as the trend-lines illustrate a close correlation between the two 
profiles and the fit of the trend-line, as indicated by the R-squared value is >89% 
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(p<0.0001).  However the results also suggest that there is more variance in the flow 
profile located 110mm along the flow channel than at 140mm, it is believed that this is 
due to the discontinuity between the Perspex and the glass slide on the front panel of the 
flow chamber.  In light of this observation measurements were made at the 140x mm 
location. 
 
Figure 4-9; Graph illustrating fully developed flow profiles in observation region (160ml/min flow 
volume; error bars represent one standard deviation). 
The following graph in Figure 4-10 illustrates the flow profiles achieved at 110x mm 
and 140x mm, for a flow volume of 350ml/min.  The quadratic trend-line at the 
110x mm location has a fit <0.8 (p<0.0001), suggesting that fully developed flow has 
not been achieved here, however at 140x mm the trend-line has an R-squared value 
>0.95 (p<0.0001) and as a result despite numerical calculations, as presented in Table 
4-1, suggesting that fully developed flow will not be reached at this flow volume, it will 
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be assumed that fully developed flow has been achieved, confirming the x=140mm 
location as a suitable co-ordinate for collecting the final results. 
 
Figure 4-10; Flow profiles collected at 110mm and 140mm along the x-axis for a flow volume of 
350ml/min. 
Before commencing the final investigations it was important to assess the reproducibility 
of the results and flow profiles collected.  The graph in Figure 4-11 shows four flow 
profiles collected at 350ml/min flow volume over two days.  Run 1 and 2 were collected 
approximately 30 minutes apart and runs 3 and 4 were collected 24 hours later 
approximately 30 minutes apart.  Before measurements 3 and 4 were collected the flow 
chamber was taken apart and reassembled to ensure that this did not affect the flow 
profiles collected.  The results illustrated in Figure 4-11 show that the flow profiles are 
highly reproducible.  
 
Laser Doppler Anemometry  127 
 
Figure 4-11; Four flow profiles collected over two days for 350ml/min flow volume. 
The final preliminary investigation involved changing the direction of the flow within 
the flow chamber.  The purpose of this investigation was to assess the effect of 
discontinuities in the flow chamber, in addition the potential for reflections or scatter 
from the agar well and IVUS channels could be eliminated.  To achieve this, the flow 
inlet and outlet were reversed and the front panel of the flow chamber was rotated 180° 
in order to carry out measurements in the flow chamber close to the outlet as illustrated 
in Figure 4-12.  
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Figure 4-12: Schematic showing how reverse flow was acheived and measured; a, showing forward 
flow direction and b, showing reverse flow direction. 
The graph in Figure 4-13 illustrates two average flow profiles collected for forward flow 
and reverse flow respectively at 140ml/min.  The correlation of both data sets is above 
85% (p<0.0001).  In addition there is little variation in the two flow profiles indicating 
that there is good continuity with results from both directions and therefore, the flow 
channel is free of artefacts which may cause significant errors in the flow profiles 
collected.  In light of this data the flow profiles were collected in the forward direction  
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Figure 4-13; Flow profiles achieved from two opposite orientations with a flow volume of 140ml/min 
4.4.4. Final Investigations 
Once all controllable sources of error had been eliminated flow profiles were collected at 
140x mm for flow volumes of 60, 80, 100, 120, 140, 160 and 180ml/min at glycerol 
and water solutions of 0 (water), 40, 60 and 80% glycerol by mass.  Additional flow 
volumes of 350ml/min were studied for water, 40% and 60% glycerol solutions, 
however higher flow volumes were not attainable with an 80% glycerol solution, due to 
equipment limitations, so the maximum flow volume studied in this case was 
250ml/min. 
The results were then analysed and the wall shear stresses produced by different glycerol 
concentrations and the above flow volumes were calculated. 
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4.5. Final Results and Discussion 
The following graphs show the flow profiles collected for water and 40%, 60% and 80% 
glycerol solutions at the flow volumes investigated.  The data represented in these 
graphs has been corrected, where necessary, to show positive flow profiles, this has been 
achieved by multiplying the raw data by (-1).  In addition the data below has been 
averaged over four investigations unless stated, and the errors illustrated represent one 
standard deviation of the data sets. 
 
Figure 4-14; Average flow profiles for water; flow volumes between 60ml/min and 350ml/min. 
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Figure 4-15; Average flow profiles for 40% glycerol solution; flow volumes between 60ml/min and 
350ml/min. 
 
Figure 4-16; Average flow profiles for 60% glycerol solution; flow volumes between 60ml/min and 
350ml/min. 
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Figure 4-17; Average flow profiles for 80% glycerol Solution; flow volumes between 60ml/min and 
270ml/min. 
The flow profiles seen above were collected over a period of one month.  Each flow 
profile was compared to a quadratic trend-line (Microsoft Excel) determined from the 
least squares principle.  All average flow profiles had a fit, as measured by the R-
squared value of at least 80%, with the exception of the lowest flow volume for 40% 
glycerol solution which had a fit of approximately 25%.  However, the first two flow 
profiles collected both had a trend-line fit greater than 80% and it is therefore believed 
that the second two flow profiles collected illustrated anomalous results which could 
have been caused by grease acquiring in the flow channel or scattering of the laser light.  
The majority of results showed a fit of over 90% to a parabola suggesting that the flow 
profiles were fully developed. 
The flow profiles in Figure 4-15 and Figure 4-16 are not as parabolic as those observed 
in Figure 4-14 and Figure 4-17, this is believed to be due to either the presence of an 
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obstruction in the flow, such as a bubble or grease smear, or light being scattered from 
the glass slide at the front of the chamber or agar sample at the back.   
The following graph which can be seen in Figure 4-18 shows the relationship between 
the peak velocities acquired for the different viscosity fluids at a flow volume of 
80ml/min.  This data shows a small initial increase in the peak velocity of the flow at 
40% glycerol solution followed a decrease in the peak velocity as the viscosity of the 
solution increases.  The initial increase in peak velocity is due to the improved 
lubrication of the pump with the glycerol in solution, and the decrease is due to the 
increased viscosity requiring a greater force to propel the fluid through the channel. 
 
Figure 4-18: Peak velocities acquired with different viscosity fluids at a flow volume of 80ml/min. 
4.5.1. Wall Shear Stresses 
The wall shear stress    was determined from the following Equation 4-6: 
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dx
du
   




 is the shear rate and can be found as the gradient of the flow profile adjacent 
to the wall.  The shear rate was attained by plotting the first three points of the flow 
profile in Microsoft Excel and adding a linear trend-line from the least squares principle, 
as seen in Figure 4-19.  The gradient of the linear trend line can be treated as an estimate 
of the wall shear rate which can in turn be used to calculate the WSS.  Three points were 
used instead of two in order to reduce the chance of anomalous results occurring.  Four 
points were not used as the flow profiles are parabolic and the slope, and therefore the 
shear rate, may decrease as more points are used giving an inaccurate result. 
 
Figure 4-19; Wall shear rate estimation for 140ml/min flow volume, showing four measurements. 
The wall shear stresses calculated can be seen in Table 4-2 below and are illustrated in 
Figure 4-20.  The errors are given as standard deviations in results. 
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Flow volume 
(ml/min) 
Wall Shear Stress (Pa) 
Water 40% glycerol 60% glycerol 80% glycerol 
60 0.31 ± 0.02 1.62 ± 0.44 4.74 ± 1.61 5.99 ± 1.02 
80 0.48 ± 0.05 2.36 ± 0.11 5.95 ± 2.08 11.40 ± 1.90 
100 0.53 ± 0.04 3.50 ± 0.09 8.02 ± 1.96 17.97 ± 4.91 
120 0.65 ± 0.09 2.94 ± 0.58 10.80 ± 0.80 19.07 ± 6.00 
140 0.88 ± 0.04 4.01 ± 0.20 17.20 ± 2.37 19.70 ± 4.12 
160 0.98 ± 0.13 3.96 ± 0.31 20.00 ± 1.83 25.04 ± 4.98 
180 1.24 ± 0.08 4.68 ± 0.18 20.50 ± 1.17 26.18 ± 1.76 
250    50.01 ± 4.37 
350 1.92 ± 0.05 7.38 ± 0.51 40.00 ± 4.74  
Table 4-2; Wall shear stress for different viscosity fluids at varying flow volumes. 
 
Figure 4-20: WSS produced by different viscosity fluids and their relationship to flow volume. 
The results illustrated here show that the flow profiles and peak velocities increase with 
increasing flow volume as expected (p<0.0001) and as a result the WSS increases with 
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increasing flow volume.  In addition it can be seen that the WSS increases with 
increasing fluid viscosity. 
4.6. Computational Fluid Dynamics 
Computational fluid dynamics (CFD) has also been used to assess the expected flow 
profiles within the novel flow chamber.  CFD is often used to predict flow velocity 
patterns within vessels and is largely regarded as reliable estimation of laminar flow (Ku 
et al. 2002; Quan et al. 2002; Versteeg and Malalasekera 2007).  David Hardman 
(Medical Physics, University of Edinburgh) has used Fluent 6.3.26 (ANSYS, USA) to 
produce flow profiles through the final flow chamber described in Section 4.3. 
The flow chamber dimensions were input into Gambit (Fluent‟s pre-processor) to 
produce a computerised model of the flow channel within the chamber.  A screen shot of 
the flow channel can be seen in Figure 4-21. 
 
Figure 4-21: Screen shot of flow channel (courtesy of David Hardman). 
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Following this, flow volumes of 80, 120 and 360ml/min were set to flow through the 
model and flow profile information was output at 0, 50, 100 and 150mm along the flow 
channel (from the central point of the flow channel). 
4.6.1. Results 
Figure 4-22 presents the flow profiles produced by Fluent for the four different viscosity 
fluids at 80, 120 and 360ml/min flow volumes.  It can be seen that the peak flow 
velocity at the centre of the flow channel can be expected to increase as a function of the 
flow volume.  However the CFD data suggests that the fluid viscosity has little or no 
effect on the flow velocity as the peak velocities observed for each flow volume do not 
vary between the different viscosity fluids, with the exception of water which does not 
have a fully developed flow profile at 350ml/min.  This is not the case for the measured 
LDA data presented in Figure 4-18 reasons for the variations in experimental data are 
described in Section 4.5.  The flow profile for water will not be fully developed at the 
observation region as the entrance length for water is longer than the channel length.  
The length of the flow chamber was not increased as a result of this due to the fragility 
of the flow chamber panels. 
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Figure 4-22: CFD flow profiles for different viscosity fluids at differing flow volumes; a, 0% glycerol 
solution (water); b, 40% glycerol solution; c, 60% glycerol solution and d, 80% glycerol solution. 
The expected WSS that will act on the flow chamber walls were calculated from the 
flow profiles output above, using the first 3 data points of the profiles as in Section 
4.5.1, and are presented in Table 4-3 and Figure 4-23 below.  Three dimensional flow 




Wall Shear Stress (Pa) 
0% glycerol 40% glycerol 60% glycerol 80% glycerol 
80 0.36 ± 0.01 1.61 ± 0.11 8.60 ± 0.60 21.46 ± 1.49 
120 0.56 ± 0.02 2.48 ± 0.17 13.23 ± 0.92 33.02 ± 2.29 
360 1.68 ± 0.12 7.44 ± 0.52 39.69 ± 2.75 99.05 ± 6.86 
Table 4-3: WSS values 
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Figure 4-23: WSS at varying flow volumes for different viscosity fluids calculated from CFD results. 
4.7. Calculation of the WSS 
The WSS (τ) within the flow chamber has also been calculated from the chamber 





   
Equation 4-7: Shear stress calculation. 
Where μ is the fluid viscosity; w and h the channel width and height respectively. 
The calculated WSS can be seen in Table 4-4 and Figure 4-24, the errors represented in 
the table are calculated from the error in the flow channel dimensions.  This data shows 
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a linear relationship between the WSS and flow volume as has been seen previously 
with experimental and CFD results. 
Flow volume 
(ml/min) 
Wall Shear Stress (Pa) 
0% glycerol 40% glycerol 60% glycerol 80% glycerol 
60 0.22 ± 0.01 1.00 ± 0.05 5.33 ± 0.27 13.31 ± 0.67 
80 0.30 ± 0.01 1.33 ± 0.07 7.11 ± 0.36 17.75 ± 0.89 
100 0.37 ± 0.02 1.67 ± 0.08 8.89 ± 0.44 22.19 ± 1.11 
120 0.45 ± 0.02 2.00 ± 0.10 10.67 ± 0.53 26.62 ± 1.33 
140 0.52 ± 0.03 2.33 ± 0.12 12.44 ± 0.62 31.06 ± 1.55 
160 0.59 ± 0.03 2.67 ± 0.13 14.22 ± 0.71 35.50 ± 1.77 
180 0.67 ± 0.03 3.00 ± 0.15 16.00 ± 0.80 39.93 ± 2.00 
250 1.00 ± 0.05 4.50 ± 0.23 24.00 ± 1.2 59.90 ± 3.00 
350 1.30 ± 0.07 5.83 ± 0.29 31.11 ± 1.6 77.65 ± 3.88 
Table 4-4: WSS for varying flow volumes calculated from Equation 4-7. 
 
Figure 4-24: Calculated WSS with different viscosity fluids at varying flow volume. 
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4.8. Comparison of results 
The WSS values for the flow chamber described in Section 4.3 have been determined 
experimentally, through a CFD analysis of the flow chamber and in addition have been 
calculated using Equation 4-7.  These results have been compared and are presented in 
Figure 4-25.  The data suggests that, at low flow volumes, the WSS for each method 
used are comparable; however the results tend to diverge as the flow volume is 
increased.  In addition, the divergence in results increases with an increase in fluid 
viscosity, such that with low viscosity fluids, for example water, the divergence is less 
than 1Pa; however with 80% glycerol solution divergence is greater than 30Pa. 
 
Figure 4-25: WSS at varying flow volumes for different methods of determination; a, for water, b, 
for 40% glycerol solution, c, for 60% glycerol solution and d, for 80% glycerol solution. 
With the lower viscosity fluids, water, 40% glycerol and 60% glycerol solutions 
(0.001Pa·s, 0.005Pa·s and 0.024Pa·s viscosities) the results presented in Figure 4-25 
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suggest that CFD provides the best approximation of the results, however for high 
viscosity fluid, 80% glycerol solution (0.060Pa·s), the calculated values for WSS 
provide the best approximation to the experimental results. 
In light of this comparison the experimentally evaluated WSS will be used as calibration 
data for the flow chamber as these are the true WSS values achieved.  However, if future 
calculations for the WSS are required at low flow volumes or with low viscosity fluids, a 
calculation or CFD approximation may be a suitable method of identifying the WSS 
within the flow chamber. 
4.9. Summary 
LDA has been used to assess the flow profiles within a specifically designed flow 
chamber and to calculate the WSS which will be acting upon attached microbubbles 
within the flow channel.  The WSS has been calculated for 4 different viscosity fluids at 
flow volumes ranging from 60-350ml/min.  Physiological flow is pulsatile and 
occasionally turbulent; however only steady flow in the laminar regime has been 
investigated here.   An accurate and reliable assessment of the WSS against the agar 
surface is more easily achieved through the use of laminar flow. 
Three different methods have been used to determine the WSS within the novel flow 
chamber, these methods are; experimental determination using LDA, computational 
determination using CFD and calculated values of WSS using flow chamber dimensions.  
The comparison of results suggests that at high flow volumes and with high viscosity 
fluids there is significant variation in the results produced, indicating that the 
experimental method produces the most accurate WSS.  However at lower flow volumes 
and with low viscosity fluids (0.001-0.005Pa·s) CFD and calculation of the WSS 
provide acceptable results.  However, since all WSS have been determined 
experimentally for the flow chamber described, this data has been used to calibrate the 
flow chamber for future investigations. 
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In conclusion, the WSS values which can be assessed within the flow chamber range 
from 0.03-50Pa.  This makes the flow chamber described in this chapter suitable for 
investigations into the attachment of microbubbles under human physiological WSS of 
approximately 3.4Pa in addition to physiological WSS in normal, non-atherosclerotic, 
mice of up to 40Pa (Cheng et al. 2007a).   
The WSS values acquired here can be used to determine the shear stresses at which 
microbubbles will remain attached to a surface and also under what shear stresses 
microbubbles in the flow will attach to a surface. 
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Chapter 5 Intravascular Ultrasound and 
Characterisation of the IVUS transducer 
 
5.1. Intravascular Ultrasound 
Intravascular ultrasound (IVUS) began development in 1971, when the first linear array 
was invented.  It was believed that ultrasound would not be able to penetrate the chest 
wall sufficiently for study of the heart and so a mechanical array catheter tip was 
developed for internal study of large blood vessels (Bom et al. 1971).  Due to flaws in 
the catheter tip production this design failed and this approach to studying the heart was 
discontinued due to the success of non-invasive cardiac imaging, although mechanical 
array catheters are still available. 
It was the mid-eighties before any further development of IVUS was undertaken.  This 
was due to the use of interventional techniques in the coronary arteries and the need for 
catheter tip visualisation.  Because the coronary arteries were smaller than the initial 
target of IVUS, the large blood vessels, a smaller catheter was required and so the 
rotating element was developed (Roelandt et al. 1993). 
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A modern IVUS system comprises an IVUS scanner and compatible rotating, single 
element IVUS catheter, or a phased array catheter.  For the purpose of investigation 
throughout this thesis a Boston Scientific Clearview IVUS unit has been used in 
combination with an Atlantis™ SR Pro coronary imaging catheter (Boston Scientific, 
USA).  The scanner and catheter can be seen in Figure 5-1 below.  Figure 5-1c shows a 
diagrammatic view of the catheter with labelled parts. 
 
Figure 5-1: IVUS system; (a) Clearview IVUS unit, (b) IVUS catheter , (c) simplified diagram of 
IVUS catheter (adapted from Lupotti (Lupotti 2002)). 
The proximal end of the IVUS catheter is connected to a motor drive which enables 
controlled and smooth pull-back of the catheter through vessels and also rotates the 
single element transducer in the tip in order to build up a cross-sectional image of the 
vessel. 
The most common use for IVUS is imaging of the coronary arteries to establish the 
degree of plaque formation in CHD.  The coronary imaging catheter is inserted into the 
artery, by use of a Doppler guide wire, to the furthest point of study and the IVUS 
catheter is then pulled-back by the motor drive through the region of study.  A typical 
IVUS image can be seen in Figure 5-2.  
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Figure 5-2: IVUS image showing cross section of an atherosclerotic coronary artery and image 
components (courtesy of Mr. T. Anderson).  
5.2. Acoustic Output of IVUS 
The acoustic output of an ultrasound transducer is unique to each transducer and scanner 
combination and is presented as a variety of parameters which quantify the amount of 
ultrasound emitted by a transducer.  The parameters used to describe the ultrasound field 
include, acoustic pressure, power and acoustic intensity. 
The acoustic output of a transducer can be used to assess performance of the system but 
is predominantly used to measure and assess the safety of ultrasound as discussed briefly 
in Chapter 2.  Since the investigations carried out for the purpose of this thesis do not 
involve the use of live subjects the safety parameters are not of primary importance.  
However, when dealing with ultrasound contrast agents, the acoustic pressure is a 
significant parameter because at lower frequencies, as discussed in Chapter 2, it has been 
shown that this governs the interaction between the ultrasound and the microbubbles.  In 
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addition by characterising the transducer a measure of the performance of the system can 
be made. 
5.2.1. Acoustic output parameters 
The information which can be obtained to assess the acoustic output of a scanner and 
transducer are detailed in Table 5-1 (Preston 1991). 
Parameter Symbol Details 
Peak pressures p+, p- 




Ispta Highest intensity in field. 
Power W Total acoustic power in the beam 
Output beam intensity Iob Power divided by radiating area of transducer 
Beam width w Width of beam at the focus 
Table 5-1: Acoustic output information 
The important parameter, when considering microbubbles and their interaction with 
ultrasound, is peak negative pressure which is the parameter measured in this chapter. 
5.2.2. Measuring Acoustic Output Parameters 
Preston (1991) describes a variety of measurement techniques which can be used to 
measure the acoustic output of an ultrasound system.  Three methods of measuring the 
acoustic pressure have been outlined, these include, the pulse-echo technique using a 
small target, optical diffraction techniques and piezoelectric hydrophones. 
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1. The pulse-echo technique involves detection of an echo from a small spherical 
target at different positions in the transducer field and measurement of the echo 
strength as a function of target position to generate a 3-d map of the ultrasound 
field distribution.  This technique is also possible using tungsten wires with a 
diameter less than the acoustic wavelength (Raum and O'Brien 1997). 
2. Compression and rarefaction of an ultrasonic wave causes small changes in the 
refractive index of the medium through which the wave is propagating.  Optical 
measurement techniques employ this phenomena using optical diffraction to 
acquire the pressure distribution from an ultrasound field.  The advantage of this 
technique is its non-perturbing and non-invasive nature making it suitable for 
more hostile environments where a sensitive hydrophone may be destroyed.  
However, this is a complex technique and therefore other techniques are more 
commonly employed. 
3. The most common method of assessing an ultrasound field is the piezoelectric 
hydrophone (Huang et al. 2001; IEEE 1990; NEMA 2004; Snook et al. 2000).  
The hydrophone consists of a thin membrane of piezoelectric elements which 
convert an incident pressure wave into an electric signal (Figure 5-3 adapted 
from Preston (Preston 1991)) from which the pressure field can be calculated 







 Equation 5-1: Peak negative pressure 
 Where p  peak negative pressure,   hydrophone sensitivity (from 
 calibration of hydrophone) and V  peak negative voltage. 
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Figure 5-3: (a) Schematic diagram of hydrophone converting an incident acoustic waveform into a 
voltage waveform and (b) screen shot of measured voltage waveform at 2mm from transducer. 
There are a variety of different types of hydrophone including ceramic, needle-probe and 
membrane, with active elements of the order of 0.5-1mm in diameter, although smaller 
elements do exist.  Sensitivity of the hydrophone increases with the size of the element; 
however an ideal hydrophone will have a small element comparable to the size of the 
acoustic wavelength.  The advantage of the hydrophone as a measurement tool is its 
small size and adaptability although this does lead to the hydrophone being very delicate 
and care must be taken when handling. 
For the purpose of this investigation a hydrophone has been used to characterize the 
IVUS transducer due to its availability within Medical Physics and its reliability.  The 
available hydrophone is a polyvinylidene fluoride (PVDF) membrane hydrophone with a 
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2mm active element which has been calibrated up to 60MHz (National Physics 
Laboratory, 19th June 2008). 
5.2.3. Method 
In order to calibrate the IVUS transducer the equipment was set-up as illustrated in 
Figure 5-4 and Figure 5-5.  The water tank was filled with deionised water 24 hours 
prior to the investigation and the hydrophone was submersed an hour before the 
investigation, ensuring visually that there were no air-bubbles trapped beneath the 
hydrophone.  The hydrophone was connected to a digital oscilloscope (Tektronix 
TDS2000, USA) for data collection.  The IVUS catheter was then fed through a 
customised, fixed tube controlled by a micromanipulator, with the tip of the catheter, 
housing the transducer, below the hydrophone.  The micromanipulator was then used to 
place the transducer at the optimum angle, approximately 12° to the surface of the water 
(achieved when the brightest echo could be observed from transducer at minimum gain). 
 
Figure 5-4: Schematic of equipment for characterisation of IVUS catheter. 
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Figure 5-5: Photograph of IVUS characterisation set-up. 
The distance of the transducer from the hydrophone was measured using the divisions on 
the screen of the ultrasound scanner.  The transducer position was controlled by the 
micromanipulator seen in Figure 5-5, and the bright echo from the hydrophone 
membrane, observed at minimum gain, was lined up with the divisions on the IVUS 
image at the required distances. 
Data from the oscilloscope was captured at 1mm intervals between 1 and 8mm from the 
transducer.  Three sets of data for each distance was collected and an average taken 
before calculating the peak pressure at set distances from the transducer using the 
sensitivity information from the hydrophone calibration certificate and  Equation 5-1.  
The sensitivity data from the calibration certificate is presented in Figure 5-6. 
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Figure 5-6: Plot of sensitivity against frequency for PVDF membrane hydrophone (calibrated by 
National Physics Laboratory, UK). 
5.2.4. Results 
The data, presented in Table 5-2 below, shows that the peak negative pressure decreases 
as the distance from the transducer increases, as expected.  The peak positive pressure 
also decreases but at a slower rate.  The decrease in signal amplitude is due to 
attenuation of the ultrasound beam as it travels through the medium (de-ionised, de-
gassed water).  Acoustic pressure data is also represented graphically in Figure 5-7. 
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Distance from transducer (mm) 
Peak pressures (MPa) 
Negative Positive 
1 2.00 ± 0.15 1.94 ± 0.30 
2 1.92 ± 0.15 1.97 ± 0.28 
3 1.92 ± 0.17 1.92 ± 0.29 
4 1.90 ± 0.20 1.89 ± 0.29 
5 1.69 ± 0.04 1.87 ± 0.28 
6 1.78 ± 0.11 1.94 ± 0.30 
7 1.69 ± 0.10 1.84 ± 0.28 
8 1.57 ± 0.16 1.82 ± 0.29 
Table 5-2: Peak negative and positive pressures as a function of distance from the transducer. 
 
Figure 5-7: Peak positive and negative pressures of IVUS transducer (peak negative pressures have 
been presented on the positive scale for comparison). 
 
Intravascular Ultrasound and Characterisation of the IVUS Transducer 154 
The acoustic pressure data presented in Figure 5-7 shows an increasing difference 
between the peak negative and peak positive pressures as the distance from the 
transducer is increased.  This is likely to be due to non-linear propagation of the 
ultrasound wave which may be distorted as it travels through the medium.  The 
unexpectedly low peak negative pressure at 5mm from the transducer could be due to a 
misalignment of the hydrophone, or environmental factors, such as external noise or 
vibrations causing a variation in result.  In addition these factors may account for the 
increase in peak positive pressure at 6mm from the transducer. 
Previously peak negative pressures for 40MHz IVUS transducers have been reported 
between 0.6 and 1.45MPa (Butler 2005) and 0.2 and 2.0MPa (Goertz et al. 2006) over a 
10mm distance from the transducer.  The peak negative pressures collected for this 
particular transducer lie between 1.6 and 2.0MPa, suggesting that the transducer is 
performing in a suitable range. 
The MI for this transducer and scanner combination has been calculated using Equation 
2-7.  The central frequency of the transducer was assessed using the RF data collected 
for analysis and was found to be 40MHz, as illustrated in Figure 5-8.  The MI was 0.32 
(± 0.10), this is within any safety recommendations on the use of diagnostic ultrasound 
(ECMUS 2008) and lies within the range of MI where the ultrasound and microbubble 
interactions produce non-linear responses as described in Chapter 2.  Despite this care 
must be taken as there is no data currently available to confirm this with respect to the 
in-house UCA. 
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Figure 5-8: Power spectrum from IVUS catheter showing a central frequency of 40MHz. 
5.3. Summary 
The characteristic information of an ultrasound field is important as an indicator of the 
safety and performance of an ultrasound transducer. 
The peak negative pressures produced by an Atlantis™ SR Pro coronary imaging 
catheter have been collected for a range of distances from the transducer and have been 
shown to decrease over distance.  The peak positive pressures have also been recorded.  
The data presented suggests that the catheter being used throughout this thesis is 
performing well with peak negative pressures between 1.5 and 2.0MPa over 1-8mm 
distances from the transducer.  The MI also suggests that the catheter is operating within 
suggested safety limits. 
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Chapter 6 Attachment of antibodies to the in-
house microbubbles 
 
In order to attach the in-house microbubbles to a cellular surface it was necessary to 
incorporate antibodies to the microbubble shell as illustrated and described in Chapter 2.  
Attachment of antibodies was achieved using a streptavidin-biotin bridge.   
A variety of factors were investigated in optimising the attachment of antibodies to the 
in-house ultrasound contrast agent.  These factors are listed below: 
 Optimum quantity of streptavidin with respect to microbubble volume. 
 Optimum ratio of antibody to microbubbles. 
 Attachment techniques. 
Initial investigations involved varying the quantity of streptavidin, however, attachment 
was unsuccessful so a fluorescein isothiocyanate (FITC) conjugated streptavidin was 
used to assess the optimum amount of streptavidin required for the in-house agent to 
have all biotin sites filled.  Once this had been established different attachment 
techniques were investigated and the optimum ratio of microbubbles to antibody by 
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volume was assessed.  A final investigation into the optimum quantity of streptavidin for 
antibody attachment was carried out. 
6.1. Streptavidin-Biotin Bridge 
Klibanov (1999; Klibanov et al. 1999) and Lindner (2004) have discussed the use of the 
avidin-biotin link to bind targeting ligands or antibodies to the surface of a microbubble.  
Other authors (Korpanty et al. 2005; Takalkar et al. 2004) have reported on the use of 
avidin or streptavidin to bind a biotinylated antibody to an acoustically active 
microbubble for targeted imaging of specific structures or proteins.  The avidin-biotin 
bond is commonly used due to its strong affinity for binding to biotin.  Avidin is a 
protein made up of four subunits, each of which is capable of binding to biotin.  
Streptavidin, although not related to avidin, has many of the same properties, including 
its affinity to bind biotin.  The avidin-biotin and streptavidin-biotin bonds are some of 
the strongest known, natural, non-covalent bonds (Chilkoti and Stayton 2002; Green 
1975) and have bond energies of 89.96kJ/mol (Moy et al. 1994; Wilchek and Bayer 
1988) and 133.89kJ/mol (Moy et al. 1994; Wong et al. 1999) respectively..  The 
streptavidin-biotin bond has a lower non-specific binding affinity (does not have a 
tendency to bind to non-target molecules) (Haugland 2002; Weber et al. 1989), making 
it more suitable for attaching ligands or antibodies to a microbubble shell. Biotin is also 
known as vitamin H and is involved in the metabolism of amino acids in addition to 
being involved in healthy hair and nail growth (Combs 1992). 
Figure 6-1 illustrates attachment of an antibody to a lipid-based microbubble via a 
streptavidin-biotin bridge.  In this case the biotin is incorporated into the microbubble 
shell and a biotinylated antibody is attached by streptavidin. 
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Figure 6-1: The streptavidin-biotin bridge. 
6.2. Assessing attachment of the antibodies 
Due to the small size of individual antibodies, 7.5-15nm (Ban et al. 1994), it was 
necessary to find a method which could identify when they had been successfully 
attached to the microbubble shell as it was not possible to visualise them.  In order to 
identify antibody attachment to the streptavidin, fluorescently tagged antibodies (F2883) 
can be added to the microbubble conjugated antibodies (CD31) as illustrated in Figure 
6-2.  When a laser is incident upon a fluorescent marker the fluorophores are excited and 
then as they relax they emit light of a specific wavelength.  As a result it is possible to 
assess antibody attachment by assessing the amount of fluorescence. 
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Figure 6-2: Schematic showing; a, antibodies attached to a microbubble shell identified by 
fluorescently tagged antibodies and b, fluorescently tagged microbubbles. 
Techniques which can be used to measure fluorescence include fluorescence 
microscopy, fluorescence spectroscopy and filter fluorometry (Guilbault 1990; 
TurnerBiosystems 2009).  Fluorescence microscopy can provide a visual indication of 
fluorescence and with the appropriate software is also capable of quantifying the amount 
of fluorescence.  Fluorescence spectroscopy and filter fluorometry techniques both 
involve irradiating the sample with a laser and using detectors to determine the 
fluorescence intensity.  Fluorescence spectroscopy returns a fluorescent spectrum from 
the emitted photons (Lakowicz 1983) and filter fluorometers give a reading of the 
intensity of fluorescence emitted.  Whilst filter fluorometers are a cost effective method 
of measuring fluorescence they require the use of appropriate filters for the fluorescence 
being observed, in addition they require regular calibration (TurnerBiosystems 2009).  
Both types of fluorometer are effected by temperature and humidity and incapable of 
identifying independent fluorescence events (Guilbault 1990). 
Another technique capable of measuring the amount of fluorescence is flow cytometry.  
This technique is capable of not only quantifying the overall fluorescence but also the 
percentage of cells with fluorescence.  Because of this and the availability of a flow 
 
Attachment of Antibodies to the In-House Microbubbles 160 
cytometer, this technique has been used to assess antibody attachment to the in-house 
microbubbles.  A brief description of flow cytometry is given below. 
6.2.1. Flow Cytometry 
Flow cytometry is an optical technique which is most commonly used to assess cellular 
structure (Givan 1992; Melamed 1990) and expression of cell surface and internal 
antigens.  The flow cytometer used for data collection in this chapter can be seen in 
Figure 6-3.  Output parameters from flow cytometry include the cell size and complexity 
(i.e. cells with more structural features, such as granules, provide a greater side scatter 
signal).  In addition the technique is able to identify different cell types and is able to 
give information regarding the internal structure of a cell through phenotypic 
characterisation using antibodies. 
 
Figure 6-3: The Tissue Injury and Repair Group's Beckman-Coulter flow cytometer. 
The cells in a solution are forced to flow one by one through a laser beam.  This single 
file flow of cells is achieved through the hydrodynamic focusing of the solution 
containing the cells.  Hydrodynamic focusing involves streamlining of the solution by 
means of a sheath fluid as illustrated in Figure 6-4. 
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Figure 6-4: Hydrodynamic focusing of a solution containing cells or microbubbles. 
Once the cells are flowing in single file they are passed through a laser beam which 
results in light scattering, this is illustrated in Figure 6-5.  As individual cells pass 
through the laser beam, laser light is scattered forwards and sideways as illustrated in 
Figure 6-6.  Data from the forward scatter can be used to determine the two dimensional 
size of the particle whilst the sideways scatter can provide further three-dimensional 
information on complexity. 
 
Figure 6-5: Flow cytometry principle. 
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Figure 6-6: Scattering of laser beam by cells or microbubbles; a, forward scatter and b, sideways 
scatter. 
Absorption and fluorescence properties of the biomolecules within the cell can provide 
the chemical analysis (Sheehan 2000), identifying which biomolecules are present.  In 
addition refractive index measurements can quantify the granularity within the cells.  
Through this chemical analysis subtle differences between subpopulations of cells can 
be detected. 
In addition to the physical and chemical information, flow cytometry can be used to 
investigate the fluorescence of a cell or particle.  Antibodies with fluorophore tags can 
be added to the cell.  When the laser is incident upon a fluorescent marker the 
fluorophores are excited and then as they relax they emit light of a specific wavelength.  
Detectors collecting side scatter can filter the emitted light and identify the fluorophore 
and intensity of the fluorescence.  Fluorescence can therefore provide information about 
the number of cells with fluorescent markers and the amount of fluorescence per cell.  
Due to the comparable sizes between the in-house microbubbles and cells it is possible 
to use flow cytometry to assess the attachment of antibodies to the microbubbles.  The 
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antibodies on the microbubbles are tagged using a fluorescent antibody as illustrated in 
Figure 6-2a.  When the fluorescently tagged microbubbles are put through the flow 
cytometer information regarding the number of microbubbles fluorescing, and the 
amount of fluorescence, can be collected.  This identifies the number of microbubbles 
with antibodies attached. 
6.3. Attaching antibodies to the in-house microbubbles 
6.3.1. Initial Investigation and Results 
Initial investigations into attachment of antibodies to the in-house microbubble involved 
adding varying amounts of 1mg/ml concentration streptavidin (Sigma-Aldrich, MO, 
USA) (0, 50, 100 and 150μl) to a millilitre sample of the in-house microbubbles, 
agitating and incubating at 2-5°C for 20-30 minutes and then incubating with 10μl of 
CD31 biotinylated antibody (R&D systems, USA) for a further 20-30 minutes.  CD31 is 
an antibody produced by the body to remove aged white blood cells.  Also known as 
platelet endothelial cell adhesion molecule (PECAM-1), the antibody will adhere to 
endothelial cells and is therefore a suitable targeting antibody for SK-Hep-1 cells used 
throughout this thesis as described later in Chapter 8. 
Figure 6-7 shows only a very small increase in fluorescence with increasing volumes of 
streptavidin over 50μl.  The number of microbubbles fluorescing is less than 10% and 
therefore the number of microbubbles with antibodies attached is inadequate and would 
result in only 10% of the microbubbles being able to attach to the cells. 
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Figure 6-7: Initial results from antibody attachment with varying volumes of streptavidin (error 
bars represent 1 standard deviation of three data sets). 
Due to the low percentage of microbubbles with antibodies attaching an investigation 
was then carried out into the attachment of streptavidin to the biotinylated microbubbles.  
In order to assess attachment of streptavidin to the in-house microbubbles using flow 
cytometry a fluorescent, fluorescein isothiocyanate (FITC) conjugated streptavidin 
(Sigma-Aldrich, MO, USA) was used so that attachment could be assessed with flow 
cytometry.  FITC conjugated streptavidin was added to the biotinylated microbubbles, 
agitated for 5s, and then incubated at 2-5°C for 20-30 minutes.  Following this the 
samples were washed twice, diluted 1:10 with phosphate buffered saline (PBS), and 
assessed using flow cytometry.  Figure 6-8 shows the number of microbubbles with 
streptavidin attached as a percentage of the microbubble population. 
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Figure 6-8: Attachment of FITC conjugated streptavidin to microbubbles  (error bars represent 1 
standard deviation). 
As the volume of streptavidin is increased, the percentage of microbubbles with 
streptavidin attached increases.  At 400μl of streptavidin the percentage of the 
microbubble population with streptavidin attached reaches 97.83 (± 0.02)%.  Beyond 
this there is no further increase in fluorescence, suggesting that 400μl is the optimum  
volume of streptavidin for attachment to the microbubbles.  Microbubble concentrations 
were found to be approximately (64.50±0.02)×10
6
microbubbles per ml as described in 
Appendix G.  However, the composite image of the microbubbles with streptavidin in 
Figure 6-9a illustrates clumping of the microbubbles in which the streptavidin attaches 
microbubbles together. 
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Figure 6-9: Clumping of microbubbles as a result of streptavidin addition; a, composite microscopic 
image confirming attachment of streptavidin to microbubbles and demonstrating clumping and b, 
schematic demonstrating clumping. 
6.3.2. Secondary Investigation and Results 
The results presented in the initial investigation indicate that the streptavidin is attaching 
to the biotinylated microbubbles.  However attachment of the antibodies to the 
streptavidin coated microbubbles was still not observed.  The potential reasons for this 
are outlined below: 
 The biotinylated antibodies were not attaching to the streptavidin on the 
microbubble surface due to denaturing or faulty product. 
 There were insufficient antibodies present to observe attachment to the 
microbubbles. 
 The fluorescent tag was not attaching to the antibodies, therefore not identifying 
antibodies attached to the microbubbles. 
 The streptavidin on the microbubble surfaces were attaching microbubbles 
together, using up all streptavidin sites or making them inaccessible to 
biotinylated antibodies. 
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The author believed this to be due to the clumping of the bubbles and a lack of available 
streptavidin binding sites, identified in the fourth point above and illustrated in Figure 
6-9.  In light of this the following variations to the procedure were introduced: 
 CD31 was added to the microbubbles before adding streptavidin. 
 Samples were agitated whilst adding the streptavidin in an attempt to encourage a 
greater number of antibodies to attach to the microbubbles. 
 The next investigation involved reducing the volume of microbubbles used as it was 
surmised that there may be insufficient antibodies present to compete for the streptavidin 
binding sites. 
Method 
The test tubes were set up with 1ml PBS in each.  Following this, CD31 biotinylated 
antibody and the in-house microbubbles were added to the test tubes in volume ratios of 
1:10, 1:5, 1:2, 1:1, 5:2, 5:1 and 15:2.  The samples were then agitated for 5s each. 
A standard quantity of 100μl of streptavidin was then added to each sample whilst 
agitating and samples were further agitated for 10s.  After agitating the samples were 
incubated at 2-5°C for 20-30 minutes.  The samples were then washed twice before 
adding the fluorescent tag to the antibodies and measuring the number fluorescing with 
flow cytometry. 
Results 
At microbubble to antibody ratios, of 0.5 or under by volume, less than 50% of the 
microbubble population had antibodies attached, whilst as the ratio was increased to one, 
the percentage of microbubbles with antibodies attached peaked at 70%.  Beyond a ratio 
of 1:1 the fluorescent population decreased rapidly reaching below 10% at a ratio of 7.5.  
This data is illustrated in Figure 6-10 below.  The targeted microbubbles can be seen in 
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Figure 6-11.  These images show that some clumping is observed when targeted (Figure 
6-11c and d), although significantly less than observed in initial investigations. 
 
Figure 6-10: Variation in fluorescent population of microbubbles as a function of antibody to 
microbubble ratio (error bars represent 1 standard deviation). 
 
Figure 6-11: Microscopic images of targeted microbubbles at 13×106microbubbles per ml 
concentration; a, x10 magnification phase contrast image, b, x10 magnification fluorescent image 
(bright dots showing existence of targeted microbubbles), c, x40 magnification cropped image of a 
cluster of microbubbles and d, x40 magnification fluorescent image of the same cluster.  White 
arrows indicate some targeted microbubbles. 
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The data presented in Figure 6-10 shows the optimum ratio of antibodies to 
microbubbles to be 1:1 as a distinct peak can be seen at this ratio.  In light of this, all 
further investigations into the attachment of antibodies to microbubbles were carried out 
with equal volumes of antibodies and microbubbles. 
6.3.3. Final investigation 
Once the optimum ratio of antibodies to microbubbles had been established a further 
investigation into the optimum volume of streptavidin, for antibody attachment, was 
carried out.   
Method 
Test tubes were set up with 1ml PBS, following this 10μl of microbubbles and 10μl of 
biotinylated CD31 were added and the solutions were agitated (an equal number of test 
tubes were set up containing 10μl of microbubbles and 50μl of a negative antibody as a 
control set).   
Streptavidin was then added to all the samples whilst agitating and samples were 
agitated for a further 10s after addition.  Initially streptavidin in aliquots of 10, 15, 20, 
25, 30, 40, 50, 60, 100 and 150μl were added to the negative and positive samples.  This 
was followed by an investigation into smaller volumes of streptavidin and aliquots of 2, 
4, 6, 8, 10 and 15μl were added to negative and positive samples. 
All samples were then incubated at 2-5°C for 20-30 minutes and then washed twice.  
Following this the fluorescent tag was added to the antibodies for assessment with flow 
cytometry. 
Results 
The data collected from the investigation involving larger volumes of streptavidin is 
presented in Figure 6-12.  From this data it can be seen that there is a minimum in 
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antibody attachment between 20 and 30µl and that optimum attachment occurs at 10 and 
50µl.   
 
Figure 6-12: Fluorescence as a percentage of the microbubble population for large volumes of 
streptavidin (error bars represent 1 standard deviation). 
Due to the peak observed at 10μl an investigation into smaller volumes of streptavidin 
was carried out and the data from this investigation is illustrated in Figure 6-13 below.  
This data shows a peak of 91.20(±0.03)% at 8μl of streptavidin suggesting that this is the 
optimum amount of streptavidin to be used in antibody attachment. 
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Figure 6-13: Fluorescence as a percentage of the microbubble population for small volumes of 
streptavidin (error bars represent 1 standard deviation). 
6.4. Discussion 
Initial investigations carried out were to determine the optimum volume of streptavidin 
to facilitate antibody attachment.  The results from this investigation, which are 
presented in Figure 6-7, suggest that little antibody attachment had been achieved with 
the original attachment method.  When observed under the microscope it was evident 
that clumping of the microbubbles was occurring.  To confirm that this clumping was a 
result of the streptavidin attaching the microbubble biotin sites together an investigation 
into the attachment of a FITC conjugated streptavidin was carried out.  This 
investigation confirmed that streptavidin was binding to the microbubble biotin sites and 
is illustrated in Figure 6-8 and Figure 6-9.  In addition Figure 6-9 confirms that the 
streptavidin is the cause of the microbubble clumping. 
Once streptavidin attachment had been confirmed changes to the attachment procedure 
for the antibodies were introduced.  The primary change was the addition of the 
antibodies to the microbubbles prior to the addition of streptavidin.  In addition it was 
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hypothesised that the low antibody attachment may be due to an uneven number of 
antibodies to microbubbles and therefore an investigation into the effect of varying the 
antibody to microbubble ratio by volume was carried out. 
The results presented in Figure 6-10 demonstrate that the hypothesis was correct and 
suggests that optimum attachment occurs at 1:1 volume ratio of antibodies to 
microbubbles.  At this ratio antibody attachment was at 80% of the microbubble 
population.   
Once attachment of antibodies was established a second investigation into varying 
volumes of streptavidin was carried out.  The first investigation, results of which are 
presented in Figure 6-12, involved volumes from 10µl to 150µl.  This data suggested 
that there was a significant drop in the percentage of microbubbles with antibodies 
attached at 20-40µl.  With peaks in the number of microbubbles with antibodies attached 
at 10 and 60µl.  The author believes that the initial peak in antibody attachment is due to 
there being sufficient streptavidin to bind the biotinylated antibodies to the 
microbubbles.  As the volume of streptavidin increases this results in many unbound 
streptavidin sites causing the microbubbles to clump together, preventing antibodies 
from being fluorescently tagged as they are trapped inside clumps of microbubbles.  
Above 60µl of streptavidin it is believed that the microbubble biotin sites are swamped 
therefore preventing clumping of microbubbles resulting in a high percentage of 
microbubbles with antibodies attached. 
Due to the economics of the project it was decided to do a further investigation into 
smaller volumes of streptavidin, from 2-15µl.  This was carried out to establish if 10µl 
of streptavidin was optimum.  The results presented in Figure 6-13 suggest that peak 
antibody attachment occurs at 8µl of streptavidin per 10μl of microbubbles. 
As a result of these investigations, it was shown that the optimum ratio of antibodies to 
microbubbles to streptavidin is 5:5:4 by volume. 
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6.5. Summary 
Antibodies have been shown to attach to the in-house microbubbles via a streptavidin-
biotin bridge.  The optimum ratio of antibodies to microbubbles to streptavidin is 5:5:4.  
This composition produces a microbubble population with 91.2% antibody attachment, 
nine times greater than the initial attachment achieved. 
In conclusion, using the streptavidin-biotin bridge, we have successfully shown that 
biotinylated antibodies can be attached to the in-house microbubble.  In Chapter 7 the 
strength of attachment of the streptavidin-biotin bond will be measured in the flow 
chamber previously described and in Chapter 9 attachment of the targeted microbubbles 
developed in this chapter will be assessed under flow. 
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Chapter 7 Attachment and Detachment of the 
UCA under Increasing WSS:  Streptavidin-
Biotin Bond. 
 
The strength of attachment of the microbubble UCA was investigated by assessment of 
the detachment of the agent under increasing WSS.  Previously Butler et al. (2005) 
determined that the agent attached to an agar surface via a streptavidin-biotin bond can 
withstand WSS of up to 3.4Pa.  As described in Chapter 4, a novel parallel-plate flow 
chamber was designed and calibrated to 50Pa WSS.  In this chapter the strength of the 
streptavidin-biotin bond has been tested up to 50Pa; over an order of magnitude greater 
than previously tested  and comparable to shear stresses found in non-diseased coronary 
arteries and in small animal vessels (Cheng et al. 2007a), the purpose of this 
investigation was to determine the feasibility of using the UCA for future small animal 
studies.  WSS values found in mouse aortas and human coronary arteries are presented 
in Table 7-1. 
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Animal Vessel Average WSS Peak WSS Methods Reference 
Mouse Aorta 22Pa 60Pa Computational 


















Table 7-1: Values of WSS found in healthy vessels of mice and humans. 
In addition attachment of the in-house UCA via a streptavidin-biotin bond has been 
investigated under flow.  For this investigation the biotinylated in-house UCA was 
introduced to water flowing over a streptavidin coated agar surface at very low WSS. 
Microbubbles containing 5% biotin were used throughout this investigation.  
Biotinylated in-house microbubbles were produced in accordance with Appendix D. 
7.1. Detachment Investigation 
For the detachment investigation, biotinylated microbubbles were attached to 
streptavidin-coated agar and placed inside the flow chamber.  The flow chamber 
incorporated an agar well to facilitate the attachment of the agent under flow conditions.  
Agar was produced using the protocol outlined in Appendix H and manufactured to fit 
into the agar well of the flow chamber.  The processes involved in attachment of the 
agent to the agar are outlined below. 
7.1.1. Methods and Materials 
Coating agar strips with streptavidin 
Streptavidin (Sigma-Aldrich, MO, USA) was dissolved in a coating buffer (1 capsule 
bicarbonate to 100ml de-ionised water) in a 1:12 (streptavidin to buffer) ratio by 
volume.  The agar was then coated with 1ml of the streptavidin buffer solution covered 
and left for a minimum of 18 hours to ensure optimum adsorption of the streptavidin.  
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Excess coating buffer and streptavidin was rinsed off the agar after 18 hours using 
saline. 
Attaching microbubbles 
The biotinylated in-house microbubbles were then added to the streptavidin coated agar 
surface.  Microbubbles were transferred to the agar surface in 1ml aliquots, the coated 
agar was then covered and left for two hours.  After two hours the agar surface was 
rinsed with saline again to remove excess microbubbles. 
Assessment of attachment 
Once microbubbles had been attached, the 200×7×2mm agar strips were placed inside 
the flow chamber.  The flow chamber was then clamped shut and connected to the 
pump, as illustrated in Figure 4-7 with the LDA set-up.  The flow chamber is shown in 
Figure 7-1. 
 
Figure 7-1: Photograph of flow chamber sealed with silicon grease (which can be seen as the texture 
on the plastic) and showing agar well. (A greater number of clamps were used, when passing flow 
through chamber, than pictured.) 
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At each interval IVUS images of the reflection from attached microbubbles was 
collected.  In addition the RF data from the IVUS images was collected and analysed in 
IDL to determine the mean backscatter from the microbubbles, as described in Chapter 
3. 
A control investigation was also carried out in which microbubbles were transferred 
onto a non-streptavidin-coated agar strip, which was then left for two hours, rinsed and 
subjected to the same shear stresses as the attached microbubbles. 
Each experiment was repeated three times and the mean backscatter compared.  An 
IVUS image and mean backscatter measurement were also collected from a plain agar 




The IVUS images collected from the control investigation are shown in Figure 7-2.  The 
baseline image, agar with no microbubbles attached, can be seen in Figure 7-2f.  In static 
conditions (at 0Pa WSS) the mean backscatter from the non-streptavidin-coated surface, 
which was exposed to microbubbles, is brighter, suggesting that microbubbles are 
attached to this surface.  As described previously the RF data from the IVUS image was 
analysed in order to quantify the mean backscatter from the microbubbles on the agar 
surface.  A region of interest was centered over the surface echo of the agar and 
analysed.  Figure 7-3 shows the decrease in mean backscatter as the WSS is increased to 
relatively low WSS values.  The mean backscatter from the non-streptavidin-coated 
surface which was exposed to microbubbles is more than 10dB greater than the mean 
backscatter from a plain agar surface in static conditions (p<0.05).  As the WSS is 
increased to 0.88Pa (a relatively low WSS) the mean backscatter decreases to -
33.5(±0.9)dB suggesting that the microbubbles have detached from the surface as, at this 
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WSS the mean backscatter value is the same as that from the plain agar surface (p=0.39).  
This is confirmed by the echo in Figure 7-2e. 
 
Figure 7-2: IVUS images from control investigation showing mean backscatter from microbubbles 
attached to an uncoated agar surface at a, 0Pa; b, 0.30Pa; c, 0.44Pa; d, 0.66Pa; e, 0.88Pa and f, a 
plain agar surface.  Agar surfaces identified by white arrows. 
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Figure 7-3: Control investigation showing mean backscatter from non-streptavidin-coated agar 
surface exposed to microbubbles in addition to mean backscatter from an agar surface.  (Error bars 
represent 1 standard deviation.) 
Streptavidin-Biotin Attachment 
Under a streptavidin-biotin attachment mechanism the in-house UCA was found to 
remain attached up to 50Pa WSS.  Figure 7-4 shows the echoes received from the 
microbubbles attached to the agar via a streptavidin-biotin bond at 0 and 50Pa WSS 
compared to the echo from a plain agar surface and a streptavidin coated agar surface.  
These IVUS images show that the echo from the agar surface with microbubbles 
attached is brighter than that from the plain and streptavidin coated agar surfaces at both 
0 and 50Pa.  This indicates that microbubbles have remained attached to the streptavidin 
coated surfaces at 50Pa WSS. 
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Figure 7-4: Echoes from agar surface with microbubbles attached at a, 0Pa and b, 50Pa WSS 
compared to echo from c, a plain agar surface and d, a streptavidin coated agar surface.  White 
arrows indicate agar surface.  
The mean backscatter analysis, which can be seen in Figure 7-5, confirms that the echo 
received from the surface with microbubbles attached is greater than the mean 
backscatter from plain agar.  Under static conditions the mean backscatter from the 
attached microbubbles is -21.5(±1.6)dB  which is 15.0(±2.4)dB greater than the mean 
backscatter from a streptavidin coated agar surface (p<0.01).  As the WSS is increased 
the mean backscatter decreases slightly but at 50Pa WSS it is -34.9(±5.5)dB, still 1.5dB 
greater (p=0.65) than that from the control surface indicating that, although potentially a 
proportion of the microbubbles remain attached even at very high WSS, this is not a 
statistically significant difference. 
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Figure 7-5: Mean backscatter from microbubbles attached to a streptavidin coated agar surface at 
increasing WSS compared to the mean backscatter from a streptavidin coated agar surface without 
microbubbles attached.  (Error bars represent one standard deviation.) 
The results from the control investigation and the streptavidin attachment investigation 
can be seen together in Figure 7-6.  The strength of attachment to the agar via a 
streptavidin-biotin bond was 75 times greater than attachment without this bond. 
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Figure 7-6: Comparison of the mean backscatter at increasing WSS for the streptavidin –biotin 
attachment and the control investigation. (Error bars represent one standard deviation.) 
7.2. Detachment over time 
An investigation into the length of time the in-house microbubbles remain attached to 
the agar surface was carried out, under low WSS.  The purpose of this investigation was 
to determine if the streptavidin-biotin bond would remain stable for the duration of an 
ultrasound examination. 
7.2.1. Materials and Methods 
Microbubbles were attached to the agar strips as described in Section 7.1.1.  The 
microbubble coated agar strips were then placed in the flow chamber and the attached 
microbubbles were subjected to a WSS of 0.48Pa for 150 minutes.  IVUS images and 
RF data were collected every 15 minutes. 
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In addition a control investigation was carried out.  Microbubbles were attached to the 
agar strips and placed inside the flow chamber.  The flow chamber was filled with water 
but the microbubbles were not subjected to shear stress for the duration of the 
investigation.  IVUS images and RF data of the attached microbubbles were collected 
every 15 minutes for 150 minutes. 
Data from a plain agar strip was collected at the same time for comparison. 
7.2.2. Results 
The IVUS images in Figure 7-7 show the reflections from microbubbles attached to an 
agar surface under 0 and 0.48Pa WSS at 0 and 150 minutes and compare this echo to the 
reflection from agar in Figure 7-7f.   
 
Figure 7-7: IVUS images collected at different time intervals for a-b microbubbles subjected to 0Pa 
WSS and d-f, microbubbles subjected to 0.48Pa WSS compared to c, the reflection from agar. 
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The reflection from the attached microbubbles under 0Pa WSS does not vary 
significantly over the 150 minute period whilst the reflection from the microbubbles 
subjected to 0.48Pa WSS decreases over 150 minutes.  However, despite a decrease in 
the reflection the echo after 150 minutes is still enhanced compared with that from plain 
agar (p<0.01). 
Analysis of the RF data confirms that the mean backscatter from the attached agent 
decreases by 5dB under 0.48Pa WSS over 150 minutes, whilst the mean backscatter 
from the agent attached under 0Pa WSS varies by only 1dB.  This data is presented in 
Figure 7-8.  
 
Figure 7-8: Mean backscatter from microbubbles subjected to 0Pa and 0.48Pa WSS over time. 
(Error bars represent one standard deviation.) 
7.3. Attachment Investigation 
Attachment of the agent to agar under low WSS was investigated.  This was achieved by 
introducing microbubbles to the flow across agar.  Agar strips were coated in 
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streptavidin, as described in Section 7.1, then placed inside the flow chamber and 
subjected to a WSS of 0.31Pa, the lowest achievable in the novel flow chamber.  
Biotinylated contrast agent was then injected directly into the flow channel and allowed 
to circulate in the flow for 10 minutes following which an IVUS image and RF data 
from the agar surface were collected and compared to IVUS data collected before 
introducing contrast agent to the flow.  This investigation was repeated three times. 
7.3.1. Initial Results 
Figure 7-9b shows the echo received from the streptavidin coated agar surface after 10 
minutes of circulating the in-house UCA under 0.31Pa WSS.  The echo is not enhanced 
compared to that received from the plain agar surface suggesting that microbubbles are 
not attaching under flow conditions.  The mean backscatter from the coated surface after 
being subjected to flow and biotinylated contrast agent was -33.8(±3.0)dB and the mean 
backscatter from the agar surface was -34.4(±1.9)dB.  This illustrates that the variation 
in echogenicity is minimal at less than 1dB suggesting that there is no attachment under 
0.31Pa WSS. 
 
Figure 7-9: IVUS images a, of  agar surface before introducing contrast agent to the flow and b, of a 
streptavidin coated agar surface after being subjected to contrast under 0.31Pa WSS 
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7.3.2. Further attachment investigations 
Since the results presented above suggested that no microbubbles were attaching, under 
even low wall shear stresses, visual observations of attachment, with a microscope were 
investigated.  Microscopic visualisation of the agar surface was attempted, however this 
proved to be inconclusive as the agar is opaque and the methods used to section very 
fine samples of the agar surface may have caused any attached agent to detach. 
Therefore the adapted rear panel of the flow chamber designed for cellular adhesion 
(described in depth in Chapter 8) was used and attachment to microscope slides was 
attempted. 
Microscope slides were coated in streptavidin using the same method used to coat the 
agar strips previously.  The slides were then placed inside the flow chamber and 
subjected to 0.31Pa WSS.  A 2.4ml volume of the in-house contrast agent was then 
injected directly into the flow channel and circulated for 5 minutes. 
Figure 7-10 shows microscopic images of slides after being subjected to biotinylated 
contrast agent at 0.31Pa WSS.  Figure 7-10b shows that there are a very small number of 




Figure 7-10: Microscopic images of slides after being subjected to contrast agent at 0.31Pa WSS a, 
x10 magnification and b, x40 magnification. 
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7.4. Discussion 
The biotinylated in-house UCA has been shown to remain attached to a streptavidin 
coated agar surface up to 50Pa WSS, showing that the streptavidin-biotin bond can 
withstand the shear stresses experienced in the coronary arteries of small animals.  This 
investigation has shown that the streptavidin-biotin bridge is a suitable method for 
attaching antibodies to the shells of the in-house microbubbles as it is capable of 
withstanding high WSS.  In addition the streptavidin-biotin bond has high specificity 
meaning that the streptavidin is unlikely to bond to other proteins, therefore optimizing 
the antibody attachment.  Antibody attachment and the streptavidin-biotin bond are 
discussed further in Chapter 6. 
In this Thesis I have demonstrated that microbubbles attached to agar via a streptavidin 
bond are able to withstand 75 times the shear stress that microbubbles with no specific 
attachment mechanism are able to withstand.  However, despite this the in-house UCA 
was shown to remain attached to a non-streptavidin coated agar surface up to 0.66Pa 
WSS.  The mechanisms behind this attachment could be either an electrostatic or 
chemical mechanism, as described in Section 2.3.  The author believes this limited 
attachment to be the result of electrostatic forces between the microbubbles and the agar 
surface. 
Investigations into the detachment of the agent over time have shown that the 
streptavidin-biotin bond is capable of withstanding a WSS of 0.48Pa for up to 2.5 hours.  
The effect of higher WSS over time on the attached agent was not assessed due to the 
leak from the flow chamber which occurred at higher WSS after a limited running time.  
The results from this investigation do however indicate that the streptavidin-biotin bond 
is capable of retaining attachment for the duration of a diagnostic ultrasound scan.  
Minimal detachment may have occurred during this time as RF analysis suggests that the 
mean backscatter from the attached microbubbles decreases very slightly over time, it is 
possible that the detachment of the agent under increasing WSS as observed in Section 
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7.1.2 may be due in part to time as the duration of the investigation was approximately 
30 minutes. 
Initial attachment investigations under flow proved to be inconclusive and were 
therefore repeated using microscope slides for a visual assessment of attachment.  The 
results from this investigation showed that there was minimal attachment of the in-house 
agent to a streptavidin coated surface under flow conditions with a WSS of 0.31Pa, the 
lowest measurable WSS in the developed flow chamber.  These results suggest that 
attachment is occurring but that it is minimal and therefore not detectable using IVUS.  
In order to use the agent in-vivo it will be necessary to optimize the attachment under 
flow conditions to produce a measurable difference in mean backscatter from the target 
surface. 
7.5. Summary 
When attached to a streptavidin-coated agar surface prior to being subjected to flow 
conditions the in-house UCA has been shown to remain attached under a WSS of 50Pa, 
although a decrease in the echogenicity of the agent and therefore the quantity of the 
agent attached is observed.  In addition the in-house agent was shown to remain attached 
via a streptavidin-biotin bond under a low WSS of 0.48Pa for over 2 hours.  This work 
suggests that a streptavidin-biotin bridge is a suitable mechanism for attaching 
antibodies to the microbubble shell. 
However, although investigations into attachment of the in-house agent under flow 
conditions have shown some microbubble attachment the attachment is limited and does 
not produce a detectable signal when used in conjunction with IVUS.  
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Chapter 8 Cellular Adhesion 
 
In order to assess attachment of the in-house UCA to a cellular surface under varying 
shear stress it was necessary to develop a flow chamber which would enable the growth 
of a cellular monolayer.  In addition it was necessary for the cells to remain adhered to 
the surface under shear stress. 
Initial investigations involved developing the optimum surface for growing cells within 
the flow chamber described in Chapter 4.  A variety of materials which were compatible 
with IVUS were investigated for cell growth as described in Section 8.2 below.  
Following this cells were grown on microscope slides and the flow chamber adapted to 
incorporate the slides for a visual assessment of cellular adhesion under flow. 
Finally cells were grown within μ-slides from Ibidi (Munchen, Germany), described in 
Section 8.4.  These cells were subjected to low WSS and observed under a microscope 
to assess cellular adhesion. 
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8.1. SK-Hep-1 Cells 
The cell lines used throughout this thesis for cellular adhesion studies and microbubble 
attachment under flow were SK-Hep-1 cells and human umbilical vein endothelial cells 
(HUVEC).  SK-Hep-1 cells are reported to be from human hepatocellular carcinomas 
(Heffelfinger et al. 1992; Lin et al. 1998) however, studies have shown that the cells 
exhibit endothelial characteristics (Heffelfinger et al. 1992; Lirdprapamongkol 2006).  A 
microscopic image of the SK-Hep-1 cells is shown in Figure 8-1.  This cell line was 
chosen due to the robust nature and endothelial characteristics of the cells. 
 
Figure 8-1: Microscopic images of SK-Hep-1 cells; a, ×10 magnification and b, ×40 magnification. 
Sk-Hep-1 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) by Linda 
Norrie (Medical Physics, The University of Edinburgh). 
8.2. Cell growth surfaces compatible with the parallel plate 
flow chamber 
Due to intended usage of the microbubble UCAs it was desirable to be able to assess the 
attachment of the UCA to cells using IVUS.  To this end, cell growth was attempted on a 
variety of materials which would be compatible with the flow chamber designed in 
Chapter 4. 
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Initial investigations into different cell growth materials involved using agar and gelatin.  
Agar was produced using the protocol described in Appendix H and has already been 
shown to be acoustically transparent in Chapter 7.  In order to assess cellular adhesion to 




 cell culture 
6-well plate (Sigma-Aldrich, MO, USA).  Cells were then seeded in both wells 
containing agar and two control wells.  The resulting cell growth caused the agar to 
dissolve and proved unsuccessful.   
Gelatin was also investigated as this could be manufactured and moulded to fit in the 
agar well of the flow chamber.  A 10% gelatin solution was mixed and allowed to set in 
a Petri dish.  Following this the gelatin was assessed with IVUS to determine the 
feasibility of using gelatin for IVUS assessment of microbubbles attached to cells under 
flow.  The IVUS image of a gelatin surface can be seen in Figure 8-2 showing the bright 
reflection from the surface.  Although every care was taken to remove bubbles from the 
solution, it is believed that the bright reflection was due to bubbles forming within the 
gelatin as it set.  Due to this reflection from the gelatin it proved unsuitable for use with 
IVUS; in addition, when attempting to grow cells on the gelatin, it was dissolved by the 
growing cells. 
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Figure 8-2: IVUS image showing reflection from a gelatin surface, as identified by the white arrow. 
Further attempts to grow cells inside the flow chamber involved the use of a Mylar
®
 
(DuPont Teijin Films, Stevenage, UK) polyester film.  In order to assess the 
echogenicity of the film it was cut to fit over the agar well and sealed within the flow 
chamber.  The surface of the Mylar
®
 was then assessed with IVUS.  Figure 8-3 below 
shows the reflection from the Mylar
®
 film in the flow chamber with water flowing 
through the channel compared to the reflection from an agar surface. 
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Figure 8-3: IVUS reflections from a, mylar film over agar and b, agar. 
Although the echo from the film is slightly brighter than that from agar the echogenicity 
is -32.80(±0.26)dB, compared to the average mean backscatter from microbubbles 
attached to an agar surface which is -23.21(±1.43)dB.  This made Mylar
®
 film a feasible, 
low backscatter option for growing cells within the flow chamber. 
8.2.1. Growing cells on Mylar film 
The next stage in the investigation was to investigate cell growth on the film.  Cell 
growth was assessed through determining the cellular confluence (percentage of area 
with cells adhered) as described in Appendix I.  Initially cells were grown without a cell 
growth substrate.  Small pieces of film were cut to fit flat within a Petri dish and cells 
were seeded directly onto the surface.  Microscopic images of cells grown on the film 
can be seen in Figure 8-4.  The cells did not grow to confluence and so different cell 
substrates were investigated to encourage cell growth.   
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Figure 8-4: Cells grown on uncoated Mylar film (×200 magnification). 
Collagen, a common cell substrate which can be produced easily and economically in 
the laboratory, was used; in addition BD Cell-Tak™ (BD biosciences, USA), a cell and 
tissue adhesive, was investigated.  Figure 8-5 shows the microscopic images of cells 
grown on film using these substrates.  The cells grown using Cell-Tak™ have a 
confluence of 5.4 (±0.7)%, this was less than the cells grown using collagen as a 
substrate, which has a confluence of 50.3 (±13.6)%.  In addition cellular adhesion was 
not improved through the use of Cell-Tak™, as demonstrated in Figure 8-6. 
 
Figure 8-5: Microscopic images of cells grown with a, Cell-Tak™ and b, collagen. 
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Figure 8-6: Microscopic images of cells grown with Cell-Tak™; a before being subjected to warmed 
PBS and b, after being subjected to warm PBS. 
8.2.2. Scratched film 
As collagen produced the higher cellular confluences, further investigations were carried 
out to attempt to improve cellular adhesion.  It was hypothesized that the membrane was 
too smooth for the cells to remain attached in the event of shear stresses, in light of this 
the film surface was scratched using fine sandpaper. 
The roughened film resulted in an improvement in cellular confluence, as can been seen 
in Figure 8-7.  Scratching the membrane improved the confluence of the uncoated films 
by 37.02(±19.44)%, whilst the collagen coated film had a confluence increase of 
37.57(±16.32)%.  These results suggested that scratching the film significantly improved 
cellular confluence. 
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Figure 8-7: Microscopic images of cells grown on; a, uncoated film, b, scratched uncoated film, c, 
collagen coated film and d, scratched, collagen coated film. 
In order to be able to assess microbubble attachment to the cells under flow it was 
necessary to be able to subject the film to flow and retain cellular confluence, therefore 
initial investigations involved dipping the cell coated membranes into warmed 
phosphate buffered saline (PBS). 
8.2.3. Method 
Cells were grown to over 60% confluence on squares of scratched film in a Petri dish.  
The PBS was then warmed to 37°C as cells do not survive for long in colder 
temperatures.  Cells were then imaged using the Leica microscope described in Chapter 
3.  Following this the cell coated films were gently dipped into the warm PBS and 
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slowly removed, before being returned to the Petri dish.  The cells were then imaged a 
second time and the confluences compared. 
8.2.4. Results 
After being subjected to warm PBS and a change of environment, the cells grown on 
membranes were found to detach very rapidly.  This is shown in Figure 8-8.  Loss of 
confluence on the collagen coated films was 67.5%, whilst loss of confluence on the 
scratched, collagen coated film was 40.5%, resulting in the confluence reducing to less 
than 2%.  The author and colleagues believe that the significant loss in confluence is due 
to tension changes in the film.  Due to the unreliability of growing cells on the film an 
alternative method of growing cells within the flow chamber was required. 
 
Figure 8-8: Microscopic images of slides (x200mag) before and after being subjected to warm PBS; 
a, a collagen coated film and b, a scratched, collagen coated film. 
8.3. Flow chamber adaptations and microscope slides 
During the previous investigations, cells were also grown on uncoated and collagen 
coated glass microscope slides successfully as illustrated in Figure 8-9.  The average 
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confluence on cells grown on the uncoated slides and collagen coated slides was 
81.5(±2.0)% and 90.8(±4.1)% respectively.  Due to the reproducibility of these 
confluences the collagen coated slides were chosen for further investigation. 
 
Figure 8-9: Cells grown on; a, an uncoated microscope slide and b, a collagen coated microscope 
slide. 
In order to assess the effect of flow on cellular confluence the flow chamber was adapted 
to allow for the incorporation of a microscope slide.  This allowed a visual assessment of 
the cellular adhesion and microbubble attachment; however, due to the acoustic 
properties of glass it was not possible to assess the microbubble attachment with IVUS.  
The adapted rear panel of the flow chamber is shown in Figure 8-10. 
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Figure 8-10: Adaptations to rear panel of flow chamber; a, schematic and b, photograph of space 
for microscope slide. 
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8.3.1. Method 
Cells were seeded onto collagen coated microscope slides and imaged with the Leica 
microscope, the slides were then placed into the flow chamber and the chamber was 
sealed with grease, care was taken to avoid getting grease close to the flow channel in 
the observation region as this would cause cell death. 
The cells within the flow chamber were then subjected to a flow of warmed medium at 
37°C with a flow volume of 60ml/min, corresponding to WSS of 0.31.  A water bath 
was used to maintain medium temperature at 37°C. 
The cells were subjected to flow for 5 minutes after which the slides were carefully 
removed and imaged again under the microscope.  The confluence before and after 
being subjected to WSS was compared. 
The investigation was then carried out a further two times before repeating at 80 and 
100ml/min flow volumes (corresponding to WSS of 0.48 and 0.53Pa). 
In addition a control was carried out at 0Pa WSS, in which the cells were subjected to 
static warmed medium for 5 minutes. 
8.3.2. Results 
It was found that even at low WSS (0-0.53Pa), the cellular confluence decreased rapidly 
during the investigations.  At 0Pa WSS, the decrease in confluence was 34.5(±6.9)%, 
showing that even with no flow a loss in confluence is observed.  At 0.53Pa the decrease 
in confluence was 74.7(±6.8)%.  Figure 8-11 shows the confluence loss at increasing 
WSS.  The data suggests that due to the large decrease in confluence, under no flow and 
relatively low WSS, this method would not be suitable for assessing attachment of 
microbubbles to cells under WSS. 
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Figure 8-11: Confluence loss at increasing WSS. 
The significant loss of confluence at low WSS is believed to be due to environmental 
conditions.  The optimum temperature for cells is 37°C and although the medium was 
warmed to this temperature the surrounding temperature was approximately 22°C.  In 
addition, the flow chamber, although sealed to prevent leaks in the flow was not a sterile 
environment, this meant that the cells were subject to contaminants such as bacteria, 
although this should not have had an effect throughout the short timescale of the 
experiment.  The last factor to consider was the use of grease with which to seal the flow 
chamber, if the grease came into contact with the cells this could have been the cause of 
cell death, resulting in cells „curling up‟ or shearing off the slides, in addition the grease 
was not sterile and may also carry contaminants. 
The resultant decrease in confluence may be due to the WSS being too high for the cells 
to withstand.  Although Kooten et al. (1994) has shown HUVECs and human adult 
saphenous vein cells (HASVC) to remain adhered to a surface up to approximately 18Pa 
no results could be found to indicate the cellular retention of SK-Hep-1 cells. 
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8.4. Ibidi flow cells 
Following these investigations into utilizing the existing flow chamber, an alternative 
flow system was required.  Ibidi (Ibidi, Germany) μ-slide I
0.8 
were used, the Ibidi flow 
slides are presented in Figure 8-12.  The flow channel of the slides measure 
50×5×0.8mm and have a volume of 200μl. 
 
Figure 8-12: Ibidi flow slides; a, schematic, b, side-view of slides and c, photograph of slide  
(reprinted with permission from Kahl at Ibidi (2009)). 
8.4.1. Shear stress 
The shear stress in the flow channel was determined from numerical calculations for 
varying flow volumes (Horn 2008) provided by the manufacturer.  A graph showing the 
calibration of WSS as relating to flow volume can be seen in Figure 8-13.  These results 
were calculated for DMEM which has a viscosity of 
4104.8  Pa·s (Gosgnach et al. 
2000). 
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Figure 8-13: WSS as a function of flow volume for DMEM. 
The EP1 Econo pump (Bio-Rad, Hemel Hempstead, UK) had previously been calibrated 
for varying flow volumes and calibration was confirmed prior to beginning each 
experiment and necessary adjustments made.  The maximum flow volume achievable 
with the pump was 6.4ml/min corresponding to a WSS of 0.19Pa, although 6.0ml/min 
was the maximum flow volume used to minimize stress on the equipment. 





 confirming that laminar flow will occur at these flow volumes. 
8.4.2. Growing cells in Ibidi µ-slides 
A volume of 200μl of cells, in a 
5105.3  ml
-1
 concentration were injected into the flow 
channel following the manufacturer‟s recommendations, as outlined in Appendix J.  The 
slides were then placed in an incubator for 24 hours after which the cells reached 
approximately 50% confluence. 
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8.4.3. Method 
Tubing with an internal diameter of 1.6mm was connected to the flow slide using Luer 
connectors.  The tubing connected the slide to a pump and a reservoir of warm medium 
at 37°C.  The slide was placed on a warm plate on the microscope platform in order to 
record images of the cells after being subjected to varying WSS.  The equipment set up 
can be seen in Figure 8-14. 
 
Figure 8-14: Flow slide experimental set up. 
Once set up an image of the cells was collected with the 40× and 10× objective lenses.  
A flow volume of 1ml/min was set and allowed to run for 2 minutes.  More images were 
collected and then the flow volume was increased to 2ml/min for two minutes.  Flow 
volume was increased every two minutes at 1ml/min increments up to 6ml/min, 
corresponding to WSS of 0.03, 0.06, 0.09, 0.12, 0.15 and 0.17Pa.  Images were collected 
after cells were subjected to each increase in WSS for two minutes. 
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In addition a control, in which the cells were subjected to 0Pa WSS was carried out.  
These investigations were repeated three times. 
8.4.4. Results 
The Ibidi μ-slides provided excellent cellular adhesion under flow.  Figure 8-15 
illustrates the loss in confluence as the WSS is increased from 0.00 to 0.17Pa.  At 0.17Pa 
the decrease in confluence is less than 1% suggesting excellent adhesion under very low 
WSS.  In addition, when compared to the control investigation the decrease is 
comparable to the confluence decrease with no WSS suggesting that confluence loss is a 
result of time and not WSS. 
 
Figure 8-15: Loss of confluence as a function of WSS. 
The loss of confluence over time is due to the cells retracting (shrinking) as can be seen 
in Figure 8-16.  These images were taken from the third control investigation.  The 
retraction of cells is believed to be due to the lack of optimal conditions, for example; 
temperature and CO2 levels. 
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Figure 8-16: Timelapse showing a cell retracting over 10 minutes, white arrow indicates cell in 
question. 
8.5. Summary 
Initial investigations involved an investigation into different acoustically suitable 
materials for cell growth and assessment with IVUS.  The first material investigated was 
agar which was already found to be acoustically suitable for use with IVUS in Chapter 
7.  Unfortunately attempts to grow a cellular monolayer on the agar were unsuccessful.  
Gelatin was then investigated but found to be unsuitable for use with IVUS due to the 
bubbles which would form on setting, in addition it was found to be unsuitable for cell 
growth. 
The next investigation carried out was into the use of a Mylar
®
 polyester film which 
could be placed over the agar and assessed with IVUS.  The film was found to be 
acoustically translucent and as such cell growth on the film was investigated.  Collagen 
 
Cellular Adhesion  207 
and Cell-Tal™ were investigated as cell substrates and although cells initially appeared 
to grow well on the film it was found that they sheared off with minimal changes in 
tension, making the film unsuitable for cell growth. 
Due to the lack of acoustically suitable materials for cell growth the flow chamber was 
adapted to allow for incorporation of a microscope slide.  Cells were shown to grow to 
confluence on collagen coated microscope slides and were therefore used in the flow 
chamber to assess cellular adhesion under shear stress.  At WSS of 0.31-0.53Pa the cells 
were found to shear off rapidly with a confluence loss of more than 60% at the lowest 
WSS achievable.  In addition the control investigation, with no WSS, demonstrated a 
confluence loss of more than 30% suggesting that the flow chamber environment was 
not ideal for cellular adhesion. 
Following attempts to use the flow chamber described in Chapter 4 for cellular adhesion 
investigations it was determined that a flow system allowing for investigations at very 
low WSS (<0.2Pa) was required.  For this reason Ibidi µ-slides were purchased and SK-
Hep-1 cells grown in them.  Cellular adhesion in the Ibidi µ-slides was excellent with 
only a 2% confluence loss at the highest shear stress achievable (0.17Pa). 
The Ibidi µ-slides were found to be the optimal method of investigating attachment of 
the microbubbles to a cellular monolayer under WSS and further investigations were 
carried out using these slides as described in the following chapter. 
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Chapter 9 Attachment of microbubbles to cells 
under low WSS 
The objective of this work was to actively target the UCA to a cellular surface under 
flow to determine the feasibility of using the agent in-vivo for targeting applications.  
The following chapter describes the methods used to achieve this objective. 
In Chapter 6 it was shown that the UCA has been successfully targeted to SK-Hep-1 
cells by optimising the attachment of CD31 antibody to the microbubble shell by way of 
a streptavidin-biotin bridge as described in Chapter 6.  Microbubble attachment to cells 
under static conditions was investigated first.  This was followed by an investigation into 
the attachment of microbubbles under very low WSS. 
9.1. Introduction 
In order to undertake future clinical trials of the agent being developed at Edinburgh 
University it is necessary to successfully target the agent under flow conditions.  To this 
end a flow system has been developed in Chapter 8 to enable assessment of attachment 
of microbubbles to cells under very low, controlled WSS. 
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Previously Villanueva et al. (1998) has visually demonstrated attachment of a lipid 
microbubble to cells expressing a surface protein which is seen in early atherosclerosis 
at a shear rate of 25s
-1
.  Other authors (Ferrante et al. 2009; Klibanov et al. 2006; 
Rychak et al. 2006b; Takalkar et al. 2004) have demonstrated the attachment of targeted 
microbubbles to P-selectin, a cell adhesion molecule found on the surface of endothelial 
cells.  
Rychak et al. (2006a) has demonstrated attachment of P-selectin targeted microbubbles 
in mouse cremaster muscles using ultrasound mediated microbubble attachment which is 
discussed later in this chapter.  Attachment of targeted microbubbles to P-selectin has 
been demonstrated by Takalkar et al. (2004) for WSS from 0.03Pa to 0.17Pa and 
Klibanov et al. (2006) has investigated the attachment of microbubbles, targeted with a 
fast binding ligand to P-selectin up to 0.5Pa WSS. 
9.2. Static attachment 
Static attachment investigations were carried out in Multiwell plates and Petri dishes 
with no flow.  Initial investigations involved assessment of attachment to seeded cells 
which was followed by an investigation into attachment to cells in solution.  Finally 
ultrasound was used to mediate microbubble attachment to cells under static conditions. 
9.2.1. Initial investigations 
Cells were seeded in 6-well plates as described in Chapter 8.  Targeted microbubbles 




 concentration, a non-targeted control 
microbubble was added to two wells and the final two wells had no microbubbles.  
These latter two wells were used as baseline data. 
The microbubbles were incubated with the cells for one hour after which the medium 
was replaced twice to remove excess microbubbles.  A FITC conjugated Anti-Mouse 
IgG, F2883 (Sigma-Aldrich, UK) was added to the wells in 50μl aliquots (0.02mg·ml
-1
) 
to identify the presence of microbubbles and cells were incubated for a further 30 
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minutes.  Medium was replaced once to remove any excess F2883 and the cells observed 
with fluorescence microscopy. 
Initial Results 
Microscopic images of the wells can be seen in Figure 9-1.  This figure shows a 
comparison of the wells observed for targeted and non-targeted microbubble addition. 
Under these conditions, no microbubbles were observed attached to the cells. Although a 
single microbubble appeared to be attached to the cells in Figure 9-1a, the lack of this in 
the fluorescent image suggested that this microbubble was not targeted 
 
Figure 9-1: Microscopic image of; a, well to which targeted microbubbles were added and b, well to 
which non-targeted microbubbles were added, white arrow shows location of suspected 
microbubble. 
9.2.2. Attachment of microbubbles to cells in solution 
It was hypothesised that the lack of attachment observed in the initial investigation 
(Section 9.2.1) was due to the buoyancy of the microbubbles resulting in the 
microbubbles not coming into direct contact with the cellular surface.   In order to 
determine if this were the case microbubbles were then added to cells in solution. 





.  Microbubbles (previously incubated at 37°C) were then added in 100μl 




.  Targeted microbubbles were added to 
two wells, Non-targeted microbubbles to two wells and the final two wells were left as a 
baseline with no microbubbles added.  The cells were then incubated over night to allow 
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them to seed.  After 24 hours the medium was gently replaced twice to remove any 
excess, unattached microbubbles.  A 50μl aliquot (0.02mg·ml
-1
) F2883 was added to all 
the wells, as in Section 9.2.1, and cells were incubated for a further 30 minutes.  Finally 
the medium was gently replaced to remove excess F2883 and the cells observed with 
fluorescence microscopy. 
Results 
Microbubbles added to cells in solution were found to adhere with a very high number 
of microbubbles per unit area.   
 
Figure 9-2: Microscopic images with 10x objective showing; a, contrast enhanced fluorescent image 
and b, bright-field image and c, merged image of microbubbles attached to cells in solution. 
When added to cells in solution, the mean number of microbubbles was 
83.3(±63.2)mm
-2
, the high standard deviation in the result suggests that there is a very 
uneven distribution of microbubbles, this may be due to the solution of microbubbles not 
being agitated sufficiently, however, once added to the well it was not possible to agitate 
thoroughly as this may have caused detachment of cells.  In addition the uneven 
distribution of microbubbles may be due to an uneven distribution of cells.  Despite the 
large variation, the average microbubble count of targeted microbubbles was 
significantly greater (p<0.0001), five times the average microbubble count from non-
targeted microbubbles indicating that the attachment was from active targeting of the 
microbubbles.  A comparison of the data is shown in Figure 9-3. 
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Figure 9-3: Microbubbles observed per square millimetre for targeted, non-targeted and baseline 
microbubble samples when attached to cells in solution. 
9.2.3. Ultrasound Mediated Microbubble Attachment 
The intended clinical application of the UCA makes the previous attachment method of 
the microbubbles unsuitable since it would not be possible to suspend the target cells 
within the body; therefore a method of forcing the microbubbles onto the cellular surface 
was required.  Ultrasound has been well documented as a means to enhance delivery of 
microbubble UCAs (Dayton et al. 1999a; Dayton et al. 1999b; Lum et al. 2006; Rychak 
et al. 2004; Rychak et al. 2006a; Zhao et al. 2004) by way of the acoustic radiation force.  
Dayton et al (Dayton et al. 1997) has derived an equation for the acoustic radiation 
force, this has been adapted by Rychak et al (Rychak et al. 2005) and can be seen in 
Equation 9-1, the parameters are identified in Table 9-1. 
 
















Equation 9-1: Primary acoustic radiation force. 
Equation 9-1 is subject to the following assumptions as identified by Rychak et al. 
(Rychak et al. 2005): 
 The magnitude of the pressure is constant with each ultrasound pulse 
 There is a unidirectional pressure gradient 
Symbol Parameter Value  Source and notes 
c Speed of sound (ms
-1
) 1500 (Rychak et al. 2005) 
P Peak pressure (Pa) 0.064 (±0.017) Measured (Appendix K) 
R Microbubble radius (μm) 5.64 (±0.36) Measured (Chapter 3) 
δ Total damping coefficient 1.27 (Chatterjee and Sarkar 
2003; Rychak et al. 2005) 
ω Microbubble resonant 
frequency (MHz) 
40 Microbubbles optimised 
for 40MHz US (Chapter 3) 
ρ Density (kg·m
-3
) 1005.5 (±6.1) Measured 
D Pulse duration (μs) 0.24 (±7.6) Measured (Appendix K) 




28.6 (±1.3) Measured (Appendix K) 
Table 9-1: Parameters and values used for determination of the primary acoustic radiation force. 
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Assuming the values outlined in Table 9-1 above and using Equation 9-1 the primary 
radiation force acting on the microbubbles is approximately 15.7(±3.2)nN.  However 
many of the values used, with the exception of those measured directly, are estimates, 
making the value subject to possible errors which cannot be calculated. 
Additional forces which may be acting on the microbubbles include the secondary 
acoustic radiation force, between microbubbles, resulting in an attractive force (Dayton 
et al. 1997; Dayton et al. 1999b; Rychak et al. 2005; Schmidt et al. 2008; Zhao et al. 
2004) and the buoyancy force due to the gas content of the microbubbles (Rychak et al. 
2005).  The secondary radiation force for the low concentrations used in these 
investigations is considered negligible as there is an inverse square relationship between 
the force and the distance between the microbubbles. 
However the buoyancy force is in the opposite direction from the primary acoustic 
radiation force.  The buoyancy force can be calculated from Equation 9-2 (Rychak et al. 
2005). 





Equation 9-2: Buoyancy force acting on microbubble. 
Where R is the microbubble radius, g, is the gravitation acceleration, ρ and ρMB are 
density of medium and microbubble respectively. 
The buoyancy force, assuming negligible microbubble density, has been estimated of the 
order of 0.1nN for a lipid microbubble (Rychak et al. 2005).  Assuming that secondary 
radiation forces are negligible and have no effect on the vertical direction of the 
microbubbles the resultant downward force on the microbubbles due to insonation with 
10-22MHz ultrasound is 15.6(±3.3)nN. 
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Method 
Cells were seeded in 90mm diameter Petri dishes overnight.  A single millilitre of 




 concentration and 37°C 
were added to the cell medium (9ml).  The microbubbles were then insonated for two 
minutes with the Diasus scanner (Dynamic Imaging, Livingston, Scotland).  The 
parameters for the scanner and transducer were set at maximum and can be found in 
Table 9-2.  The transducer was kept at a focal distance of 2mm, as measured on the 
scanner screen, and gently moved across the central area of the Petri dish and back as 
illustrated in Figure 9-4.   
The cells and microbubbles were then gently washed through replacement of medium 
twice before the addition of F2883 in the same manner as for Section 9.2.2.  This was 
repeated with non-targeted fluorescent microbubbles. 
In addition the investigation was repeated in an identical manner without insonation as a 
control.  The entire process was repeated three times on three different days. 
Parameter Value 
Mechanical Index (MI) 0.19 
Transmit Power (%) 97-99% 
Frequency L 10-22MHz 
Table 9-2: Parameters of Diasus scanner. 
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Figure 9-4: Ultrasound mediated microbubble attachment to SK-Hep-1 cells, schematic diagram. 
Results 
The primary acoustic radiation force is a viable method of directing microbubbles 
towards a target surface to facilitate attachment.  The targeted microbubbles, which were 
insonated with ultrasound (L10-22MHz) demonstrated greater attachment than a control 
investigation in which ultrasound was not used.  In addition, non-targeted microbubbles 
did not exhibit significant attachment relative to the positively targeted microbubble 
samples.  A microscopic image of a microbubble attached using ultrasound can be seen 
in Figure 9-5. 
 
Figure 9-5: Microscopic image of a microbubble attached to cells using ultrasound (×400 
magnification) 
Ultrasound mediated microbubble attachment increased attachment of microbubbles by 
11mm
-2
.  In addition, attachment of targeted microbubbles was 26mm
-2
 greater than 
attachment of non-targeted microbubbles, a statistically significant difference (p<0.001).  
This data can be seen in Figure 9-6. 
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Figure 9-6: Ultrasound mediated microbubble attachment. 
9.3. Attachment to cells in Ibidi μ-slides 
Previously in Chapter 8 cellular adhesion has been assessed in Ibidi μ-slides.  In order to 
determine the feasibility of attaching the contrast agent under flow conditions 
attachment was assessed under very low WSS within the μ-slides. 
9.3.1. Method 
Cells were seeded in the Ibidi μ-slides over night by Linda Norrie (Medical Physics, 
University of Edinburgh).  The seeding procedure is outlined in Appendix J.  Once the 
cells had reached approximately 60% confluence fluorescent microbubbles were added.  
Due to the unpredictable nature of cells on some occasions it was necessary to feed the 
cells and allow longer for them to reach confluence, this procedure is also outlined in 
Appendix J.  It was decided that above a confluence of 60% there would be enough 
cellular matter for microbubble attachment. 
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Static attachment in flow slides 
The first investigation carried out was regarding static attachment of microbubbles 
within the flow slides.  This was achieved by adding fluorescent, positively targeted 





and adding the medium to the slides as described for medium replacement in Appendix 
J.  The slides were then incubated for 30minutes at 37°C.  After incubation any excess 
unattached microbubbles were removed by very gently replacing the medium twice.  
The slides were then imaged with the fluorescence microscope.   
The static attachment investigation was also repeated with a negatively targeted 
microbubble and a non-targeted microbubble.  The negatively targeted microbubble was 
produced in the same way as the positively targeted microbubble as described in Chapter 
6, however the CD31 antibody was replaced with the same volume and concentration of 
biotinylated Mouse IgG1 Negative isotype control (AbD Serotec, Martinsried, 
Germany). 




 concentration of 
microbubbles. 
Attachment under very low WSS in flow slides 
Following static attachment investigations in the flow slides a study of attachment under 
flow with very low WSS was undertaken.  The flow system described in Chapter 8, 
Section 8.4 and illustrated in Figure 8-14 was used.  Positively targeted microbubbles 




 concentration and warmed to 37°C before 
use.  During flow the temperature of the medium was maintained through immersion in 
a water bath at 37°C. 
The flow system was set-up and the cells in the slides subjected to microbubbles at 
0.03Pa WSS for 10 minutes.  Following this the reservoir was replaced for one 
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containing medium with no microbubbles and the cells washed for a further 10 minutes 
at 0.03Pa WSS as illustrated in Figure 9-7. 
 
Figure 9-7: Removal of excess microbubbles. 
Following washing the slides were then immediately observed under the fluorescence 
microscope to assess attachment of microbubbles. 
Ultrasound Mediated attachment under flow 
In order to determine if ultrasound can facilitate and improve attachment of the 
microbubbles under flow the microbubbles were subjected to 10-22MHz ultrasound. 
The flow system was set up as illustrated in Figure 8-14.  The flow slide, with tubing 
securely attached, was immersed in a warm water bath (37°C) above a block of acoustic 
absorber.  The L10-22MHz transducer was set up at a distance of 2mm from the surface 
of the slide as shown in Figure 9-8.  The distance between the transducer and slide was 
measured using the calipers on the Diasus scanner screen as illustrated in Figure 9-9.  
The focal distance of the scanner was set to lie at the centre of the flow channel. 
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Figure 9-8: Ultrasound mediated attachment of microbubbles within μ-slides. 
 
Figure 9-9: Diasus image showing measurement of distance between transducer and slide and 
identifying slide structures; a, along the length of flow channel and b, cross section of flow channel. 
Fluorescent microbubbles were added to the reservoir in the same concentration as 
described in Section 9.3.1 above.  Cells were then subjected to microbubbles in flow 
with a WSS of 0.03Pa for 10 minutes.  The slides were insonated for the duration of the 
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investigation, parameters of the ultrasound scanner and transducer are defined in Table 
9-2. 
Following the investigation the slides were washed as described previously and observed 
using fluorescence microscopy. 
9.3.2. Results and Discussion 
Static attachment in flow slides 
Targeted microbubbles have been successfully attached to a cellular monolayer in the 
Ibidi flow slides under static conditions.  Positive targeting of the microbubbles 
increased microbubble attachment by 15mm
-2





 and by 10mm
-2





.  An increase in microbubble concentration did not cause an increase in microbubble 
adherence for the positively targeted microbubbles, however there was an increase of 
5mm
-2
 in microbubble adherence for the negatively targeted microbubbles.  This 
increase in adherence of the non-targeted microbubbles suggests that only a portion of 
adherence of positively targeted microbubbles is a result of active targeting.  The data 
from this investigation can be seen in Figure 9-10. 
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Figure 9-10: Microbubble adherence as a function of concentration for positively and negatively 
targeted microbubbles. 
Images of microbubbles attached to the cells can be seen in Figure 9-11.  This confirms 
that adherence does occur for negatively targeted microbubbles, however, there is an 
observable increase in adherence of positively targeted microbubbles. 
 
Figure 9-11: Microscopic images (10× objective) of microbubbles adhered to cells in the Ibidi flow 
slides; a, positively targeted microbubbles and b, negatively targeted microbubbles (white arrows 
indicate some of the microbubbles present in the image). 
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Attachment under very low WSS in flow slides 
Attachment of microbubbles under 0.03Pa WSS was investigated. Figure 9-12 shows the 
average number of microbubbles attached per square millimetre at 0 and 0.03Pa WSS.  
At 0.03Pa the average microbubble count for positively targeted microbubbles was 
4.0(±2.4)mm
-2
, whilst at 0Pa this value was 29.1(±10.0)mm
-2
.  Suggesting that under 
flow conditions fewer microbubbles attach to the cellular surface.  This could be a result 
of the antibody-cell interaction being too slow to form attachment in flow, or due to 
attached microbubbles washing off during the removal of excess microbubbles.  
Alternatively the lack of attachment may have been due to microbubbles not coming into 
contact with the cellular surface as a result of microbubble migration towards the vessel 
axis (Rychak et al. 2006a).  Hence ultrasound was investigated as a means to facilitate 
microbubble attachment. 
 
Figure 9-12: Microbubble adherence as a function of WSS for positively and negatively targeted 
microbubbles. 
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Figure 9-13 shows microscopic images of microbubbles attaching to a cellular surface 
under 0.03Pa WSS.  The microbubbles demonstrate grouping which is likely to be due 
to microbubble manufacture, however, this may also be a result of the secondary 
radiation force as described previously.  Further investigations would need to be carried 
out to determine the reason for this grouping of microbubbles. 
 
Figure 9-13: Microscopic images of; a, positively targeted microbubbles attached to cells and b, cells 
subjected to negatively targeted microbubbles, under 0.03Pa flow (×400 magnification). 
Overall positively targeted microbubble attachment under 0.03Pa WSS was 3.2mm
-2
 
greater than that of negatively targeted microbubbles suggesting that the attachment 
observed is a result of active microbubble targeting.  However this demonstrates very 
limited attachment. 
Ultrasound Mediated attachment under flow 
Ultrasound mediated microbubble attachment has been demonstrated under 0.03Pa 
WSS.  An increase in microbubble adherence of 15.5(±7.9)mm
-2
 has been observed for 
ultrasound mediated attachment (p<0.01).  Figure 9-14 illustrates the increase in 
attachment as a result of the primary acoustic radiation force. 
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Figure 9-14: Microbubble adherence for positively and negatively targeted microbubbles with and 
without ultrasound. 
Images of microbubbles attaching with and without ultrasound can be seen in Figure 
9-15.  This confirms that increased attachment occurs under flow conditions as a result 
of the acoustic radiation force.  However, attachment is still limited and it is therefore 
necessary to investigate attachment of microbubbles under flow in order to optimise 
such attachment. 
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Figure 9-15: Microscopic images of microbubble attachment (x100 magnification); a, positively 
targeted microbubbles without ultrasound, b, positively targeted microbubbles with ultrasound, c, 
negatively targeted microbubbles without ultrasound and d, negatively targeted microbubbles with 
ultrasound.  Microbubbles on a and b identified by white arrows, no microbubbles were observed 
on c and d. 
Although attachment of microbubbles using acoustic radiation force has been successful 
it is possible that the technique is limited due to the plastic slides used for the attachment 
investigations.  Since plastic reflects much of the ultrasound, as demonstrated in Figure 
9-9, it is probable that the primary acoustic radiation force is significantly reduced and 
that with an alternative flow model, with an acoustic window, greater attachment may be 
observed when insonated with ultrasound.  Unfortunately such an investigation was not 
possible within the time scales of this PhD. 
9.4. Summary 
Positively targeted microbubbles have been shown to actively target SK-Hep-1 cells 
when added to cells in solution and using acoustic radiation force to facilitate 
attachment.  In addition the acoustic radiation force acting on the microbubbles has been 
calculated and found to be 15.6(±3.3)nN. 
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Attachment of microbubbles to cells under flow has been investigated in Ibidi µ-slides 
under very low WSS of 0.03Pa.  This is at the same WSS investigated by Klibanov 
(2006) and Rychak (2006a).  Limited microbubble attachment was observed under 
0.03Pa WSS and relative to the negatively targeted microbubbles there is a 3.2mm
-2
 
increase suggesting that active attachment has been observed.  However some 
attachment may not be due to active targeting but as a result of other targeting 
mechanisms, for example chemical or electrostatic interactions, indicated by very 
limited attachment of the negatively targeted microbubbles. 
Ultrasound has been used to facilitate the attachment of microbubbles under flow.  The 
acoustic radiation force has increased attachment of microbubbles under 0.03Pa WSS by 
15.5(±7.9)mm
-2
.  These results suggest that ultrasound is a viable method of facilitating 
attachment of the microbubbles under flow by using acoustic radiation force to drive the 
microbubbles towards the target surface. 
Prior to pre-clinical trials of the UCA it is necessary to demonstrate significant active 
targeting of the microbubbles.  In addition it would be advantageous to be able to 
investigate the echogenicity of the microbubbles attached to a cellular surface in order to 
determine the feasibility of IVUS investigations.  As a result, further investigations 
regarding microbubble targeting under higher WSS are necessary prior to future animal 
investigations.  Possibilities for further investigations and alternative targeting strategies 
are discussed in Chapter 10. 
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Chapter 10   Conclusions and Evaluation 
A lipid-based microbubble UCA has been developed which upon further development 
will be targeted to vulnerable plaques observed in coronary heart disease.  Vulnerable 
plaques have been identified as the leading cause of mortality in people suffering from 
heart disease (Kurzweil and Grossman 2004) and currently there are limited methods 
capable of distinguishing vulnerable plaques from stable plaques.  The in-house contrast 
agent, which will be targeted to inflammation markers exhibited by vulnerable plaques, 
(Lindner 2002a) has been developed for use with high-frequency (40MHz) IVUS.  The 
investigations presented in this thesis represent the initial development stages of the 
UCA in optimisation of the echogenicity of the agent and demonstrating targeting 
feasibility under varying shear stress. 
10.1. Optimization of the UCA 
10.1.1. Conclusion 
Optimisation of the UCA for 40MHz IVUS has been achieved through investigating the 
effect of various methods on the echogenicity of the agent.  Methods investigated 
included agitation, high-shear mixing, sonication and diffusion.  In addition the effect of 
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temperature on production was investigated.  It was found that the optimum manufacture 
method was use of the high-shear mixer before heating of the lipids and use of the 
CapMix™ for rapid agitation after heating of the lipids.  The optimum production 
temperature was determined to be 78ºC and optimum length of agitation was 45s. 
Various compositions were also investigated and the most echogenic composition was 
found to be the 30% cholesterol composition.  This was in a comparison with two 
alternative compositions. 
In addition to optimisation of the agent, stability of the agent over three months was also 
investigated.  The agent was found to remain stable for three months when stored in the 
refrigerator at 2-5ºC as demonstrated in Section 3.4.2. 
10.1.2. Statistical Analysis 
An ANOVA test was carried out on the comparison of techniques data in order to 
determine if the differences between the data were statistically significant.  The F test 
value was found to be 7.093 and p value <0.001 suggesting a significant difference 
between the results.  Further analysis shows that there was a 95% confidence interval of 
-33.71dB to -27.46dB for agitation which was similar to the confidence interval of the 
sample involving high shear mixing after. (-33.82dB to -27.58dB).  These were both 
greater than the confidence intervals for alternative techniques, this further supports the 
decision to use both techniques in production of the agent. 
10.1.3. Evaluation and possible sources of error 
The microbubble production techniques described in Chapter 3 were investigated as they 
have previously been used by other authors to produce UCAs (Fry et al. 1995; Klibanov 
et al. 2004; Schneider et al. 2004; Schneider et al. 2006; Talu et al. 2006).  For the 
sonication method it was necessary to position the tip of the sonicator in the centre of the 
vessel containing the microbubble sample visually.  Although every care was taken to 
ensure that the sonicator tip was central visual assessment of its location is subjective 
 
Conclusions and Evaluation  230 
which may have lead to variations in the result.  However, an average of three samples 
was collected in order to eliminate such variations. 
Analysis of the RF data was carried out in order to quantify the mean backscatter 
produced by each sample.  The software used to determine the mean backscatter of each 
sample calculated the mean backscatter relative to a perfect reflector.  The perfect 
reflector used throughout this thesis was the reflection from an air-water interface.  A 
perfect reflector signal was collected each time a sample was analysed in order to take 
into account any changes in signal from the IVUS transducer.  The reflector data was 
subject to a degree of variation as it was assessed visually, as demonstrated in Appendix 
C.  However the variation in three data sets collected was 1dB suggesting that the 
method used to acquire the reflector data was highly reproducible.   
Errors in the RF analysis of the mean backscatter were not possible to calculate due to 
the complexity of the software program, however, since all the results were analysed 
using the same program and compared against each other any errors will be consistent 
between samples.   
All backscatter results from the different compositions are the mean of a minimum of 
three sets of experiments, with the exception of the stability investigation.  Three regions 
of interest (ROI) were analysed for each microbubble sample and the average of the 
three ROIs determined in order to take into account any variation in the sample.  This 
value was then averaged over the three data sets collected.  All data was presented with 
the standard deviation from the three data sets as an error.  It was not possible to collect 
more than one data set for the three month stability trial due to the consumption of 
resources required for this trial and the time scale of the trial. 
During the stability trials it was also noted that some samples presented with mould, 
despite the sustained echogenicity of the samples the contaminated samples were not 
considered suitable for use in further investigations and were discarded.  Currently the 
agent is manufactured in a non-sterile environment due to the in-vitro nature of the early 
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development stages; however, further development of the agent for in-vivo use will be 
carried out in sterilised surroundings. 
10.2. Calibration of a novel flow chamber 
Laser Doppler anemometry was used to calibrate a novel flow chamber designed to 
investigate attachment of the UCA to an agar surface using IVUS.  The flow chamber 
was successfully calibrated up to 50Pa WSS.  Higher WSS was achieved through use of 
higher viscosity fluids produced from glycerol solutions.  In addition to the LDA 
investigation, CFD and calculations were also used to determine the WSS within the 
flow chamber.  A comparison of the different methods suggests that there is good 
correlation between the calculations, CFD and experimental values for low flow 
volumes.  However at higher flow volumes the WSS values differ by as much as 20Pa.  
In conclusion, at low flow volumes, calculated WSS values are suitable for estimating 
expected WSS within a vessel. 
10.2.1. Evaluation and Sources of Error 
Glycerol solutions of 40, 60 and 80%, used to produce high viscosity fluids, were 
calculated by mass.  Required volumes were calculated and measured using a measuring 
cylinder, resulting in an accurate solution.  However, the glycerol was found to settle out 
of solution after time and if there was any variation in the solution this would have 
resulted in an inaccurate viscosity estimate.  This was avoided through stirring of the 
solution at regular intervals and the solution was covered when stored to ensure that 
evaporation was minimised.  In addition, viscosity values were determined through 
interpolation of data from Kaye and Laby (Kaye and Laby 2004).  Since interpolation 
involves determination of a value from an observed trend it may not be a truly accurate 
value, this would result in an inaccurate calculation of the WSS.  However, the tables 
presented by Kaye and Laby are very comprehensive and so the values determined are 
assumed to be accurate. 
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The resolution of LDA is dependent upon the direction of the measurements.  The 
measurement volume, as illustrated in Figure 4-3 measures 200×45×45µm; this results 
in resolutions of 200µm in the z (forward) direction, 45µm in the x-direction and 45µm 
in the y-direction.  The resolution of the measurements of flow velocity presented in this 
thesis was 200µm.  Ideally the flow velocities would have been measured in the planes 
with the optimal resolutions; however, in order to be able to investigate the attachment 
of microbubbles to agar with an IVUS catheter it was necessary to be able to introduce 
the catheter behind the agar.  In order to investigate agar in the y-direction using IVUS 
the catheter would have needed to be introduced to the flow which would have resulted 
in a disruption to the flow.  Alternatively the depth of the central panel could have been 
increased to allow for an IVUS inlet, the 3×3mm cross-section was used as this is the 
closest approximation to a 3mm diameter coronary artery possible with a parallel plate 
flow chamber. 
When determining the shear rate within the flow chamber from the flow profiles as 
described in Section 4.5 three data points adjacent to the wall were used.  Three data 
points were selected to reduce any shear rate errors resulting from an anomalous result 
as illustrated in Figure 10-1a.  Due to the parabolic shape of the flow profile it was 
decided that the use of four points was more likely to result in an inaccurate increase in 
the measurement of shear rate as demonstrated in Figure 10-1b. 
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Figure 10-1: Errors resulting from a, the use of two data points and b, the use of four data points. 
Any extreme outliers observed in the flow profile were assumed to be anomalous 
resulting from reflections of the laser from discontinuities in the flow chamber, or 
scattering from the agar surface or Perspex.  However, it is possible that outliers were a 
result of turbulent flow.  Since the flow chamber has been designed such that laminar 
flow should be observed at low flow volumes it was assumed that these results were 
anomalous. 
Statistical analysis of the flow profiles was carried out using the R-squared value as 
determined by the parabolic trendline produced using the available function within the 
Microsoft Excel software.  An R-squared value greater than 90% was accepted as 
significant correlation and above 80% was assumed to be good correlation.  All R-
squared values were greater than 80% with the majority greater than 90% suggesting 
good correlation of the data.  In addition correlation p values were calculated for all 
trendlines presented. 
The maximum WSS observed using 80% glycerol solution, with a viscosity of 0.06Pa·s, 
at 270ml·min
-1
 flow volume was 50Pa.  Although higher WSS has been observed in 
stenosed vessels (Li et al. 2007) and mice (Table 7-1) it was not possible to reach higher 
WSS within the flow chamber described.  The maximum flow volume that could be 
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passed through the flow chamber with the 80% glycerol solution was 270 ml·min
-1
 and 
although it was attempted to pass higher glycerol solutions through the system, this 
caused the pump to seize and was therefore not possible.  In order to investigate 
attachment or detachment of the agent at higher WSS it would be necessary to design a 
different flow system. 
Other sources of error in the flow system include discontinuities in the flow channel 
resulting from the agar well and microscope slide.  In addition, discontinuities or scatter 
may be observed if the silicone grease, used to seal the flow chamber, projects into the 
flow channel.  The former issue was addressed by visual and tactile assessment of the 
points where the agar meets the Perspex, or microscope slide meets the Perspex.  Every 
effort was made to ensure that the discontinuity was minimal.  The latter issue was 
addressed through regular cleaning of the flow channel and visual observations to ensure 
that no grease could be seen in the channel. 
The flow system has been designed to assess attachment and detachment of UCAs under 
varying, controlled WSS and calibrated to 50Pa.  Calibration of the flow chamber can be 
considered accurate, assuming that laminar, non-turbulent flow is observed at all times. 
10.3. IVUS Characterisation 
The IVUS scanner and transducer described in Chapter 5 was characterised in order to 
determine the acoustic pressure output of the scanner.  The maximum acoustic peak 
negative pressure was found to be -2.0 ± 0.15MPa, at 1mm from the transducer, as 
determined from the peak negative voltages measured using a membrane hydrophone.  
The MI was then calculated and found to be 0.32 ± 0.10, suggesting that the insonated 
microbubbles could behave non-linearly, but that microbubble destruction is unlikely at 
this pressure. 
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10.3.1. Statistical Errors 
The error presented for the peak negative pressure was the standard deviation of the data 
sets collected ( 3n ).  The error presented for the MI was calculated using the standard 
deviation of the data sets averaged and the uncertainty in the sensitivity measurements, 
provided by the calibration certificate (National Physics Laboratory).   
10.3.2. Evaluation and sources of experimental errors 
The distance of the hydrophone from the transducer was measured using the distance 
divisions on the IVUS scanner screen as shown in Figure 5-2.  The axial resolution of an 
IVUS system lies between 80μm (Rosales and Radeva 2005) and 190μm (Elliott and 
Thrush 1996) for frequencies of 20-50MHz, suggesting that for 40MHz IVUS the 
resolution enables an accurate measurement of the distance between the transducer and 
hydrophone, to within 20%. 
Positioning of the hydrophone was achieved through visual observation of the brightest 
echo on the IVUS scanner screen achieved at minimum gain, as described for reflector 
data collection in Appendix C.  Although this method is highly subjective the error was 
minimised through lowering the gain on the screen, making the contrast on the screen 
more obvious. 
Another source of error was the potential presence of bubbles in the water bath and in 
particular, underneath the hydrophone.  The former issue was addressed through the use 
of de-ionised water which was allowed to sit for 24 hours prior to running experiments.  
The latter was assessed through careful placement of the hydrophone in the water bath 
and allowing the hydrophone to be completely submerged before clamping in place.  
The hydrophone was then left for an hour to allow any bubbles formed in placing it to 
disperse or dissolve. 
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10.4. Attachment of Antibodies to Microbubbles 
10.4.1. Conclusion 
Targeting of the microbubbles was achieved through the attachment of antibodies to the 
microbubble shell by means of a streptavidin-biotin bridge as illustrated in Figure 6-1.  
CD31 antibodies have been successfully attached to the microbubbles with over 90% of 
the microbubble population being targeted.  As a result the microbubbles have been 
successfully targeted to SK-Hep-1 cells. 
10.4.2. Evaluation and sources of error 
Antibody attachment was optimised for small volumes of microbubbles in order to 
minimise project expenses; however when attaching antibodies to larger volumes of 
microbubbles a 20% drop in the population of targeted microbubbles was observed with 
only 70% of microbubbles having antibodies attached.  This could be due to a number of 
reasons; the number of microbubbles with biotin in the shell being less, the solution of 
antibodies and microbubbles being unevenly distributed or there being insufficient 
antibodies or streptavidin to fill all the biotin sites.  Distribution of the antibodies and 
microbubbles was achieved through use of the Rotamix and the samples were agitated 
for 5s before addition of streptavidin which would ensure an even distribution.  In order 
to investigate the effect of biotin and the number of biotin sites per microbubble further 
investigations would have been advantageous but were not conducted due to time 
restrictions. 
Fluorescence measurements of antibody attachment were achieved through the addition 
of a fluorescent antibody (F2883) to the CD31 attached to the microbubbles.  It is 
possible that there were CD31 antibodies attached to the microbubbles which did not get 
tagged by the F2883, giving a falsely low value of antibody attachment, alternatively 
unattached F2883 may have remained in solution, unattached to the CD31 which would 
have given a false high value.  In order to minimise errors from the latter the samples 
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were washed after the addition of F2883.  The former was addressed through a brief 
investigation into different concentrations of F2883 being added to the microbubbles, no 
variation greater than that observed between samples was seen. 
10.5. Attachment and Detachment via a streptavidin-biotin 
mechanism 
10.5.1. Conclusions 
The streptavidin-biotin bond has been assessed under flow conditions up to 50Pa WSS.  
The bond was found to be capable of withstanding 50Pa WSS making it over 75 times 
stronger than a suspected electrostatic bond.  This is of an order with the difference in 
rupture forces between a streptavidin-biotin bond (160pN) and a weak non-covalent 
(electrostatic) bond (4pN) making the rupture force of the streptavidin-biotin bond 40 
times greater than that required for the electrostatic bond (Picotwist 2009).  In 
conclusion, the streptavidin-biotin bond is strong enough to withstand the shear stresses 
it might experience in healthy human coronary arteries and of an order with the shear 
stress observed in mice, as described in Table 7-1.  However, the maximum WSS under 
which the streptavidin-biotin bond will remain attached has not been investigated due to 
flow chamber limitations as described in Section 10.2.  In order to determine if the bond 
is able to withstand the higher WSS expected in diseased mouse coronary arteries further 
investigation would be required.  Use of the streptavidin-biotin bond however is itself 
under question as it may cause an unwanted immune response (Anderson et al. 2009) 
due to its being a foreign protein, it is therefore necessary to investigate more 
biocompatible targeting techniques. 
Attachment of the microbubbles under flow was observed at low WSS, however the 
attachment was minimal.  In order to be able to assess attachment using IVUS it will be 
necessary to improve the number of microbubbles attaching under flow.  In addition the 
attachment could not be confirmed since the microbubbles were not observed using 
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fluorescence microscopy, it is possible that the bubbles observed were a result of the 
water flow and not in fact targeted microbubbles. 
10.5.2. Statistical Analysis 
Correlation P-values and Pearsons correlation coefficients have been calculated and 
presented where possible.  A p<0.01 is considered a significant correlation and 
correlation coefficients greater than 80% (0.8) are considered significant.  Errors are 
presented as one standard deviation ( 3n ) unless identified otherwise. 
In addition t-tests were carried out and p-values calculated for comparisons of the 
average data points to controls.  These are presented alongside the data. 
10.5.3. Sources of Error and Evaluation 
Potential sources of error from the investigation in Chapter 7 come from the WSS 
estimate, discontinuities in the flow chamber will cause a large error in the measurement 
of WSS and turbulent flow may occur within the flow chamber.  This was avoided 
through regular cleaning of the flow chamber and visual observations of the flow 
channel as described in Section 10.2.1. 
Mean backscatter analysis of detachment of the microbubbles was carried out at two 
locations along the flow channel and averaged.  It was not possible to observe the 
attachment of microbubbles to agar visually and it is possible that distribution of the 
microbubbles was not even across the agar surface.  In addition, it was not possible to 
observe the exact same position of the agar with the IVUS at each increase in WSS 
therefore resulting in some variation of the mean backscatter in each position. 
Placement of the transducer during the detachment investigations was done carefully due 
to very bright echoes observed from the edges of the flow channel.  Positioning was 
carried out through identifying these very bright echoes and ensuring that the transducer 
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was as central to the flow channel as possible as illustrated in Figure 10-2.  The flow 
channel was identified from other echoes by the occasional bubble observed in the flow. 
 
Figure 10-2: Positioning of transducer behind agar. 
10.6. Cellular Adhesion 
10.6.1. Conclusions 
Cellular adhesion under varying WSS has been investigated.  The flow chamber 
developed in Chapter 4 was adapted to allow for cell growth within the flow channel.  
However due to environmental situations, such as temperature and toxins it was found 
that cells rapidly detached under low WSS.  An alternative flow system was developed 
with the use of Ibidi μ-slides to allow for assessment of cellular adhesion under very low 
WSS.  Cellular retention under WSS up to 0.17Pa was found to be greater than 90% 
making the Ibidi flow cells suitable for assessment of microbubble attachment to cells 
under very low WSS. 
10.6.2. Sources of Error and Evaluation 
Cellular adhesion was assessed through an investigation into the confluence of cells 
before and after being subjected to increasing WSS.  The confluence of the cells was 
determined through the use of a confluence grid as described in Appendix I.  This 
technique was accurate to within 1%.  Accuracy could have been improved by 
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increasing the number of squares in the grid used; however this would have increased 
the time required to determine the confluence of each image and was therefore limited 
by time constraints and image resolution. 
In addition to the confluence calculations it was also not always possible to compare the 
confluence in the same region as the slides were moved to and from the microscope 
platform.  In order to rectify this, the final investigation was carried out in the Ibidi 
slides with the slides stationary on the microscope platform.  This however resulted in 
only one data set being available per investigation and did not take into account the 
possibility of uneven cellular distribution. 
Finally the use of live cells resulted in some limiting factors in the experimental 
procedures.  It was necessary to ensure that the environment was kept as close to 37°C 
as possible throughout the investigations, this was achieved through the use of warm 
water baths and a specially designed warm plate for the microscope.  In addition cells 
were subjected to toxins and bacteria in the air which may have resulted in greater 
confluence loss than expected; this was remedied through the use of the Ibidi flow cells 
which were enclosed and sterile. 
10.7. Attachment of microbubbles to cells 
10.7.1. Conclusions 
The microbubbles have been successfully attached to SK-Hep-1 cells under very low 
(0.03Pa) WSS through the use of the primary acoustic radiation force.  This was 
achieved through targeting of the agent by attachment of CD31 antibodies as described 
in Chapter 6.  Attachment of the agent under flow conditions is a significant step in the 
development of a targeted UCA; however, in order to be able to observe the attached 
microbubbles with IVUS it is necessary to optimize the number of microbubbles 
adhered to the cells.  Potential further investigations to optimize this attachment are 
discussed in Section 10.9. 
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10.7.2. Statistical Analysis 
ANOVA tests have been used to identify the statistical significance for the data 
presented in Chapter 9 and p values have been presented.  A p value less than 0.05 has 
been considered statistically significant. 
10.7.3. Sources of Error and Evaluation 
Observation of the attached microbubbles was achieved through the use of fluorescence 
microscopy.  The fluorescent microbubbles were assessed with flow cytometry to 
determine the number of microbubbles containing the fluorescent lipid.  Since only 50% 
of the microbubbles in a sample contained the fluorescent lipid it is possible that there 
were microbubbles present which weren‟t observed under the microscope.  In order to 
try to eliminate this problem the attached microbubbles were observed with fluorescence 
and bright-field microscopy and an average of the microbubbles counted in each image 
was calculated (errors represent the standard deviation). 
In addition to the problem described above the fluorescent lipid is also known to wear 
off if subjected to bright lights for any length of time, the microbubbles were therefore 
kept in the dark as long as possible, however, for health and safety reasons it was not 
always possible to carry things out in the dark. 
The distribution of microbubbles attached to cells was not even, suggesting that there 
were either areas of lower WSS or that some cells were not able to adhere to the 
antibodies attached to the microbubbles.  For the purpose of this investigation the slides 
were studied to find areas of highest microbubble attachment and images collected from 
these areas.  Since visual observation is subjective it is possible that this technique may 
have resulted in manual errors.  
Ultrasound was investigated as a means to facilitate the attachment of microbubbles to 
the cellular surface due to the tendency of microbubbles to float, or under flow, migrate 
to the centre of the flow channel.  The force acting on the microbubbles was calculated 
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(Section 9.2.3) using an equation described by Rychak et al. (Rychak et al. 2006a).  The 
force calculated does not take into account the secondary radiation forces and assumes 
that the buoyancy force is of the order of 0.1nN.  Since these forces do exist, 
determination of the force acting on the microbubble could be subject to error.  In 
addition, Equation 9-1 assumes that the microbubbles are insonated at their resonant 
frequency, since the microbubbles have been optimized for resonance at 40MHz US and 
the scanner used for this investigation operates at 10-22MHz this may also be a source 
of error in the calculation. 
In Section 9.2.3 the microbubbles are being attached to cells in Petrie dishes, when 
studying the ultrasound to which the microbubbles and cells were subjected to, as 
described in Appendix K, a significant increase in acoustic pressure was observed at 
4mm from the transducer, this is believed to be due to generation of standing waves.  It 
is possible therefore that the microbubbles were subjected to greater pressures and forces 
than estimated. 
When using the ultrasound with the Ibidi flow slides it is probable that ultrasound wave 
is reflected by the top surface of the slides since the slides are produced from plastic.  
Despite this an increase in microbubble attachment was observed when using the 
acoustic radiation force. 
10.8. Overall 
The field of ultrasound contrast agents is continually expanding.  Researchers around the 
world are developing new UCAs and investigating the properties and potential 
diagnostic and therapeutic uses of different agents.  Medical Physics at Edinburgh 
University is playing a significant role in the development of new agents for specific 
targeting purposes.  The agent being developed is intended for use in the diagnosis of 
coronary heart disease.     
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The work presented in this Thesis, in addition to demonstrating the development of the 
agent described, also provides a description of the different methods used to this end.  
The novel flow chamber described in Chapter 4, designed specifically for the assessment 
of detachment and attachment of the agent under very high WSS, could easily be 
adapted or used for the assessment of alternative targeting mechanisms.  In addition the 
flow set-up described in Chapter 9 has been shown to be suitable for assessment of 
microbubble targeting to a cellular monolayer. 
Antibody attachment to the microbubbles, as described in Chapter 6, demonstrates the 
potential problems arising from this technique.  A major step in the development of the 
agent, the techniques investigated and described, both for attachment and assessment of 
attachment, will prove useful for the development of alternative targeting strategies both 
in future development of the agent produced at Edinburgh University and for other 
researchers investigating antibody attachment. 
Ultrasound mediated delivery of microbubble UCAs using acoustic radiation force has 
been investigated by a variety of authors (Dayton et al. 1999a; Fowlkes et al. 1993; Lum 
et al. 2006; Rychak et al. 2004; Rychak et al. 2005; Rychak et al. 2006a).  This 
technique has been demonstrated in Chapter 9.  The acoustic radiation force has been 
shown to improve attachment of the agent to a cellular surface both in static conditions 
and under very low WSS. 
Although other research is being carried out into UCAs targeted to inflammation and 
atherosclerotic plaques (Klibanov et al. 2006; Lindner 2002a; Lindner et al. 2001; 
Villanueva et al. 1998), to the author‟s knowledge, Edinburgh University is the only 
group investigating the targeting applications of a UCA designed specifically for use 
with high-frequency ultrasound.  This will allow for higher resolution imaging of the 
vulnerable plaques to which the agent will be targeted. 
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10.8.1. Conclusion 
The microbubble being developed at Edinburgh University has been shown to 
successfully attach to a cellular monolayer under very low WSS confirming the 
feasibility of the agent for targeting applications.  The agent will be targeted to 
atherosclerotic plaque and initial in-vivo investigations will be carried out in small 
animals.  The streptavidin-biotin bond has been shown to be able to withstand flow with 
a WSS up to and over 50Pa which is of an order with WSS observed in healthy mice 
(Table 7-1), however as described in Section 10.5 this may not be an ideal attachment 
mechanism for in-vivo applications. 
In addition the UCA has been successfully optimized for use with high-frequency 
40MHz IVUS. 
10.9. Future Investigations 
Preclinical investigations with the agent will involve the assessment of contrast agent 
targeting in small animals, notably mice.  Small animal imaging is a continually 
developing field of study and the Medical Physics department recently purchased a 
Vivo770, high frequency, high resolution in-vivo ultrasound imaging system 
(Visualsonics B.V, Amsterdam, The Netherlands) for pre-clinical imaging purposes.  
Prior to preclinical investigations in small animals further development of the UCA will 
be required.   
Future development of the agent will involve further optimization of antibody 
attachment, demonstrated in Chapter 6, to enable attachment of a greater number of 
microbubbles to the cells.  The greater number of microbubbles which can adhere to 
cells under flow would result in a greater contrast to tissue ratio which is highly 
desirable. 
Suggested future investigations include an assessment of detachment of the agent from 
cells under controlled shear stress in addition to investigating the maximum WSS under 
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which the agent will attach.  Attachment of the agent under very low WSS, as 
demonstrated in Chapter 9, is limited, in order to be able to investigate attachment using 
IVUS a greater number of adhered microbubbles is required.  This could be achieved 
through further development of the flow chamber presented in Chapter 4.  Schmidt et al 
(2008) have developed a flow cell with an acoustically transparent plastic, Rexolite 
(C-Lec Plastics, Inc., Beverly, NJ, USA).  This flow cell could potentially allow for the 
development of an optically and acoustically suitable flow chamber for future 
attachment investigations. 
Currently attachment of the targeted agent to excised ovine and swine aortas is being 
investigated in the Department.  This involves the use of alternative antibodies targeted 
to the endothelial cells of the vessels.  Increasing the attachment of antibodies to large 
volumes of microbubbles will help to improve the attachment.  However in order to 
investigate the attachment in-vivo it is suggested that alternative antibody attachment 
methods be developed to eliminate potential auto-immune reactions from the 
streptavidin. 
Development of the UCA here at Edinburgh University is still in its early stages; 
however, the work presented throughout this thesis has shown significant advances.  The 
next steps in development of the agent have been outlined above.  The field of 
ultrasound contrast imaging is still continuing to expand and shows significant promise 
in both diagnostic and therapeutic applications.  The work described throughout this 
thesis has focused on development of the UCA for diagnosis purposes through targeting 
of vulnerable plaques in CHD; however the agent also has therapeutic potential as a drug 
or gene delivery vehicle which could also be investigated.  In addition the agent could be 
used to target alternative structures as a diagnostic tool for diseases other than CHD. 
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Appendices 
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Appendix A Resonance Frequency of Microbubbles 
 
Optimisation of the microbubble agent being produced at Edinburgh University has been 
achieved through assessment of the maximum echogenicity achievable using different 
production methods.  However, an estimate of the optimum microbubble size for 
resonance at 40MHz has been carried out using Equation 2-6. 
 
Symbol Description Value Reference 
f0 Resonance frequency Variable n/a 
r Radius of encapsulated 
microbubble 
Variable n/a 
γ Polytropic exponent for 
encapsulated gas 
1.4 (MacDonald 2004) 
χ Shell elasticity parameter 8Nm-1 (MacDonald 2004) 
ρ0 Liquid density 998.2kgm
-3
 (Kaye and Laby 2008) 
σst Surface tension 0.072Nm
-1
 (MacDonald 2004) 
P0 Ambient static pressure 100kPa (MacDonald 2004) 
Table A-1: Resonance frequency data 
Using the data provided in Table A-1 the graph in Figure A-1 has been produced in 
order to provide an estimate of the microbubble size which will resonate at 40MHz.  The 
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blue line on the graph represents the estimated optimum radius size of 0.7µm.  This 
suggests that a microbubble of diameter 1.4µm would resonate with 40MHz ultrasound. 
 
Figure A-1: Resonance against frequency. 
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Appendix B   Radio Frequency Data Analysis 
 
Radio frequency data was collected using a program developed in LabView (National 
Instruments, USA).  A screen shot of the program user interface is shown in Figure B-1.  
This allows the various controls of the digitizing card (Gage Applied CS8500, Gage 
Applied Technologies, Lachine, Canada) to be adjusted to the optimum settings for use 
with the IVUS scanner. The data captured by the card is stored as unformatted raw 
binary data as a „.sig‟ file. 
 
Figure B-1: Screen Shot of LabView software. 
Once RF data has been collected in LabView for all microbubble samples the RF signal 
from a standard reflector is collected.  Collection of reflector data is outlined in 
Appendix C. The raw data is then scan converted using a program written in IDL as 
explained in Chapter 3.  This program outputs a bitmap image of the raw data as 
illustrated in Figure B-2 and a scan converted image as illustrated in Figure B-3. 
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Figure B-2: Bitmap image of raw RF data. 
 
Figure B-3: Scan converted images a, of a perfect reflector showing bright reflection and 
reverberations and b, of a contrast sample showing a selected region of interest. 
After the RF data has been scan converted the „reflector‟ program is run.  This allows 
the user to select the reflection from the air-water interface (identified on Figure B-3a) 
using a cursor; the program then determines the peak signal within that region and fast 
Fourier transforms (FFT) the raw data, saving it to a data file for comparison with 
sample data, in addition the power spectrum is shown on screen.   
Analysis is carried out using a further IDL program called „Analyse_ROI.pro‟ program.  
This allows the user to select which reflector data the file should be compared to and to 
select a region of interest (ROI) within the sample scan converted image using either the 
cursor or co-ordinates, as illustrated in Figure B-3b.  When collecting data from contrast 
samples co-ordinates were used to select the ROI in order to maintain continuity.  Once 
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the program has run, a text file is output with a number of computed values including the 
mean, maximum and minimum backscatter power for the ROI. 
The mean backscatter power was used throughout this thesis to compare the 
echogenicity of microbubble samples. 
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Appendix C  Collection of Perfect Reflector Data 
 
The reflector data used in the analysis of mean backscatter was collected from an 
air-water interface.  In order to accurately analyse sample data it was necessary to 
achieve the brightest reflection from the interface.  The optimum reflection was 
observed when the ultrasound beam was perpendicular to the surface.  Due to the angle 
of the transducer within the catheter it was necessary to maintain a 12° angle between 
the catheter and the air-water interface.  The optimum angle was determined from a 
visual study of the brightness of the echo at varying angles in addition to maximising the 
number of multiple reflections from the air-water interface.  The accuracy of this could 
have been further improved through use of a hydrophone, however one was not 
available initially and in order to maintain continuity it was decided that a visual 
assessment was to be used throughout. 
C.1 Method: 
A micromanipulator (Narishige, Japan) was used to position the transducer at the 
optimum angle and 2mm depth from the air-water interface. This set up can be seen in 
Figure C-1. 
 
Appendices  253 
 
Figure C-1: Reflector data collection a, photograph of set-up detailing equipment and b, schematic 
of set-up illustrating angle and depth of transducer (not to scale). 
Perfect reflector calibration data was collected after each set of contrast evaluation scans 
to take into account any variations in transducer performance.  In order to determine 
reproducibility of the reflector data three sets of RF data were collected in one day with 
the equipment being taken apart and reconstructed for each data collection.  The RF data 
was then collected for a random sample.  The same co-ordinate of the microbubble 
sample was then analysed against each perfect reflector data to evaluate any variations in 
the perfect reflector data.  This was repeated with a different sample of microbubbles to 
produce two sets of data. 
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C.2 Results: 
The mean backscatter from the sample collected for each reflector can be seen in Figure 
C-2.  The first data set collected had an average backscatter of -44.09(±0.88)dB with a 
range of 1.63dB, the second data set had an average backscatter of -41.13(±0.65)dB with 
a range of 1.28dB.  The small range of the data collected confirms the reproducibility of 
the perfect reflector data. 
 
Figure C-2: Mean backscatter comparison for two sets of reflector data. 
In conclusion, visual assessment of the perfect reflector data is reproducible to within a 
deviation of approximately 1dB.  Visual determination of the brightest reflection is a 
suitable method of collecting reflector data and was used throughout this thesis in order 
to determine the echogenicity of microbubble samples.   
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Appendix D  In-house microbubble protocol 
 
Production of the in-house microbubble UCA was optimised in Chapter 3.  A variety of 
techniques were investigated.  These techniques included; agitation, sonication, high 
shear mixing, varying production temperatures and altering the lipid composition of the 
microbubble shell.  The optimised production procedure involved high shear mixing of 
the initial lipid solution and agitation of the microbubble suspension.  This procedure is 
outlined below. 
D.1 Lipids:  
The optimal lipid composition determined in Chapter 3 was the 30% cholesterol 
composition.  Therefore the ratio of lipids used throughout this thesis was 56:30:11:3 
(PC:Chol:PE:PG).  Each 100mg of lipids is dissolved in 4ml saline. 
When incorporating biotin into the microbubble shell for antibody attachment the 
following composition was used: 56:30:6:3:5 (PC:Chol:PE:PG:Biotinylated PE). 
D.2 Procedure: 
1. Prepare a hot water bath set to 78°C. 
2. Weigh out dry lipids and dissolve in saline. 
3. Homogenize lipids in solution using a hand held high-shear mixer for one 
minute. 
4. Place flask containing lipid solution into hot water bath and set up stirrer to 
1000rpm and attach condenser.  Leave lipids to heat for one hour. 
5. Remove microbubbles from water bath and agitate vigorously for 45s. 
6. Store microbubbles for up to 3 months in glass container at 2-5°C. 
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Appendix E Flow volume calibration 
 
Flow through the flow chamber was controlled by a pump (Micropumps Ltd, UK) which 
in turn is controlled by a power supply (Eagle Power Ltd, UK).  In order to accurately 
assess the flow volumes through the flow chamber it was necessary to calibrate the 
power supply.  This was achieved by measuring the flow volumes over a one minute 
period at varying voltage settings. 
E.1 Method 
Flow chamber was clamped together and tubing attached.  Following this, the voltage of 
the power supply was increased in 5V intervals and flow volume measured at each 
interval.  This was repeated four times for each voltage interval and for the four different 
viscosity fluids identified in Chapter 4. 
E.2 Measurement of flow volumes 
Flow volumes at each voltage interval were measured using a measuring cylinder.  Flow 
through the flow chamber was collected in a measuring cylinder for one minute.  This 
was repeated three times.  In addition repeat measurements of the flow volume were 
collected on different days due to environmental effects upon this parameter such as 
temperature and pressure.  The average was calculated from all data sets. 
E.3 Results 
The calibration graph can be seen in Figure E-1.  Flow volume increases linearly with 
the pump voltage, the Microsoft Excel (Microsoft
®
, USA) linear trend line has been used 
to determine correlation of the data.  
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Figure E-1: Flow volumes produced at varying voltages.  Error bars represent one standard 
deviation. 
A calibration table was produced by interpolation of the above data using the Microsoft 
Excel trend line function.  Table E-1 suggests the necessary voltages needed to produce 
required flow volumes.  Since flow volumes can vary dependant upon environmental 
conditions a calibration check was carried out at the beginning of each investigation to 
confirm the flow volumes achieved and necessary adjustments carried out. 
 












60 5.8 ± 0.38 4.8 ± 0.41 4.9 ± 0.40 3.9 ± 0.38 
80 7.3 ± 0.38 6.4 ± 0.41 6.5 ± 0.40 5.4 ± 0.38 
100 8.8 ± 0.38 8.0 ± 0.41 8.1 ± 0.40 6.9 ± 0.38 
120 10.4 ± 0.38 9.7 ± 0.41 9.7 ± 0.40 8.4 ± 0.38 
140 11.9 ± 0.38 11.3 ± 0.41 11.3 ± 0.40 9.9 ± 0.38 
160 13.4 ± 0.38 12.9 ± 0.41 12.9 ± 0.40 11.4 ± 0.38 
180 15.0 ± 0.38 14.5 ± 0.41 14.5 ± 0.40 12.9 ± 0.38 
350 28.1 ± 0.38 28.4 ± 0.41 28.0 ± 0.40 25.7 ± 0.38 
Table E-1: Calibration table for pump.
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Appendix F  Flow Profiles 
Figure F-1 shows some flow profiles collected in the z-plane in order to determine the 
location of the centre of the flow channel, determined as the location of the peak 
velocity.  This technique was used to set up the LDA rig to measure the flow profile 
adjacent to the agar surface.  The variations observed at the sides of the chamber are due 
to reflections from the edges of the flow channel.  These flow profiles suggest a central 
co-ordinate of 5mm. 
 
Figure F-1: Flow profiles used to set up central location of LDA. 
Figure F-2 shows the three dimensional flow profiles produced by CFD analysis of the 
flow chamber described in Chapter 4. 
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Figure F-2: Three dimensional CFD flow profiles at observation region for flow chamber.
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Appendix G  Calculation of Microbubble Concentration 
 
A cell counting technique has been used in order to determine the microbubble 
concentration.  The microbubbles were diluted, with a dilution factor of 100, and 
introduced to a Neubauer chamber as illustrated in Figure G-1. 
 
Figure G-1: Neubauer chamber (reprinted with permission from David Caprette (Caprette 2000)). 
The microbubbles within the large central grid, illustrated in Figure G-2, were counted 
for each side of the chamber and the average determined.   
 
Figure G-2: Counting grid of Neubauer chamber as observed under microscope (reprinted with 
permission from David Caprette (Caprette 2000)). 
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Equation G-1 was then used to calculate the concentration of microbubbles. 
  410 DMbemicrobubbl total  
Equation G-1: Microbubble concentration calculation (Perez 2006). 
Where [microbubble] is the microbubble concentration, MBtotal is the total average 
microbubble count and D is the dilution factor. 
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Appendix H Agar Production 
 
The following protocol was used for production of agar throughout this thesis.  Agar was 
poured into a suitable mould and then cut to size for the flow chamber in Chapter 4. 
H.1 Ingredients (% by mass)  
 De-mineralised water (82.40) 
 Glycerol (99% solution) (11.32) 
 Benzalkonium Chloride (50% solution) (0.92) 
 Agar (3.00) 
H.2 Method 
1. Combine all ingredients in a fume hood. 
2. De-gas the solution to remove any air bubbles. 
3. Heat to 96°C for one hour in a water bath.  Stir throughout. 
4. Cool to 42°C and pour into mould or container. 
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Appendix I  Calculation of Cellular Confluence 
 
Cellular confluence is the area of a surface to which cells are seeded, presented as a 
percentage.  In order to accurately and repeatedly quantify the confluence of cells seeded 
to a variety of surfaces, bright-field microscopic images were collected and overlaid 
with a grid as illustrated in Figure I-1.  The confluence was then calculated from 







Equation I-1: Calculation of cellular confluence. 
Where Nx is the number of grid squares with cell matter in and Ntotal is the total number 
of grid squares. 
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Figure I-1: Microscopic image (×400 magnification) overlaid with confluence grid. 
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Appendix J Preparation of Ibidi μ-slides 
 
J.1 Seeding cells within μ-slides 
Cell concentration was determined using the cell counting procedure outlined in 
Appendix G for calculation of microbubble concentrations.  Once the cell concentration 





concentration as per manufacturer‟s recommendations. 
The cell containing medium was then injected into the flow channel of the μ-slides with 
1ml syringes as illustrated in Figure J-1.  The slides used for the experiments in this 
thesis are described and illustrated in Chapter 8, Section 8.4. 
 
Figure J-1: Injecting cellular medium into Ibidi μ-slides. 
J.2 Replacing medium 
If the cells did not reach 50% confluence after 24 hours it was necessary to replace the 
medium to allow the cells longer to reach a suitable confluence for the experiments.  
This was achieved by adding 5% fetal calf serum to the medium, by volume, and 
replacing the medium as illustrated in Figure J-2. 
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Figure J-2: Replacing medium in flow slides. 
Care had to be taken when injecting medium into the flow slides to prevent the 
accumulation of bubbles.  If bubbles did form when adding medium it was possible to 
remove them by gently tapping the bottom of the slide, however this technique was not 
ideal to use when cells had already been seeded within the slides as this could cause 
cells to detach from the surface. 
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Appendix K Diasus Characterisation and Determination of 
Acoustic Radiation Force Parameters 
 
It was necessary to characterise the Diasus scanner used to facilitate microbubble 
attachment to cells in Chapter 9 to determine the force and other factors which the 
microbubbles were subjected to.  The Diasus scanner was characterised using the same 
equipment described in Chapter 5 for IVUS characterisation. 
K.1 Method 
The hydrophone was anchored in place, level, using a specially designed holder on top 
of a piece of acoustic absorber.  The transducer used in Chapter 9 was clamped above 
the hydrophone and could be moved up and down.  The set-up is illustrated in Figure 
K-1. 
 
Figure K-1: Diasus characterisation, experimental set-up. 
The hydrophone was levelled using a spirit level and transducer was levelled using the 
callipers on the scanner and making sure that there was an equal distance between the 
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transducer and hydrophone face at either end of the transducer.  This is illustrated in 
Figure K-2. 
 
Figure K-2: Using callipers on Diasus scanner to ensure that transducer was parallel to the 
hydrophone. 
The signals produced by the hydrophone were collected using the oscilloscope for 
distances of 2, 4, 6, 8 and 10mm from the transducer face.  Distances were measured 
using the callipers on the scanner.  It was not possible to collect data for smaller 
distances than 2mm due to the risk of damage to the fragile hydrophone membrane.  The 
investigation was then repeated placing a Petri dish base-up 16mm from the bottom of 
the hydrophone to investigate the effects of the plastic surface on the waveform.  This 
was the closest it was possible to get the Petri-dish to the hydrophone. 
The entire investigation was repeated four times over the course of two weeks. 
In addition to peak negative pressures, calculated using  Equation 5-1, waveforms 
over a greater time scale were collected in order to determine the pulse repetition 
frequency (PRF) and pulse duration. 
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K.2 Results 
The variation in Peak negative pressure can be seen in Figure K-3.  The peak negative 
pressure decreases as the distance between the hydrophone and transducer increases, 
with the exception of a large increase in pressure at 4mm when the Petri dish was placed 
beneath the hydrophone.  The author and colleagues believe that this change in pressure 
is the result of standing waves being formed on reflection of the ultrasound from the 
Petri dish plastic.  Since this occurred at 4mm from the transducer face it was assumed 
that the suspected presence of standing waves had no effect on the forces acting on the 
microbubbles as calculated in Chapter 9 due to the distance between transducer and 
plastic surface being 2mm. 
 
Figure K-3: Peak negative pressure as a function of distance from transducer face.   
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The PRF was calculated from Equation K-1, where T was the time between the start of 










Equation K-1: PRF 
 
Figure K-4: Determination of T. 
Finally the pulse duration (D) was determined from the waveforms as illustrated in 
Figure K-5.  The pulse duration was determined to be 0.24(±0.08)μs (n=9). 
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Figure K-5: Determination of D.
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Conferences and Publications 
Abstracts accepted for presentation at national and international conferences: 
„Characterization of a High Frequency In-house Ultrasound Contrast Agent‟, Adele 
Edgeworth, Carmel Moran, Jim Ross, Mairead Butler, Tom Anderson and Norman 
McDicken, Scottish Society for Experimental Medicine Annual Meeting 2007, Glasgow. 
Poster presentation. 
„Laser Doppler Anemometry, a Method to Assess the Targeting Strength of an In-house, 
Targeted, Microbubble, Ultrasound Contrast Agent‟ AL Edgeworth, JA Ross, T 
Anderson, MB Butler, WJ Easson, WN McDicken and CM Moran, British Medical 
Ultrasound Society Annual Scientific Meeting 2008, Liverpool. Poster presentation. 
„A method for assessing the strength of an avidin-biotin attachment mechanism of a 
targeted, high-frequency, in-house microbubble ultrasound contrast agent.‟ Adele 
Edgeworth, Mairead Butler, Jim Ross, Tom Anderson, Linda Norrie, Norman McDicken 
and Carmel Moran.  Fourteenth European Symposium on Ultrasound Contrast Imaging 
2009, Rotterdam, The Netherlands. Oral presentation. 
Conference papers: 
„Strength of Attachment of an in-house Ultrasound Contrast Agent‟, A.L. Edgeworth, T. 
Anderson, J.A. Ross, I.F. Ansell, M. Butler, L. Norrie, W.N. McDicken, C.M. Moran.  IEEE 
International Ultrasonics Symposium 2009, Rome, Italy.  Defended in a poster presentation. 
Papers accepted for publication to BMUS Ultrasound Journal 
„Novel Flow Chamber to Investigate Binding Strength of a Lipid-Based, High-
Frequency, Ultrasonic Contrast Agent', A.L. Edgeworth, T. Anderson, J.A. Ross, M. Butler, 
W.N. McDicken, C.M. Moran.  Awaiting publication . 
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